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 RESUME 
 
Suite à un accident vasculaire cérébral (AVC) ischémique, les cellules gliales du 
cerveau deviennent activées, de nombreuses cellules inflammatoires pénètrent dans le 
tissu lésé et sécrètent une grande variété de cytokines et chémokines. Aujourd’hui, il 
existe des interrogations sur les effets bénéfiques ou délétères de cette inflammation sur 
la taille de la lésion et le pronostic neurologique.  
 
Ce projet vise à évaluer l’effet d’un peptide neuroprotecteur, D-JNKI1, inhibiteur de la 
voie pro-apoptotique de signalisation intracellulaire c-Jun N-terminal kinase (JNK), sur 
l’inflammation post-ischémique.  
 
Nous montrons d'abord que la microglie est largement activée dans toute la région lésée 
48 h après l’induction d’une ischémie chez la souris. Cependant, malgré l’inhibition de 
la mort neuronale par D-JNKI1 évaluée à 48 h, nous n'observons de modification ni de 
l’activation de la microglie, ni de son nombre. Ensuite, nous montrons que le cerveau 
peut être protégé même s’il y a une augmentation massive de la sécrétion de médiateurs 
inflammatoires dans la circulation systémique très tôt après induction d’un AVC 
ischémique. De plus, nous notons que la sécrétion de molécules inflammatoires dans le 
cerveau n’est pas différente entre les animaux traités par D-JNKI1 ou une solution 
saline, bien que nous ayons obtenu une neuroprotection significative chez les animaux 
traités.  
 
En conclusion, nous montrons que l’inhibition de la voie de JNK par D-JNKI1 
n’influence pas directement l’inflammation post-ischémique. Ceci suggère que 
l’inhibition de l’inflammation n’est pas forcément nécessaire pour obtenir en haut 
degré de neuroprotection du parenchyme lésé après ischémie cérébrale, et que les 
mécanismes inflammatoires déclenchés lors d’une ischémie cérébrale ne sont pas 
forcément délétères pour la récupération du tissu endommagé. 
 SUMMARY 
 
After cerebral ischemia, glial cells become activated and numerous inflammatory cells 
infiltrate the site of the lesion, secreting a large variety of cytokines and chemokines. It 
is controversial whether this brain inflammation is detrimental or beneficial and how it 
influences lesion size and neurological outcome.  
 
This project was aimed at critically evaluating whether the neuroprotective peptide D-
JNKI, an inhibitor of the pro-apopotic c-Jun N-terminal kinase (JNK) pathway, 
modulates post-ischemic inflammation in animal models of stroke. Specifically, it was 
asked whether JNK inhibition prevents microglial activation and the release of 
inflammatory mediators. 
 
In the first part of this study, we showed that microglia was activated throughout the 
lesion 48 h after experimental stroke. However, the activation and accumulation of 
microglia was not reduced by D-JNKI1, despite a significant reduction of the lesion 
size. In the second part of this project, we demonstrated that neuroprotection measured 
at 48 h occurs even though inflammatory mediators are released in the plasma very 
early after the onset of cerebral ischemia. Furthermore, we found that secretion of 
inflammatory mediators in the brain was not different in groups treated with D-JNKI1 
or not, despite a significant reduction of the lesion size in the treated group. 
 
Altogether, we show that inhibition of the JNK pathway using D-JNKI1 does not 
influence directly post-stroke inflammation. Inhibition of inflammation is therefore not 
necessarily required for neuroprotection after cerebral ischemia. Thus, post-stroke 
inflammation might not be detrimental for the tissue recovery. 
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 1 
1. INTRODUCTION 
 
FIRST PART: CLINICAL AND CELLULAR ISSUE OF STROKE  
 
1.1 STROKE EPIDEMIOLOGY AND CLINICAL IMPORTANCE  
 
Stroke is a frequent and devastating disease. Up to one in five persons suffer from 
stroke during lifetime. Stroke is fatal for almost one-third of cases, making it the third 
cause of death in developed countries after coronary heart disease and cancer. Among 
those who survived, half are permanently disabled, making stroke a major cause of 
long-term physical, cognitive and social invalidity. The incidence of stroke is roughly 
equal in men and women, but increases dramatically with age. The absolute number of 
cases is likely to rise due to the aging of the population. There are several risk factors: 
men have a slightly greater risk of stroke particularly from the age of 45, family history 
of stroke, prior stroke or transient ischemic attack (TIA), high blood pressure, tobacco 
smoking, overweight, diabetes and heart condition. For the general population the 
warnings signs and symptoms of stroke might be difficult to detect because they are not 
exclusive to stroke. ‘Stroke’ was first named as ‘stroke apoplexy’ from the Greek 
word : apo-plixia which mean : a ‘shock’ that happens ‘on, above’. Thus signs of 
stroke appear suddenly without warning. The main symptoms of stroke are: sudden 
numbness or weakness in one or both sides of the body, sudden difficulty to speak, to 
understand speech or confusion, sudden loss of vision, sudden vertigo, loss of 
coordination, amnesia and sudden severe headache with no known cause. Some 
symptoms like dysarthria or dizziness are not necessarily associated to stroke when 
there are isolated. Basically the diagnosis of stroke is made if the symptoms 1) are 
neuroanatomically localized; 2) correspond to a loss of function; 3) are of sudden 
onset; 4) evolve over minutes rather than over hours and days (Hankey, 2007; 
Williams, 2010). 
 2 
1.2 ISCHEMIC STROKE 
 
1.2.1 Acute management of ischemic stroke 
Stroke is caused by arterial occlusion in 80% of all cases, while intracerebral 
hemorrhage and subarachnoid hemorrhage have a lower incidence. The more common 
thrombo-embolic stroke, which is discussed herein, appears when a blood clot occludes 
a cerebral artery and causes a focal interruption of cerebral blood flow. The vessel 
occlusion leads rapidly to impaired motor and sensory brain function such as 
hemiplegia, aphasia or hemineglect (see above). If the blood clot is not rapidly lysed 
within 3 to 4.5 hours with recombinant tissue plasminogen activator (rtPA) the 
neurological deficit can be irreversible and in severe cases lead to death (The NINDS & 
Stroke rt-PA Stroke Study Group, 1995; Furlan et al., 1999; Hacke et al., 2008). 
Indeed, when the blood flow drops, the brain tissue is affected in two steps : above a 
threshold neuronal function is compromised but recoverable which is described as the 
ischemic penumbra, but if the blood flow goes below this limit, irreversible neuronal 
damage occurs. Thus, early reperfusion could rescue the penumbral area and minimize 
brain damage. Figure 1 shows an ischemic stroke caused by the occlusion of the left 
middle cerebral artery and the favorable outcome induced by the thrombolytic agent. 
 
Figure 1. Ischemic stroke in the left middle 
cerebral artery 
(A) Perfusion cerebral computerized 
tomography (CT) shows an ischemic core 
(red) surrounded by penumbra (green) 
(Wintermark et al., 2002). The core 
corresponds to the irreversible ischemic insult 
(infarction), whereas the penumbra represents 
brain parenchyma which is suffering from 
ischemia but which can be rescued if the blood 
perfusion is rapidly restored. (B) The diffusion 
weighted sequences on brain magnetic 
resonance imaging (MRI) show a 
hyperintensity in the territory of the left middle 
 3 
cerebral artery. Of note, only the infarcted territory, which corresponds to the core in (A) is 
visible. (C) Angiographic sequences of cerebral CT show a sub-occlusion of the left middle 
cerebral artery (arrow). (D) The patient benefited from an intra-venous thrombolysis with rtPA. 
Few days later, angiographic sequences on brain MRI showed a complete repermeabilisation 
of the left middle cerebral artery, which paralleled a favorable clinical outcome (Benakis et al., 
2009). 
 
1.2.2 Other treatments 
The thrombolysis is limited to a small number of patients, because of very strict 
selection criteria including a narrow time-window. Restoring the cerebral blood flow 
after a too long period from symptom onset is no longer beneficial and there is an 
increased risk of developing a symptomatic intracerebral hemorrhage (The NINDS & 
Stroke rt-PA Stroke Study Group, 1997). Other acute phase treatments are: 
administration of the intra-arterial of tPA or pro-urokinase directly into the occluded 
artery which extends the time window to six hours, and ‘mechanical embolus removal 
in cerebral ischemia’ (MERCI), a surgical technique that leads to the removal of the 
clot within 30 minutes. Both treatments are used in the acute phase and because of the 
need of advanced technology and specialized personnel, not all patients can benefit. If 
patients are not treated with rtPA they can receive aspirin in the acute phase to thin the 
blood and weeks after to avoid a subsequent ischemic stroke. Aspirin and other 
antiplatelet and anticoagulant drugs reduce the absolute risk of death and dependency 
several months after the episode, suggesting that it provides secondary prevention of a 
subsequent stroke rather than a direct protection. Other treatments are also focused on 
the prevention of a recurrent stroke, such as antihypertensive agents which aim at 
reducing the blood pressure or statins which reduce the cholesterol. A modification of 
the lifestyle and diet reduces the causal risk factors such as blood pressure, cholesterol 
and diabetes and therefore have an effect on reducing the risk of stroke. Surgical 
procedures are also used when a high grade carotid artery stenosis (artery not totally 
occluded) caused by atherosclerotic plaques leads to stroke (Haynes et al., 1994). An 
intervention is performed to remove the plaque and avoid an subsequent stroke. 
(Hankey, 2007; Williams, 2010). 
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Acute stroke treatments are very limited in time and technology. Other treatments listed 
above are mostly used to avoid recurrent stroke. As the damage extends with time there 
is a great need for new treatments for the patients who cannot be thrombolysed at first. 
Therefore new therapeutic strategies, which for instance target the delayed cellular and 
molecular mechanisms that follow cerebral ischemia, may be used with an extended 
therapeutic window for the protection of brain tissue. 
 
1.3 CELLULAR AND MOLECULAR MECHANISMS FOLLOWING STROKE 
 
Importantly, while ischemia at first induces a loss of function at its very early stages, 
structural damage appears rapidly thereafter and progresses as minutes and hours go by. 
Reduction of cerebral blood flow leads to a lack of oxygen and glucose supply to the 
brain parenchyma. This nutrient deficiency triggers multiple events including a 
dramatic depletion of energy (ATP) production, perturbation of the cellular ionic 
homeostasis, peri-infarct depolarization, water influx, neurotransmitter release and 
activation of many cytotoxic enzymes. Indeed the release of the excitatory 
neurotransmitter glutamate leads to excessive stimulation of glutamate receptors in 
energy-deprived neurons, termed excitotoxicity. As a result, the intracellular 
concentration of the secondary messenger calcium is dramatically increased and 
promotes numerous enzymes that degrade structural constituents of the cells as well as 
organelles such as mitochondria. Other proteases activate intracellular pathways or 
induce the production of free radical species, which activate apoptotic proteins, 
secretion of inflammatory mediators or damage the DNA. These mechanisms triggered 
by excitotoxic stimulation start in the early stages of the progression of the ischemic 
brain injury and can cause both acute cell death (necrosis) and delayed programmed 
cell death (apoptosis or autophagy) (Dirnagl, 1999; Lo et al., 2003; Puyal et al., 2009). 
 
An important mechanism beginning within hours from the onset of ischemia is the 
robust inflammatory response in the ischemic tissue. During the acute phase of stroke, 
inflammation is a response leading either to restrict or to aggravate the progression of 
tissue damage. During the sub-acute phase, inflammation further induces 
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immunosuppression and favors opportunistic infections such as bronchopneumonia 
(Dirnagl et al., 2007). Figure 2 represents a schematic summary of the fundamental 
mechanisms taking place after focal cerebral ischemia: excitoxicity, oxidative and 
nitrosative stress, apoptotic-like cell death (Lo et al., 2003). 
 
 
Figure 2. Major pathways implicated in ischemic cell death 
Within minutes after cerebral ischemia excitotoxic mechanisms are activated in neurons in the 
territory of the occluded artery which lead to necrotic and apoptotic cell death. Ca2+ (calcium), 
RNS (reactive nitrosative species), ROS (reactive oxygen species). (Reprinted from Nature 
Reviews, 4, Lo et al., Mechanisms, challenges and opportunities in stroke, p400., Copyright 
(2003), with permission from nature publishing group). 
 
1.4 NEUROPROTECTION TARGETING EXCITOTOXICITY 
 
Excitotoxic mechanisms are activated within the first sixty minutes after cerebral 
ischemia. Thus, different strategies aimed at blocking these mechanisms have been 
developed for stroke therapy. These include inhibition of N-Methyl-D-Aspartic acid 
(NMDA) or Amino-Methyl-Propanoic acid (AMPA) receptors that are activated by 
glutamate, blockade of calcium channel, chelation of calcium, overexpression of anti-
apoptotic components, etc [for review see: (Barone & Feuerstein, 1999; Lo et al., 2003; 
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Shuaib & Hussain, 2008)]. Most of these neuroprotection strategies are targeting very 
early mechanisms which might not be relevant in clinical therapy as most of the 
patients do not reach the emergency room early enough. Therefore inhibiting 
downstream events is likely to be more beneficial for neuroprotection.  
 
1.4.1 The c-Jun N-terminal kinase pathway 
Interesting candidates for stroke therapy are compounds that inhibit a single protein 
involved in deleterious events much downstream to the early cytotoxic effect. The 
Mitogen-Activated Protein Kinases (MAPKs) are a family of proteins kinases that 
respond to extracellular stimuli and regulate cellular signal pathways by cascades of 
phosphorylations. They consist of three enzymes activated in series: MAP kinase 
kinase kinase (MKKK, MEKK or MAP3K), MAP kinase kinase (MKK, MEK, or 
MAP2K) and MAP kinase. The p38 and the intracellular c-Jun NH2-terminal kinases 
(JNK) are members of the MAPK family and are key signaling pathways activated by 
stress stimuli and further activate transcription factors that regulate cell survival, 
apoptosis and inflammatory cytokines production (Davis, 2000; Chang & Karin, 2001; 
Pearson et al., 2001). Indeed, Schwarzschild and colleagues have published that 
glutamate induces the activation of the JNK pathway (Schwarzschild et al., 1997). JNK 
activation triggers in turn the phosphorylation of several transcription factors including 
the nuclear c-Jun component of the transcription factor activator protein-1 (AP-1) and 
intracellular proteins as for instance members of the Bcl-2 family involved in apoptosis 
(Akins et al., 1996; Bogoyevitch et al., 2006). Evidence for JNK mediated c-Jun 
activation in apoptotic cells (TUNEL positive staining) was shown in animal models of 
transient focal ischemia (Herdegen et al., 1998). Therefore, c-Jun nuclear labeling is a 
hallmark of delayed neuronal death. Based on these findings, several therapeutic 
interventions aimed at inhibiting specifically the JNK pathway are under investigations. 
 
JNKs activation is a complex mechanism that requires cascades of phosphorylation as 
in all MAPKs families. Ten isoforms resulting from alternatively spliced transcripts of 
the jnk1, jnk2, jnk3 genes were identified in humans. JNK1 and JNK2 are expressed 
ubiquitinously whereas JNK3 is predominantly expressed in the nervous system. Thus, 
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the activation pathways of each JNK isoform might be cell and stimuli dependent but 
all require 1) three steps of consecutive kinase activation by phosphorylation and 2) 
specific localization. First, upstream to JNK activation, several different MEK kinases 
(MEKK1,2,3,4) will activate the second MAP kinase kinase : MKK4 and MKK7, both 
these kinases are the immediate activators of JNK. To be fully active JNK need to be 
phosphorylated on both threonine and tyrosine residues. Secondly, JNK interacting 
proteins (JIP) are scaffold proteins which bring together specific members of the JNK 
signaling pathway and allow their consecutive activation. When JNK is activated, it can 
interact with mitochondrial apoptosis-related proteins in the cytoplasm and mediate 
transmission of apoptotic signals (Okuno et al., 2004). Furthermore, JNK can be 
translocated into the nucleus and phosphorylates c-Jun on serine-63 and serine-73. This 
leads to the transcription of potent activators of apoptotic cell death such as those 
coding for Fas-ligand or Bim (Herdegen et al., 1998; Kyriakis & Avruch, 2001; Weston 
& Davis, 2007; Raivich, 2008). 
 
1.4.2  Strategy of neuroprotection 
Taking advantages of this tight regulation of the JNK pathway activation, small 
inhibitors were designed based on protein-protein interactions. To inhibit JNK, two 
strategies were used: 1) molecules that inhibit the ATP binding site of JNK which leads 
to inactivate the kinase (known as ATP-competitive inhibitors) or 2) small peptides that 
inhibit the interaction of the kinase with its targets (known as ATP-noncompetitive 
inhibitors) (Manning & Davis, 2003; Bogoyevitch, 2005a; Bogoyevitch et al., 2005b). 
The most used compound which inhibits the ATP binding site of JNK is the molecule 
SP600125 (Celgene Corporation). Several studies showed that SP600125 treatment 
prevented cell death following transient ischemia of the brain [as for instance (Gao et 
al., 2005)]. Despite the obvious efficacy of SP600125, some questions arose 
concerning its specificity for JNK. Indeed, these ATP-competitive inhibitors must 
discriminate between the ATP-binding sites of all protein kinases and must compete 
with high intracellular ATP concentrations. The second strategy using ATP-
noncompetitive inhibitors was shown to be more efficient because the specificity was 
higher. Thus, small peptides of 10 to 30 amino acids derived from the JNK binding site 
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of the scaffold JIP were designed. To enhance their efficacy these peptides were linked 
to a cell-permeable sequence (HIV-TAT sequence) and to avoid its enzyme degradation 
D-amino-acids peptide were used instead of L-residues (Brugidou et al., 1995; Vivès et 
al., 1997; Haeusgen et al., 2009). A schematic cartoon of the action of such a peptide 
following stress stimuli is illustrated in Figure 3.  
 
 
Figure 3. Inhbition of the JNK pathway using ATP-noncompetitive peptide 
Consecutive activation of JNK by phosphorylation leads to its translocation into the nucleus 
where it can phosphorylate c-Jun which further leads to transcription of pro-apoptotic genes. 
The TAT-coupled peptide (here : D-JNKI1) binds specifically to JNK and inhibits its interaction 
with cytoplasmic and nuclear targets. (Figure was produced using Servier Medical Art). 
 
1.4.3 Neuroprotective effect of  D-JNKI1 
As mentioned above D-JNKI1 is a selective ATP-noncompetitive inhibitor that 
prevents the interaction of JNK with its targets including c-Jun. Its sequence was first 
designed based on the JNK binding domain (JBD) of the islet brain-1/JNK-interacting 
protein (IB-1/JIP-1) in pancreatic beta-cells (Bonny et al., 2001). D-JNKI1 consists of a 
10-amino-acid TAT-sequence, followed by two prolines and the 20 amino-acid JNK 
binding domain of the IB-1/JIP-1 protein in their D-configurations. This peptide shows 
a high degree of neuroprotection in several in vitro and in vivo models of cerebral 
ischemia (Borsello & Bonny, 2004). Indeed D-JNKI1 prevents NMDA-induced 
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neuronal death in primary cultures (Borsello et al., 2003; Centeno et al., 2007) as well 
as rescues the evoked potential response recorded in the CA1 region after oxygen and 
glucose deprivation (OGD) in organotypic hippocampal slice cultures (Hirt et al., 
2004). Moreover, D-JNKI1 remarkably attenuates the lesion size in transient and 
permanent models of cerebral ischemia in both rats and mice (Borsello et al., 2003; Hirt 
et al., 2004; Repici et al., 2007; Esneault et al., 2008), even with delayed intravenous 
administration (Wiegler et al., 2008). These experimental studies have also shown that 
D-JNKI1 improves functional outcome at later time points after ischemia. All together, 
these data strongly suggest that the inhibition of the JNK pathway using D-JNKI1 
would be very promising for stroke patients. 
 
Several therapeutic strategies aimed at decreasing the effect of the ischemia-induced 
excitotoxicity have been successful in animal stroke models, but not so far in stroke 
patients. The efficacy of inhibitors of cell death would be greater if they target multiple 
mechanisms such as combined inhibition of excitotoxic events and of the detrimental 
effects of inflammation. The inflammation reaction is an attractive target for stroke 
therapy because of its rapid activation and progression within hours and days after 
stroke. However inflammation can have both favorable or unfavorable consequences on 
the ischemic lesion, it is fundamental to discuss its role in cerebral ischemia in order to 
better target drugs. 
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SECOND PART: INFLAMMATION DURING CEREBRAL ISCHEMIA  
 
In cerebral ischemia, brain inflammation plays a role in the clearance of cell debris and 
initiates repair mechanisms; however, it can also enhance the damage to the tissue 
when the inflammatory response is not adapted or exacerbated. Thus, whether this 
brain inflammation is beneficial or detrimental in cerebral ischemia is still 
controversial. This short introduction gives insight on the key inflammatory players of 
this complex process.  
 
1.5 ACTIVATION OF GLIAL AND INFLAMMATORY CELLS 
 
The inflammatory response at the site of injury is characterized by the infiltration, 
accumulation and activation of glial cells and peripheral immune cells. Within hours 
from the onset of focal cerebral ischemia peripheral leukocytes adhere to the cerebral 
endothelium, cross the vessel wall and invade the damaged parenchyma (Petty & 
Wettstein, 2001; Wang et al., 2007). At the same time astrocytes and microglia become 
activated. These cellular events depend on the secretion of immunomodulators, which 
are produced by neuronal and glial cells in response to an ischemic insult. Once 
activated in the site of injury inflammatory cells start to secrete a large variety of 
inflammatory mediators such as cytokines, chemokines and promote the expression of 
adhesion molecules on the endothelial wall. Local brain inflammation is a pathological 
hallmark of ischemic stroke lesions and is related in space and in time to the occurrence 
of neuronal cell death (Barone & Feuerstein, 1999). Therefore, an assumption is often 
made regarding the possible role of inflammation in exacerbating the injury or its 
consequences. 
 
 1.5.1.Glial cells 
Microglia are the resident macrophages of the brain, forming the 5-15% of the total 
cellular content of the brain. They are very sensitive to subtle alterations in their 
neuronal microenvironment. Microglia in their resting or rather in their ‘surveying’ 
state have a very ramified cytoplasm, covering a territory of 30-40 µm in diameter. 
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Their processes and ramifications are highly mobile which enable microglia to 
continually scan their environment. Thus, they can sense signs of slight functionnal and 
structural disturbance of the neighbors cells (Davis et al., 1994; Nimmerjahn et al., 
2005; Hanisch & Kettenmann, 2007; Jinno et al., 2007). In response to an injury, 
microglia quickly become activated and undergo morphological transformations as 
well as functional changes. They start to retract their long processes and their shape 
becomes rounded - so called phagocytic, ameboid microglia (Raivich et al., 1999; Streit 
et al., 1999; Ladeby et al., 2005). When neurons die, microglia transform into brain 
macrophages and apoptotic cells are removed by phagocytosis. Figure 4 represents the 
different morphologies of microglia upon activation. 
 
 
Figure 4. Activation of microglia after cerebral ischemia 
Examples of immunohisto-chemical staining for CD11b, an integrin surface marker on 
microglial cells, after 48 h of reperfusion following 30 min middle cerebral artery occlusion 
(MCAO) in mice. Very ramified microglia (A, arrowhead) are detected in the cerebral 
hemisphere contralateral to the lesion. Activated microglia (B, arrowhead) and ameboid 
phagocytic microglia (C, arrowhead) are present in the injured brain tissue. Below is shown a 
cartoon of the graded activation of microglia. 
 
Activated microglia were identified in patients with ischemic stroke within the territory 
of the middle cerebral artery (Gerhard et al., 2005; Thiel & Heiss, 2011). Gerhard and 
colleagues labeled microglia with a specific ligand for the translocator protein 18kDa 
(formely the peripheral benzodiazepine receptor PBR) present on activated microglia 
([11C](R)-PK11195) (Stephenson et al., 1995). Using positron emission tomography 
(PET) scan they saw an increase of the marker in all the six patients examined between 
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3 and 150 days after the infarct. Figure 5 shows the lesion by MRI and the activation of 
microglia by PET scan for one patient at 5 and 13 days. Microglia are seen early after 
ischemia, initially at the periphery of the lesion (Figure 5e), then in the infarct core 
(Figure 5f) and finally in peri-infarct regions (Gerhard et al., 2005; Thiel & Heiss, 
2011). This progression of microglial activation is not yet well understood. 
 
 
Figure 5. Activation of microglia in a patient after ischemic stroke 
[11C](R)-PK11195 PET and MRI scans for patient 2 at different time points: Patient 2 was 
examined 5 (a) and 13 (b) days after the infarct. (e) and (f) illustrate the relationship between 
the increasing size of the post-ischemic lesion delineated by T1-weighted MRI hypointensity 
and the changes in the distribution pattern of increased [11C](R)-PK11195 binding after 5 (e) 
and 13 (f) days, respectively. (Reprinted from NeuroImage, 24, Gerhard et al., Evolution of 
microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study, p593., 
Copyright (2005), with permission from Elsevier). 
 
These stimulated microglial cells rapidly proliferate to focal sites of injury due to an 
increasing expression of immunoreactive cell surface molecules and to the secretion of 
various pro- and anti- inflammatory molecules as well as chemotactic factors which 
induce the recruitment of other microglial cells. The morphological changes are 
accompanied by an increased expression of cytokines: interleukins (IL1β, IL4, IL6, 
IL10), tumor necrosis factor-α (TNFα), interferons and chemokines such as MCP1 and 
GROα (or KC) (Hanisch, 2002; Garden & Möller, 2006). The surrounding astrocytes 
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are sensitive to the increased release of these immunomodulatory molecules and 
undergo enlargement of cell bodies and thickening of processes as well. Activated 
astrocytes modulate in turn the phagocytotic functions of microglia, and promote the 
expression of adhesion molecules in the neurovascular unit on endothelial cells and 
circulating leukocytes. (Stoll et al., 1998). Glial cells secrete also different factors that 
are neuroprotective, like the nerve growth factor and brain-derived neurotrophic factor 
(BDNF) (Matsushima et al., 1998). On one hand, the release of these protective factors 
and inflammatory molecules may contribute to the rescue of damaged neurons and 
restrain the propagation of the injury, on the other hand the massive accumulation of 
inflammatory mediators and activated inflammatory cells may enhance the neuronal 
death. 
 
1.5.2 Inflammatory cells 
Shortly after the onset of injury the blood brain barrier opens by the disruption of the 
endothelial tight junctions (Zoppo & Hallenbeck, 2000). As mentioned above the 
release of inflammatory mediators from activated glial cells induces in turn the 
expression of proteins on the outer cell membrane of vascular endothelial cells. The 
opening of the barrier and the release of inflammatory mediators leads to the migration 
of circulating immune cells to the site of injury (Gelderblom et al., 2009). Infiltration of 
leukocytes (monocytes, neutrophils, lymphocytes) occurs in three steps: rolling on the 
surface of endothelial cells, adhesion to the endothelial wall and migration or 
diapedesis. The initial capture and migration is mediated by three main groups of cell 
adhesion molecules: selectins (P-, E- and L-selectins), immunoglobulins (VCAM-1, 
ICAM-1) and integrins (CD11a-c) (Petty & Wettstein, 2001; Sughrue et al., 2004). 
Activation and accumulation of leukocytes in the injured parenchyma results in the 
production of several agents in the ichemic tissue, such as reactive oxygen species 
(nitric oxide, superoxide) and metalloproteinases (Iadecola et al., 1999; Zoppo et al., 
2000; Zhu et al., 2002). Their up-regulation triggers damage to the DNA and other cells 
constituants as well as the extracellular matrix and basal lamina (Dirnagl, 1999; Rosell 
et al., 2008). These factors potentiate neuronal death and may contribute to 
hemorrhagic complications after ischemic stroke. On the contrary, some of the agents 
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released might be protective, such as for instance nitric oxide which inhibits platelet 
aggregation (Iadecola, 1997). 
 
Inflammation following cerebral ischemia differs by some aspects from inflammation 
of peripheral tissues. In the periphery, dendritic cells (DCs) participate to the immune 
response during local infection or other inflammatory situations. They are professional 
antigen-presenting cells which lead to the stimulation of T lymphocytes against 
pathogenic antigens (Steinman, 1991). The central nervous system was thought to be an 
immunologically privileged site and would not normally contain dendritic cells 
(Pedemonte et al., 2006). However, increased numbers of DCs in the ischemic 
parenchyma were observed in a permanent model of cerebral ischemia and the increase 
was correlated with the brain lesion area (Kostulas et al., 2002). In an other mouse 
experimental model of stroke, DCs were found in the border zone of the infarct and 
remote from the lesion and seemed to be associated with phagocytosis function 
(Reichmann et al., 2002). Thus tissue injury could lead to the activation of DCs in the 
parenchyma. Others by using labeled DCs transgenic mice found resident DCs in the 
healthy brain which increase in number and up-regulated the major histocompatibility 
complex II (MHC II) after transient experimental cerebral ischemia. Therefore they 
would be able to act as antigen-presenting cell and stimulate T cells (Felger et al., 
2010). Thus, interestingly DCs could be resident immune cells of the brain and can be 
activated upon injury. This activation seems to be associated with phagocytosis and 
stimulation of T cells. Furthermore, Felger and colleagues showed that peripheral DCs 
could also infiltrate the ischemic parenchyma. Indeed due to the leakage of the blood 
brain barrier (BBB) after cerebral ischemia, cells from the periphery invade the 
parenchyma and it is postulated that by their capability to phagocytose dead cells, DCs 
would have immunogenic competence, activate T lymphocytes and enhance the 
inflammatory response in the brain tissue (Savill et al., 2002; Felger et al., 2010). 
However the function of DCs in the central nervous system (CNS) is not well 
characterized. Their role as immuno-competent cells and their contribution to damage 
require further investigations. 
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1.5.3 Ambivalent aspects of interleukin-6 (IL6) following ischemic stroke 
Several clinical and experimental studies have found that cerebral ischemia promotes 
an important secretion of IL6 in the brain, in the cerebrospinal fluid (CSF) and in the 
systemic circulation. Indeed, the serum level of IL6 stroke patients was elevated early, 
within 24 h after the injury and sustained up to 5 to 7 days (Emsley et al., 2003). This 
increased concentration of IL6 was correlated with lesion size, early neurological 
impairment, body temperature and long-term poor outcome [for review see: (Suzuki et 
al., 2009; Denes et al., 2010a)]. However, Tarkowski and colleagues showed that only 
increased initial CSF level of IL6 and not the serum level was associated with infarct 
volume 2 to 3 months after stroke (Tarkowski et al., 1995). They also suggest that the 
main source of cerebral IL6 was the brain since IL6 level in the CSF was significantly 
higher than systemic level. Even though the exact origin of the peripheral IL6 is 
unknown, the fact that CSF concentrations are higher than serum concentrations at 
early time points strongly suggests that the source of IL6 is in the brain. Furthermore 
IL6 cellular localization in a context of experimental cerebral ischemia was principally 
in neurons as well as in glial cells (microglia and astrocytes) and endothelial cells 
(Suzuki et al., 2009). Additionnally, autopsy of a stroke patient showed IL6 positive 
neurons (Suzuki et al., 2002). Regarding the early increase of IL6 in the plasma and 
CSF and its correlation with infarct volume, IL6 was proposed as an early biomarker 
for ischemic lesion and poor outcome. However, it is not clear whether the production 
of IL6 in stroke patients may be the result and not the cause of enlarged cerebral 
infarction, and whether the IL6 increase is linked to other mechanisms such as 
physiological stress, previous inflammatory disease or vascular risk factors, or both 
(Zhou et al., 1993; Dziedzic et al., 2003). Instead, many experimental studies propose a 
non-detrimental effect of IL6 following experimental cerebral ischemia. A 
neuroprotective effect of exogenous IL6 has been observed in cultured cortical neurons 
exposed to NMDA-induced excitotoxic necrosis and in vivo 24 h after permanent 
MCAO (Loddick et al., 1998; Ali et al., 2000). However, in a model of transient 
MCAO of IL6 deficient mice, the infarct size and neurological function were not 
different from the control group (Clark et al., 2000). To clarify the endogenous role of 
IL6 mediated neuroprotection, an anti-mouse IL6 receptor monoclonal antibody (IL6-
 16 
ra) was administered to mice after MCAO (Yamashita et al., 2005). IL6 has been 
described to activate the intracellular Janus Kinase-Signal Transducer Activator of 
Transcription (JAK-STAT) pathway, which leads to the phosphorylation of Stat3 in 
neurons and subsequent modulation of expression of target genes. In normal conditions 
Stat3 is not phosphorylated, whereas a peak of activation is seen 24 h after MCAO 
(Suzuki et al., 2001). Yamashita and colleagues have shown that IL6-ra administration 
inhibits Stat3 phosphorylation and that was correlated with enlarged infarct volume. 
Furthermore, the majority of apopotic cells (caspase-3 positive) were p-Stat3 negative. 
Therefore, p-Stat3 activation mediated by IL6 might be associated with neuroprotection 
(Yamashita et al., 2005; Wang et al., 2009).  
 
The role of IL6 release after cerebral ischemia remains complex and ambivalent. 
Suzuki and colleagues suggest that IL6 secretion might be time dependent as illustrated 
in Figure 6 (Suzuki et al., 2009). 
 
 
Figure 6. Ambivalent aspects of interleukin-6 after cerebral ischemia 
In the CNS, IL6 works as an inflammatory cytokine during the acute phase of cerebral ischemia 
and may contribute to both injury and repair. However, the peak in IL6 expression is associated 
with neuroprotection in conjunction with leukemia inhibitory factor (LIF) and ciliary neurotrophic 
factor (CNTF). (Reprinted from Journal of Cerebral Blood Flow & Metabolism 29, Suzuki et al., 
Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic 
aspects, p474., Copyright (2009), with permission from nature publishing group). 
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1.5.4 Role of chemokines following ischemic stroke 
Chemokines are highly up-regulated during cerebral ischemia. The CXC chemokines 
are capable of inducing migration and activation of neutrophils into inflammatory sites. 
An increase level of CXC chemokines such as CXCL1 (also named keratinocyte-
derived chemokine KC or growth-regulated oncogene (GRO)/cytokine-induced 
neutrophil chemoattractant (CINC) in rodents which has the same function as IL8 in 
human) was found in the brain in pathological conditions. The major source of CXC 
chemokines upon brain injury are activated microglia, astrocytes, endothelial cells and 
infiltrated neutrophils, but not neurons [for review see (Semple et al., 2010)]. Transient 
cerebral ischemia in the rat correlated with an increase of CINC concentration first in 
the systemic circulation and then in the brain, preceeding brain neutrophilic infiltration 
(Yamasaki et al., 1995). Others have found the same spatial and temporal pattern of 
chemokine secretion and support the role of this chemokine leading to the potentiation 
of neutrophil-induced brain injury (McColl et al., 2007; Chapman et al., 2009). McColl 
and colleagues showed as well a reduction of the lesion volume and severity of the 
neurological deficit in neutrophil-depleted mice challenged to IL1β, suggesting that 
IL1β-mediated recruitement of neutrophil via CXC chemokines induction is 
detrimental for outcome after experimental stroke (McColl et al., 2007). Furthermore, 
repertaxin, an inhibitor for the receptor of the inflammatory chemokine CXC ligand 8 
(CXCL8/IL8) was shown in transient cerebral ischemia to reduce neutrophilic 
infiltration, infarct volume, long-term reactive gliosis and microglial staining and, 
importantly, to improve the long-term outcome (Garau et al., 2005; Villa et al., 2007). 
Peripheral blood of patients with ischemic stroke was assessed for circulating IL8 and 
blood mononuclear cells expressing IL8 mRNA from day 1 to day 7 after onset, both 
were elevated compared to healthy patients (Kostulas et al., 1998). Systemic circulation 
of chemokines and their secretion in the ischemic parenchyma could lead to a 
concentration gradient over the BBB and would promote the influx of neutrophils into 
the damaged area. 
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1.6 IMMUNOSUPPRESSION FOLLOWING STROKE 
 
Systemic inflammation is important in the context of stroke. Indeed there is clinical 
studies supporting the concept that systemic inflammation can be: 1) a risk factor for a 
stroke (McColl et al., 2009) and 2) a response to brain injury. It has been suggested that 
the latter could influence the outcome and long-term prognosis following stroke. 
 
Bacterial pneumonia is the most frequent severe infectious complication occuring after 
stroke. It is estimated that 10% of deaths following admission for stroke are caused by 
pneumonia (Prass et al., 2006; Chamorro et al., 2007; Emsley & Hopkins, 2008). In an 
experimental model of cerebral ischemia Prass and colleagues showed that mice 
suffered from spontaneous bacterial infections within three days. The infection was 
accompanied with reduction of lymphocyte counts in the blood and the spleen already 
within a few hours after ischemia and lasting for several weeks (Prass et al., 2003). 
This phenomenon of brain-induced immunosuppression is also described in stroke 
patients with some evidence that these systemic changes occur before clinical 
manifestations of infection [for review see (Meisel et al., 2005; Emsley & Hopkins, 
2008)]. This suggests that the peripheral immune system and the central nervous 
system are closely related, so that a brain injury causes a systemic immunological 
response. However, the mechanism by which the CNS injuries trigger immuno-
supression remain unknown. One can assume that in response to the activation of 
numerous inflammatory cells and mediators in the ischemic tissue, the nervous system 
would counteract this response by the release of immunomodulators which 
downregulate the immune system. On the other hand, infections occuring after stroke 
might be a cause of adverse conditions of the patients as, for instance, immobilization, 
invasive procedures or dysphagia. Studies on the influence of post-stroke infection on 
clinical outcome have been disappointing due to confounding factors (Emsley & 
Hopkins, 2008). 
 
There is evidence of systemic inflammation occurring after stroke but whether there is 
a direct link between these ‘supersystems’ (Tada, 1997): the nervous system and the 
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immune system, is still not well defined. Overall a better understanding of the 
relationship between the brain and the immune system might lead to more effective 
therapies in patients with acute stroke. 
 
1.7 NEUROPROTECTION TARGETING INFLAMMATION 
 
The general hypothesis that inflammation following cerebral ischemia could harm the 
brain and contribute to the progression of the damage comes initially from 
experimental studies focusing on the inhibition or reduction of post-stroke 
inflammation. 
 
1.7.1 Targeting inflammatory cells and immunomodulators 
Different strategies aimed at preventing the inflammatory response after cerebral 
ischemia have been successful in rodent models. Ischemic damage was shown to be 
attenuated: by inhibition of microglial activation using the minocycline tetracycline 
derivative, by systemic leukocyte depletion, by diminishing the free radical generating 
enzymes such as the inducible nitric oxyde synthase (iNOS) or the cyclooxygenase-2 
(COX-2), by inhbition of cytokines secretion or by reduction of proteolytic degradation 
of the BBB [for review (Dirnagl, 1999; Iadecola & Alexander, 2001; Benakis et al., 
2009]. 
 
1.7.2 Targeting inflammatory gene expression 
The secretion of inflammatory mediators is tightly regulated by intracellular signaling 
pathways [for review see: (Kaminska, 2005)]. The strength and duration of the 
induction of inflammatory genes expression is essential to adapt correctly the intensity 
of the inflammatory response. Krause and colleagues showed that the JNK pathway, 
upon activation by a stress stimuli, namely IL1, induced the expression of IL6 and the 
chemokine IL8 (the human ortholog of CXCL1/KC) through the AP-1 complex in 
human keratinocyte cells (Krause et al., 1998; Holtmann et al., 1999). Thus modulation 
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of the JNK pathway could regulate the expression level of inflammatory mediators and 
might give insights on their function in cerebral ischemia. 
 
Based on the hypothesis that inflammatory mediators enhance the damage of the 
ischemic tissue, several studies have found beneficial outcome by inhibiting gene 
expression of pro-inflammatory cytokines (del Zoppo et al. 2000). In reaction to stress 
signals p38 and JNK pathways positively regulate transcription of inflammatory genes, 
such as those coding for TNFα, IL1β, IL6, IL8 (Waetzig et al., 2005). The role of p38 
and JNK on the regulation of transcription of these inflammatory mediators makes 
them interesting targets for anti-inflammatory therapeutic intervention [for review see 
(Barone & Feuerstein, 1999; Kaminska, 2005)]. The inhibition of these intracellular 
pathways activated upon injury leads to a reduction of inflammatory molecule 
production, as for instance using the upstream inhibitors of both JNK and p38 
pathways: CEP1347, which reduces the production of cytokines after 
lipopolysaccharide (LPS) administration induced cytokine release in human and murine 
microglia, as well as after intracerebroventricular injection of LPS in mice (Lund et al., 
2005). Using SP600125, a JNK inhibitor, Waetzig and colleagues showed that upon 
LPS stimulation of microglial cell cultures, there was a reduction of the induction of 
the AP-1 target genes: COX-2, TNFα, MCP1 and IL6 (Waetzig et al., 2005). However, 
Nijboer and colleagues showed that in a model of perinatal hypoxia-ischemia of rats, 
the inhibitor of JNK: L-JNKI1 was neuroprotective but did not reduce the expression of 
cytokines and chemokines (Nijboer et al., 2010). Because of the redundancy and 
overlap of inflammatory mediator function in vivo, it is uncertain that a specific 
inhibitor targeting a single site would have any detectable effect on the reduction of 
inflammatory molecules. Besides others have found opposite results using the mixed-
lineage kinases inhibitor: CEP-11004, the release of cytokines was enhanced when 
JNK was inhibited in cultivated microglia (Hidding et al., 2002). Thus, the inhibition or 
activation of inflammatory gene expression might dependent of: the cellular type, the 
target of the inhibitors and their concentration, the model used (in vitro or in vivo) and 
the type of stimulation. 
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1.7.3 Bench to clinical trials  
Unfortunately attempts to translate anti-inflammatory therapeutic interventions to 
stroke patients have been more disappointing than promising. For instance, the 
selective IL1 receptor antagonist, IL1-ra, which limits the pro-inflammatory action of 
IL1, has been tested in randomised patients with acute stroke (Emsley et al., 2005). 
Despite a conclusive phase II study no recent publications have reported the 
recombinant human IL1-ra as a therapeutic agent for acute stroke. More than a 
thousand potential agents underwent clinical evaluation (O'Collins et al., 2006). 
However none of these drugs have demonstrated benefit in stroke clinical trials as for 
instance the application of murine mono-clonal anti-ICAM-1 in the Enlimomab trial 
(Enlimomab Acute Stroke Trial Investigators, 2001) and NXY-059, a nitrone-based 
free radical trapping agent (Lees et al., 2006). Reasons for failure have been 
highlighted in the sections above and include morphological and functional differences 
between rodents and humans, timing of the intervention, ambivalent role of 
inflammatory mediators as well as evaluation of efficacy, pharmacokinetic issues 
(plasma concentration of drugs) and side effects [for review (Dirnagl, 2006)]. Anti-
inflammatory strategies have also in some cases promoted deleterious infections and 
fever (Enlimomab Acute Stroke Trial Investigators, 2001). 
 
Until now, researchers have focused mostly on the negative role of inflammation after 
stroke and thus have attempted to inhibit post-stroke inflammation. Nevertheless, there 
is evidence suggesting that inflammation might also be beneficial in stroke: it is a 
crucial mechanism to clear damaged tissue after an infarction, it promotes 
angiogenesis, tissue remodeling and regeneration (Dirnagl, 1999; Chamorro & 
Hallenbeck, 2006). Therefore, there is clearly a need to better understand the subtle 
balance between the beneficial and deleterious effects of inflammation in stroke. 
Furthermore, experimental studies on cerebral ischemia have mostly targeted one single 
cell type: neurons, while endothelium, astrocytes and microglia have been considerably 
neglected; or studies were focused on one single target rather than several targets as for 
instance different signaling pathways which are involved in the production of 
inflammatory mediators and apopototic proteins.  
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Future research on experimental stroke models should consider the important role of 
non-neuronal cells, the bivalent function of inflammation and probably the time 
dependency of post-stroke cellular and molecular mechanisms. A better insight in these 
aspects is important before planning future clinical trials. 
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AIMS OF THE PRESENT WORK 
 
The aim of the present work was to explore the contribution of the JNK pathway in the 
modulation of neuro-inflammation using the specific inhibitor D-JNKI1 in 
experimental models of cerebral ischemia, in the purpose to better understand: 1) how 
D-JNKI leads to its neuroprotective effect and 2) the role of inflammation following 
stroke. 
 
FIRST PART: EFFECT OF NEUROPROTECTION ON INFLAMMATORY CELLS 
 
Our objective was to test whether D-JNKI1 can modulate the JNK pathway in 
microglia and if this contributed to the strong neuroprotective effect of delayed D-
JNKI1 administration in our stroke models. First, we examined whether the activation 
of microglia was modulated in D-JNKI1-treated animals, subjected to transient MCAO 
in mice by investigating morphological changes and accumulation of microglia within 
the infarct area. Secondly, we looked at the cellular localization of D-JNKI1 and its 
effect on microglia in an in vitro model of cerebral ischemia.  
 
SECOND PART: EFFECT OF NEUROPROTECTION ON THE SECRETION OF 
INFLAMMATORY MEDIATORS 
 
Our second objective was to investigate the role of D-JNKI1 on the release of 
inflammatory mediators in the systemic circulation, peripheral organs and in the brain 
tissue following transient MCAO in mice.  
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2. METHODS 
 
2.1 ANIMALS 
Outbred male Crl:CD1/ICR mice (25-35 g, 4- to 5-week-old) and gestant Sprague-
Dawley (OFA) rats were purchased from Charles River Laboratories Inc. (Charles 
River France, L’Abresle, France). All procedures were in accordance with the Swiss 
Law and were approved by the Swiss Federal Veterinary Office. 
 
2.2 TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION (MCAO) 
Focal cerebral ischemia was induced in CD1 mice using the filament method [see 
(Wiegler et al., 2008) and references therein]. Mice were anesthetized with isoflurane 
(induction: 3%, maintenance: 1.8% and reperfusion: 1.8% to 0%) in 70% nitrous oxide  
and 30% oxygen using a face mask. Body temperature was maintained at 37 ± 0.5°C 
throughout surgery (FHC Inc., Bowdoinham, ME, US). Regional cerebral blood flow 
(CBF) was continuously recorded by laser Doppler flowmetry (LDF, Periflux 5000, 
Perimed, Sweden) with a fiber optic probe fixed on the left lateral surface of the skull 
(1 mm posterior and 6 mm lateral from the bregma) during a period covering the 
induction of ischemia until 10 min after the end of ischemia. Transient cerebral 
ischemia (30 min, 45 min or 60 min) was induced by occlusion of the left middle 
cerebral artery (MCA). A silicone-coated nylon monofilament (diameter: 0.17 mm, 
Doccol Co., Redlands, CA, USA) was inserted through the common carotid artery and 
advanced into the internal carotid artery until mild resistance was felt and a decrease of 
CBF below 20% of the baseline indicated occlusion of the origin of the MCA. The left 
MCA was occluded for a given time and then the filament was withdrawn to allow 
reperfusion above 50% of the CBF baseline. Mice were given 0.025 mg/kg of 
buprenorphine subcutaneously for post-surgery analgesia and were housed in an 
incubator at 31°C for 24 h for recovery. Sham animals underwent the same procedure 
except for the MCA occlusion and were anesthetized during the same time as MCAO 
mice. 
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2.3 GROUPS, TREATMENT AND NEUROLOGICAL DEFICITS 
2.3.1 Intra-venous administration of D-JNKI1 
Randomly, saline solution used as a vehicle solution (NaCl 0.85% Medium, 
bioMérieux) or D-JNKI1 (0.1 mg/kg, manufactured by NeoMPS, obtained from Xigen 
SA, Epalinges, Switzerland) was injected intravenously (i.v.) into the tail vein of CD1 
mice using a 1 ml syringe (Omnifix - 1 ml, Terumo needle 25G) and a mouse restrainer 
(Braintree Scientific Inc.) 3 h after ischemia onset. Sham mice received saline solution, 
or D-JNKI1 in a separate set of experiment. 
 
2.3.2 Neurological deficit 
The mice were sacrificed at different time points after MCAO. The lesion volume was 
quantified 48 h after cerebral ischemia. The neurological deficit was evaluated just 
before sacrifice. Neuroscore was graded for severity using the following scale: 0 = no 
observable neurological deficit, 1 = failure to extend the right forepaw, 1.5 = 
intermittent circling behavior, 2 = circling behavior, 3 = loss of walking or uncontrolled 
movement (Bederson et al., 1986; Hirt et al., 2004). 
 
2.4 QUANTIFICATION OF NEURONAL DAMAGE 
Mice were anesthetized with intra-peritoneal injection of 8 mg/kg xylazine (Rompun® 
2%, Bayer) + 100 mg/kg ketamine (Ketanarkon 100, Streuli Pharma AG) and 
transcardially perfused with phosphate buffer solution (PBS) followed by 4% 
paraformaldehyde (PFA). In Figure 7, mice were sacrificed, brains were removed and 
directly frozen in liquid nitrogen vapor. Serial coronal 20-µm thick, 620-µm (perfused 
brain) or 720-µm (frozen brain) distant cryostat sections were used for lesion size 
measurements. Digitalized images of the Nissl stained tissue were acquired under a 
light stereomicroscope (Leica MZ16FA) and the ischemic area was measured by a 
blinded observer with ImageJ 1.38x software (NIH, http://rsb.info.nih.gov/ij/). The 
direct infarct volume was calculated by multiplying the sum of the infarct areas on each 
section by the distance between the sections. For a separate set of experiments (Figure 
21), lesion size was evaluated qualitatively using 2,3,5-triphenyltetrazolium chloride 
(TTC, Sigma-Aldrich) staining (Schilichting et al., 2004). Mice were sacrificed and 
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brains were removed, sliced in 2-mm-thick sections and one slice was stained with 2% 
TTC for 10 min at in the dark at room temperature (RT), followed by an overnight 
fixation with PFA. 
 
2.5 ORGANOTYPIC HIPPOCAMPAL SLICE CULTURES (OHC) 
Three hundred and fifty micrometers thick coronal hippocampal slices from 10- to 12-
day-old Sprague-Dawley rats were cultured on porous membrane units (Millicell-CM, 
Millipore, UK) in wells containing 1 ml of culture medium with 25% horse serum 
(Oxoid, UK), 50% minimal essential medium supplemented with HEPES and sodium 
bicarbonate (MEM, Gibco, UK), 25% Hanks’ balanced salt solution (HBSS, Gibco, 
UK), 2 mM L-glutamine and 36 mM D-glucose. Cultures were grown at 33°C, 100% 
humidity and 5% CO2. After 3 days the medium was replaced by fresh culture medium 
and, after 6 days, by a medium with 15% horse serum, 60% MEM, 25% HBSS, 2 mM 
L-glutamine and no glucose (Badaut et al., 2005). 
 
2.6 OXYGEN AND GLUCOSE DEPRIVATION (OGD) 
Hippocampal slice cultures were subjected to in vitro ischemia by exposure to reduced 
oxygen and glucose concentrations as described previously (Hirt et al., 2004). At day 8, 
slices were transferred to a serum-free hypoglycemic medium, DMEM (D5030; Sigma, 
USA) supplemented with 1 mM D-glucose and 2 mM L-glutamine, in a humidified 
hypoxia chamber (COY, USA) with a hypoxic atmosphere of 5% O2, 5% CO2 and 90% 
N2 at 37°C for 30 min. Control cultures were placed at 37°C for 30 min, in a humid 
normoxic atmosphere. D-JNKI1 diluted in PBS (final concentration 12 nM) or an equal 
volume of PBS was added 6 h after OGD. Cell death was determined in the CA1 region 
using the fluorescent viability indicator propidium iodide (PI, final concentration 5 
µg/ml, Sigma). PI fluorescence emission (excitation wavelength 568 nm) was measured 
48 h after OGD and quantified densitometrically, using ImageJ software. After 
subtracting the background fluorescence, the results were expressed as a percentage of 
maximal cell death obtained by incubating the hippocampal slice cultures in PBS for 24 
h at 4°C. Cell death was averaged for the four slices of each culture. 
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2.7 IMMUNO-STAINING 
2.7.1 Staining of degenerating neurons: FluoroJade B 
FluoroJade B staining (0.0004% FluoroJade® B, Millipore, UK) was performed on 
frozen sections according to the Chemicon International Company protocol. Sections 
were then mounted in Eukitt (O. Kindler GmbH & Co., Freiburg, Germany). 
 
2.7.2 Immunohistochemistry staining for glial and inflammatory cells 
Sections were blocked in 0.3% H2O2 for 20 min at RT followed by 10% normal goat 
serum (NGS, Invitrogen, Paisley, UK) in PBS with 1% bovine serum albumin (BSA) 
for 1 h at RT. Sections were incubated overnight at 4°C with the following primary 
antibodies: rat anti-CD11b (Mac-1, 1:100, AbD SEROTEC) or biotinylated Isolectin 
B4 (IB4, 1:500, Griffonia simplicifolia lectin I, Vector Laboratories) to label microglia, 
mouse anti-GFAP (1:500, Millipore) for astrocytes, hamster anti-TCRbeta (1:200, 
BioLegend) for T lymphocytes, hamster anti-CD11c (1:200, BioLegend) for dendritic 
cells. Using the immunoperoxidase method, biotinylated anti-rat (1:500, BA-9400, 
Vector Laboratories, Burlingame, CA), anti-mouse (1:500, Vector Laboratories, 
Burlingame, CA) or anti-hamster (1:500, Biolegend) IgG antibodies were applied for 1 
h followed by avidin-biotin-horseradish peroxidase complex (Vectastain kit, Vector 
Laboratories, Burlingame, CA). Incubation with biotinylated secondary antibody was 
omitted for Isolectin B4. The immunocomplex was visualized by 3,3’-
diaminobenzidine (DAB kit, Vector Laboratories, Burlingame, CA) and mounted with 
Eukitt. 
 
2.7.3 Double immunofluorescence 
After blocking in 10% NGS (±0.1% Triton X-100) sections were incubated overnight at 
4°C in various combinations of the following primary antibodies: mouse anti-NeuN 
(1:500, Millipore), mouse anti-GFAP (1:500), biotinylated Isolectin-B4 (1:500) and 
rabbit anti-phospho-c-Jun(Ser63) or phospho-c-Jun(Ser73) (1:100, Cell Signaling). 
Antigens were visualized with the appropriate fluorochrome-conjugated secondary 
antibodies: alexa fluor 488 anti-rabbit (1:500, Invitrogen), alexa fluor 594 anti-mouse 
(1:500, Invitrogen), Cy3-conjugated Streptavidin (1:500, Jackson ImmunoResearch 
 29 
Laboratories) for 1 h at RT. Sections were counterstained with DAPI (1:10,000, 1 
mg/ml, SIGMA) and mounted in Vectashield Mounting Medium (Vector Laboratories, 
Burlingame, CA). Images were acquired with the Aviovision v3.1 software in a Zeiss 
Axiovision microscope. No specific immunoreactivity was observed in control sections 
prepared by omitting primary antibodies. 
 
2.7.4 Immunofluorescence on OHC 
OHC were fixed in 4% paraformaldehyde for 1 h at 4°C, blocked 1 h at RT in 10% 
NGS and incubated overnight at 4°C with the following primary antibodies: 
biotinylated IB4 (1:500), mouse anti-NeuN (1:500), rabbit anti-phospho-c-Jun(Ser63) 
or phospho-c-Jun(Ser73) (1:100) and rabbit anti-D-JNKI1 (1:300, Xigen SA). After 
rinsing in PBS, slices were incubated with Cy3-conjugated Streptavidin (1:5000), alexa 
fluor 594 anti-mouse (1:200) or alexa fluor 488 anti-rabbit (1:200) for 1 h at RT, 
mounted using Vectashield Mounting Medium and viewed under a Leica SP5 confocal 
laser-scanning microscope. 
 
2.8 QUANTIFIACTION OF CD11B POSITIVE MICROGLIAL CELLS 
The rat CD11b antigen was revealed using the secondary antibody IRDye 800-labeled 
anti-rat IgG (1:2,000, Rockland) for 1 h at RT. CD11b infra-red emission was 
measured at 800 nm with an Odyssey infrared imaging scanner (Li-COR, Biosciences, 
Lincoln, Nebraska, USA). The sections were counterstained with Nissl after the first 
scan to avoid detection of Nissl blue staining in the 800 nm channel, and rescanned at 
700 nm for delimitation of the ischemic zones. The average intensity of microglia 
(AvIntCD11bTotal) was calculated within the ischemic region for each brain as follows: 
AvIntCD11bTotal = (ΣiRawIntensity/Σipixels) - AvIntBackground, with i = ith coronal 
section of a brain, ΣiRawIntensity/Σipixels = AvIntCD11b without background 
correction and AvIntBackground = average intensity of the background measured by 
omitting the primary antibody. One animal was excluded in the vehicle-treated group, 
because of unconvincing IRD-800 labelling. 
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2.9 PREPARATION OF SAMPLES FROM CD1 MICE FOR CYTOKINE/ 
CHEMOKINE RELEASE ASSAY  
 
Plasma was obtained from anticoagulated (1/16 v/v of 4% Sodium Citrate) cardiac 
blood samples after centrifugation with 2,500 rpm for 15 min at 4°C. Control (no 
surgical procedure), MCAO or sham mice were transcardially perfused with PBS. 
Brain, spleen, liver and lung of mice were removed for organs culture. Two millimeters 
thick coronal brain slices and a fifty square milimeter fragments of spleen, liver and 
lung were incubated in wells containing 1.5 ml of DMEM culture medium (Dulbecco’s 
Modified Eagle Medium 1X, 4.5 g/L Glucose, L-Glutamine, GIBCO) with 10% horse 
serum (Oxoid, UK) and supplemented with 11.0 mg/ml Sodium Pyruvate (100 mM, 
SIGMA) and 10 ml/L Penicilin : Streptomycin (SIGMA). Organs were incubated for 
20 h in a cell culture incubator at 37°C with 5% CO2 humidified air. The next day the 
liquid supernatants were removed and centrifuged for 5 min at room temperature 
(20°C) with 12,000 rpm. The supernatants were collected and frozen at -80°C. Plasma 
and supernatants samples were stored at -80°C until use for Enzyme-linked 
Immunosorbent Assay (ELISA). 
 
2.10 PROTEIN EXTRACT FROM ORGAN CULTURES 
Brain slices and fragments of spleen, liver and lung were homogenised in buffer (62.5 
mM Tris-HCl pH 6.8, 50 mM DTT, 0.3% SDS) containing protease inhibitors. Each 
fragment was first chopped with scissors and then sonicated for 10 sec. After 
centrifugation (10,000 rpm, 15 min, 4°C), supernatants were collected and protein 
concentrations was calculated according to the Bradford method (Bradford, 1976). 
 
2.11 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) ON PLASMA AND 
ORGANS CULTURE SUPERNATANTS 
 
Plasma and culture supernatants from brain, spleen, liver and lung of control, sham 
(vehicle or D-JNKI1) and MCAO (vehicle or D-JNKI1) mice were tested by ELISA for 
detection of the mouse Interleukin-6 (IL6, OptEIA TM Set, BD Biosciences) and the 
mouse Keratinocyte Chemoattractant protein (CXCL1/KC, DuoSet ELISA 
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Development System). Ninety six-well plates were coated with 100 µl anti-mouse IL6 
(70 ng/ml, 1/500) or KC (360 mg/ml, 1/360) capture antibody in 0.1 M Sodium 
Carbonate or PBS coating buffer. Plates were incubated at 4°C over-night, washed 
three times with buffer (1X PBS, 0.01% Tween 20) and blocked with assay diluent (1X 
PBS + 10% FCS or 1% BSA) for 1 h at RT. Plates were then washed three times and 
50 µl of sample (1/3 for plasma and 1/5 for supernatant samples) or standard was added 
to each well. After 2 h incubation at RT, plates were washed three times. IL6 plates 
were incubated with 50 µl of the working detector solution (1/250 Detection Ab, 1/250 
Sav-HRP) 1 h in the dark while KC plates were first incubated in 50 µl of KC detection 
Ab (1/160) for 2 h at RT, followed by a wash step and then 50 µl of the diluted Sav-
HRP (1/200) was added for 20 min at RT in the dark. IL6 and KC plates were then 
washed five times. This was followed by addition of 50 µl TMB chromogen (DAKO, 
DiaLine). The color was allowed to develop for 15-20 min, and the reaction stopped by 
adding 50 µl stop solution (1 M H3PO4). Optical density was then measured at 450 nm.  
 
2.12 STATISTICAL ANALYSIS 
Results were expressed as mean ± SD (lesion volume) or SEM (inflammatory 
mediators release), except for neurological scores which were expressed as [median, 
min, max]. For comparing two groups, Student’s t-test (two-tailed) was used 
(GraphPad Prism software 5.0). Analysis of correlation were done using the SAS 
software package. Normalization test was performed to check for significant violations 
in the distribution assumptions. For the analysis of the cytokine/chemokine 
concentrations in the second part of the results, were transformed into square-roots to 
obtain a normal distribution. Comparison of three or more groups was done by one-way 
or two-way ANOVA. For post-hoc comparisons, a Brown-Forsythe test for equality of 
variances between groups was first performed, followed by Tukey comparisons of 
means when variances were equal or Games–Howell test when variances were unequal 
(JMP Version 9.0.0 and IBM SPSS statistics Version 19.0.0). For analysis of survival 
difference between groups, the product limit method of Kaplan and Meier was used, 
and comparison of survival curves using the Log-Rank test. P values < 0.05 were 
considered significant. 
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3. RESULTS 
 
FIRST PART: EFFECT OF NEUROPROTECTION ON INFLAMMATORY 
CELLS 
 
3.1 EVALUTAION OF THE INFARCT VOLUME 48 H AFTER TRANSIENT 
MCAO UNDER ISOFLURANE ANESTHESIA IN CD1/ICR MICE 
 
Because of toxicity issues, our lab replaced halothane anesthesia by isoflurane. Several 
durations of ischemia were tested under isoflurane anesthesia in order to match the 
lesion volume to our previously published data under halothane anesthesia (Clarkson, 
2007; Wiegler et al., 2008). We hypothesized that the longer the ischemia lasts, the 
more we would obtain necrotic cell death and the less the anti-apoptotic peptide D-
JNKI1 would have an effect on reducing the lesion size. Similarly, if the mice are less 
exposed to ischemia, the lesion volume would be smaller and the efficiency of the 
treatment would be harder to detect. Mice were subjected to ischemia for 30 min, 45 
min or 60 min. The direct infarct volume was quantified on Nissl stained brain sections 
48 h after the beginning of the occlusion. Figure 7 shows the direct lesion volume after 
30 min MCAO (V = 15.7 ± 7.0 mm3, n = 7), 45 min (V = 39.6 ± 14.8 mm3, n = 4) and 
60 min (V = 77.9 ± 6.9 mm3, n = 4). As we found a smaller lesion volume than 
previous experiments for the same duration of ischemia (30 min: 62 ± 14.8 mm3, 
Wiegler et al 2008), we chose to adapt the time of ischemia. Accordingly, MCAO was 
performed for 30 min (Figure 8, Figure 11 and Second part) or 45 min (First part).  
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Figure 7. Infarct volume after transient MCAO 
Mice were sacrificed 48 h after MCAO, brains were removed and directly frozen in liquid 
nitrogen vapour. Quantification of the direct infarct volume on Nissl stained coronal brain 
sections after 30 min, 45 min and 60 min MCAO shows a bigger infarct as a function of the 
duration of the occlusion: 15.7 mm3 (30 min) <  39.6 mm3 (45 min) < 77.9 mm3 (60 min). Results 
are presented as mean ± SD, n = 4 to 7. 
 
3.2 TRANSIENT MCAO INDUCES AN ACCUMULATION OF INFLAMMATORY 
CELLS IN THE ISCHEMIC TISSUE AT 48 H 
 
In order to evaluate the effect of D-JNKI1 on inflammation, we investigated the 
activation and accumulation of glial and inflammatory cells after focal cerebral 
ischemia in mice by immunohistochemistry. We first characterized microglial 
activation at different time points after ischemia onset (9 h, 24 h, 48 h and 7 days). In 
our MCAO model, we found a peak of CD11b positive microglial cells in the ischemic 
tissue at 48 h (Figure 8). At earlier time-points, there was either no detectable CD11b-
staining (9 h), or microglia were in a ramified state with a less dense staining (24 h). At 
48 h, there were numerous microglia in the infarct area with an ameboid morphology. 
Seven days after MCAO, highly ramified microglia were present only in the injured 
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hippocampal tissue, whereas no positive staining was seen in the striatal ischemic 
region. Further experiments with microglia were performed 48 h after surgery when 
CD11b staining was most prominent. 
 
 
Figure 8. Time course of microglial activation after MCAO 
The presence of CD11b microglial cells was analyzed by immunohistochemistry in the 
ipsilateral (ischemic) hemispheres at 9 h, 24 h, 48 h and 7 d after 30 min MCAO in vehicle 
mice. Two distant slices are shown (A: frontal cortex and anterior commissure, B: parietal 
cortex and hippocampus). Their location is indicated in the representative 3D scheme of a mice 
brain. Bar scale: 100μm. 
anterior 
posterior 
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At 48 h after 45 min transient MCAO, the infarct areas were localized in the striatal and 
cortical regions of the left hemisphere (Figure 9A, left) highlighted by a specific 
marker for degenerating neurons (FluoroJade B, Figure 9B). The cellular changes 
resulting in reactive astrocytes are an important component of glial activation after 
ischemia. It has been previously described that the function of reactive astrocytes is to 
create a physical barrier between damaged and healthy cells (Anderson et al., 2003). In 
our model of MCAO, we found that glial fibrillary astrocytic protein positive cells 
(GFAP+) with a stellate morphology were restricted to the infarct border, outside the 
ischemic zone, while hypertrophic GFAP+ cells were found within the ischemic tissue, 
suggesting a reactive gliosis 48 h after MCAO (Figure 9C). Activated microglia, 
characterized by an increase in size of the cell body and a decrease of ramifications, 
were highly present in the ischemic tissue as shown by Isolectin B4 and CD11b 
positive staining (Figure 9D and 9E). It has been postulated that dendritic cells (DCs) 
are activated in the ischemic tissue and have a phagocytic function (Reichmann et al., 
2002). Staining for DCs using CD11c was found in the ischemic region (Figure 9F). 
Activation of microglia, dendritic cells and restriction of the extent of damaged tissue 
by astrocytes after stroke as well as the breakdown of the blood brain barrier could 
promote the infiltration and accumulation of T lymphocytes within the infarcted area 
(Raivich et al., 1996; Ishikawa et al., 2004). We performed immunohistochemistry 
using an antibody against the beta chain of the T cell receptor (TCRβ) and found 
positively stained T lymphocytes especially in the ischemic striatum (Figure 9G1). 
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Figure 9. Glial and inflammatory cells in the ischemic tissue  
CD1 mice were subjected to 45 min MCAO and brain sections immunostained 48 h after 
surgery. (A) Representative Nissl-stained coronal sections of the total infarct area 48 h after 
MCAO (left). Striatal and cortical damaged regions of the ipsilateral hemisphere are 
represented in blue-green and purple, respectively. The location of striatal (blue-green square) 
and cortical (purple square) ischemic areas where all immunohistochemistry data were 
analyzed are showed in the upper right panel. (B) Representative histological section 48 h after 
MCAO showing degenerating neurons (FluoroJade B) located within striatal (B1) and cortical 
(B2) ischemic lesions in the territory of the left MCA. (C) Reactive astrocytes (GFAP positive 
cells) are predominantly located in the spared parenchyma bordering the ischemic zone (C1, 
arrowhead), whereas hypertrophic astrocytes are within the demarcated area (C2, arrowhead). 
(D and E) A robust inflammatory response shown by activated (Isolectin B4 and CD11b 
positive) microglial cells is restricted to the infarct area clearly separated from immediately 
adjacent viable neural tissue. Inserts show high magnification of typical activated microglia.  
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(F and G) Dendritic cells (CD11c) and T lymphocytes (TCRβ), especially in the striatum (G1) 
are also detected within the ischemic area and not in the healthy contralateral parenchyma 
(data not shown). 
 
Our data showed marked inflammatory changes 48 h after transient MCAO with a high 
degree of activation of glial cells, with reactive astrocytes surrounding the lesion and an 
accumulation of microglia within the ischemic tissue as well as the presence of 
inflammatory cells such as DCs and T cells. 
 
3.3 MCAO INDUCES C-JUN PHOSPHORYLATION IN NEURONS AND GLIAL 
CELLS 
 
Activation of the JNK pathway after ischemia is well described, resulting in the 
phosphorylation of JNK targets, including transcription factors in the nucleus such as 
the immediate early gene c-jun (Borsello & Bonny, 2004; Gao et al., 2005; Repici et 
al., 2007). Using specific antibodies directed against the phosphorylated serine-63 or -
73 residues of c-Jun, we found phospho-c-Jun(Ser73) in cortical region as early as 9 h 
after MCAO (Figure 10) even though we could not detect marked tissue damage, by 
Nissl staining (see Figure 8). When the lesion was formed, activation of c-Jun was 
detected essentially in the cortical infarcted areas 24 h after MCAO, while at 48 h 
positive staining was in both cortical and striatal regions. As late as 7 days after MCAO 
induction we still observed p-c-Jun labeling in the ischemic hemisphere. The same time 
course was observed using the specific phospho-c-Jun(Ser63) antibody (data not 
shown). 
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Figure 10. Time course of phospho-c-Jun activation after MCAO 
Double immunofluorescence for p-c-Jun(Ser73) (green) and NeuN (red) was performed at 9 h, 
24 h, 48 h and 7 d after 30 min MCAO in vehicle mice. Photomicrographs show activation of c-
Jun in the striatal and cortical ipsilateral (ischemic) regions. 
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In order to further characterize the role of the JNK inhibitor D-JNKI1, not only in 
neurons but also in glial cells, we performed double-labelling of p-c-Jun(Ser63) using 
different cell-specific markers as NeuN (neurons), Isolectin B4 (microglia) and GFAP 
(astrocytes) within the ischemic tissue 48 h after MCAO (Figure 11).  
 
Despite early activation of c-Jun at 9 and 24 h, we chose to analyze a possible effect of 
D-JNKI1 at 48 h after ischemia onset, because we detected a peak of microglial 
activation (see Figure 8) and c-Jun is activated in the entire ischemic tissue at this time 
point (see Figure 10). p-c-Jun(Ser63) (green) was detected as expected in the nucleus of 
neurons, located predominantly in the cortex (red preserved shape, Figure 5A1, 
arrowheads), while in the striatal ischemic region we found apparently degenerating 
neurons and rare co-localizations with p-c-Jun (Figure 11A2, arrowheads). We also 
found a high degree of co-localization of microglia with p-c-Jun (Figure 11B1–B2, 
arrowheads). Higher magnification shows a nuclear localization of p-c-Jun in 
microglial cells in an activated ameboid-phagocytic macrophage-like morphology. p-c-
Jun was also detected in GFAP+ cells in the cortical and striatal ischemic areas (Fig. 
11C, arrowheads). 
 
Figure 11. Activation of c-Jun in neurons and glial cells 
The boxes on the brain section in the upper left show the striatal (blue-green) and cortical 
(purple) ischemic areas where immunofluorescence experiments were carried out. (A–C) 
MCAO promotes nuclear phosphorylation of c-Jun(Ser63) (p-c-Jun) (lines A1–C1). (A and B) 
Double fluorescent immunolabelling experiments show that p-c-Jun was highly detected in 
neurons (NeuN) (A1 and A2, arrow heads) as well as in activated microglia (Isolectin B4, B1 
and B2, arrow heads). (C) Cytoplasmic GFAP positive cells merged with p-c-Jun are found in 
the striatal and cortical ischemic areas (C1 and C2, arrowheads). Inserts show high 
magnification of double labelling. Scale bar: 100 μm. 
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Taken together, these data demonstrate that c-Jun phosphorylation occurs in the 
ischemic areas (Fig. 11, boxes on the coronal brain section in the upper left) and is 
detected in neurons as well as in glial cells 48 h after MCAO. 
 42 
3.4 THE HIGHLY NEUROPROTECTIVE JNK INHIBITOR D-JNKI1 DOES NOT 
REDUCE THE ACCUMULATION OF MICROGLIA IN THE ISCHEMIC TISSUE 
48 H AFTER MCAO 
 
To analyze whether D-JNKI1 has an inhibitory function on the activation and 
accumulation of microglia at 48 h, we quantified microglial cells after MCAO in 
treated and vehicle groups (D-JNKI1 or saline solution). First, mice were subjected to 
45 min MCAO and treated i.v. with a single dose of 0.1mg/kg D-JNKI1 or saline 
solution 3 h after MCAO onset. 48 h after surgery, the lesion area could be clearly 
outlined by Nissl staining (Figure 12A, red line in microphotographs above the 
diagram). The direct lesion volume was 28.2 ± 8.5 mm3 in vehicle mice (n = 7), and 
13.9 ± 6.2 mm3 in the D-JNKI1-treated mice (n = 6), with a significant 51% reduction 
of the lesion size (p < 0.01), confirming our previous findings (Wiegler et al., 2008). 
Figure 12B illustrates a typical Doppler curve measuring the cerebral blood flow from 
the beginning of the surgery until 10 min after reperfusion.  
 
 
Figure 12. Neuroprotection with D-JNKI1 3 h after transient MCAO  
(A) Intravenous administration of 0.1 mg/kg D-JNKI1 3 h after 45 min MCAO significantly 
reduced the infarct volume compared to vehicle-injected mice. Nissl-stained coronal sections 
show typical examples of lesion (**p < 0.01). Results are presented as mean ± SD, n = 6 to 7. 
(B) Representative diagram of the cerebral blood flow (CBF) as a function of time. The CBF 
was monitored from the beginning of the surgery until 10 min after withdrawal of the filament to 
follow the reperfusion. 
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Regional cerebral blood flow was measured by laser Doppler in all animals and is 
shown in Table 1. Data indicate satisfactory reduction in laser Doppler flow during 
ischemia in all animals and satisfactory reperfusion, slightly better in the D-JNKI1-
treated group (p = 0.033). This minor difference in level of reperfusion does not explain 
the important reduction in lesion volume (Wiegler et al., 2008). Table 1 also shows 
similar weight and temperature measurements during surgery in both groups. 
Temperature at sacrifice was slightly lower in vehicle-animals than in D-JNKI1-treated 
mice (p = 0.048), which correlated with the reduction of the infarct volume in the D-
JNKI1-treated group. There was no difference in weight between groups 48 h after the 
operation, probably due to the high distribution level of the lesion size in this MCAO 
model. Neuroscore scaled from 0 (best functional outcome, no deficit) to 3 (worst 
outcome) was not significantly better in the D-JNKI1-group (1.0, 0, 2.0) than in 
vehicle-group (1.0, 1.0, 2.0); p = 0.701, most likely due to the lack of sensitivity of this 
test. We have shown previously a beneficial effect of D-JNKI1 on functional outcome 
after MCAO using more sensitive tests (Borsello et al., 2003; Hirt et al., 2004; Wiegler 
et al., 2008). 
 
Table 1 
Measurements of CBF, weight, temperature and neuroscore in the group vehicle or treated with 
D-JNKI1. There was a slightly better reperfusion in the D-JNKI1 treated group (p = 0.033). 
Temperature at sacrifice was slightly lower in vehicle- than in D-JNKI1-treated mice (p = 0.048). 
Results are represented as mean ± SEM, except for neurological scores which are expressed 
as [median, min, max]. *p < 0.05 indicates a significantly difference between groups.  
 
 
 
 
 
 
 
 
 
 Vehicle (n = 7) D-JNKI1 (n = 6) 
CBF during ischemia (%) 15.4 ± 2.1 13.2 ± 1.5 
CBF after ischemia (%) 50.7 ± 2.3 63.0 ± 4.9* 
Weight (g) 25.1 ± 0.9 25.0 ± 0.7 
Weight at sacrifice (g) 19.6 ± 1.7 18.5 ± 1.0 
T during ischemia (°C) 37.0 ± 0.1 36.7 ± 0.1 
T at sacrifice (°C) 35.4 ± 0.2 36.3 ± 0.3* 
Neuroscore at 48 h 1.0, 1.0, 2.0 1.0, 0, 2.0 
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In order to investigate the effect of D-JNKI1 treatment on the activation of microglia, 
we performed immunohistochemistry using a CD11b-specific antibody in sections 
from all animals 48 h after surgery. In a blinded study we could not identify 
morphologic changes (activated-ameboid microglia versus resting-ramified cells) 
between animals and groups. Representative CD11b immunostainings in the ischemic 
striatum of one animal per group are shown in Figure 13A. This suggest that D-JNKI1 
does not influence changes in microglial shape in our MCAO model. We then 
quantified the number of microglial cells by measuring the average intensity of CD11b 
(Figure 13B, green) in the total ischemic area (Figure 13B, red staining, white line) in 
vehicle mice (n = 6) and D-JNKI1-treated mice (n = 6) 48 h after MCAO. 
Quantification analysis of CD11b average intensity did not show a significant 
difference between the vehicle and D-JNKI1 group (Figure 13C), suggesting that D-
JNKI1 does not prevent the accumulation of microglia in the ischemic tissue. Figure 
13D shows the correlation between the expression of CD11b and the brain lesion 
volume in both groups. As no modification of microglial activation was detectable after 
D-JNKI1 treatment, we hypothesized that there was a direct link between the activation 
of microglia and the size of the lesion independently of the treatment. There was a 
strong linear correlation between CD11b and lesion volume in the vehicle group (red 
square, p < 0.01). In the D-JNKI1 treated group, this correlation was negative and 
interestingly was not significant (blue green square) as it was in the vehicle group. 
However linear regression between groups showed that there was no significant 
difference. 
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Figure 13. Quantification of microglia in the ischemic region in treated and vehicle 
groups  
(A) Representative CD11b immunohistochemistry of vehicle- and D-JNKI1-treated animals. 
Inserts show high magnification of CD11b+ microglia. (B) Representative CD11b infrared 
emission staining (green) and Nissl-stained section (red) 48 h after MCAO. The measurements 
were done in the outlined ischemic area (white area). Merged scanned microphotograph shows 
that CD11b staining is localized within the ischemic tissue. (C) Quantification of CD11b average 
intensity in vehicle- (n = 6) and D-JNKI1-treated (n = 6) animals in the ischemic tissue. (D) 
Correlation between infarct volume and the average intensity of CD11b in D-JNKI1 (blue-green 
square) and vehicle groups (red square). There is a correlation between the infarct volume and 
the average intensity in vehicle-treated group (R = 0.94, p = 0.005). This correlation is negative 
and non-significant in the D-JNKI1-treated group (R = -0.36, NS). A linear regression analysis 
of slopes of D-JNKI1 and vehicle groups gives a non-significant difference between groups (R 
= -0.01, NS). NS, not significant. Results are represented as mean ± SD, n = 6. 
 
These data showed that in our stroke model, D-JNKI1 strongly reduces the infarct 
volume but has no effect on the morphology and accumulation of microglia within the 
damaged tissue 48 h after MCAO. This suggests that neuroprotection with D-JNKI1 
could occur independently of microglial activation in our cerebral ischemia model. 
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3.5 D-JNKI1 IS PRESENT MAINLY IN NEURONS 48 H AFTER OGD 
 
The finding that MCAO activates p-c-Jun in microglia and that D-JNKI1 fails to inhibit 
the activation and accumulation of microglia despite a strong neuroprotective effect 
prompted us to investigate the cellular localization of D-JNKI1. The peptide was not 
detectable in the brain after i.v. injection of 0.1 mg/kg. Co-localization experiments 
were therefore assessed in our in vitro model of cerebral ischemia as depicted 
schematically in Figure 14A. First, we exposed organotypic hippocampal slice cultures 
to OGD for 30 min and treated cultures 6 h after OGD with 12 nmol/l of D-JNKI1. We 
measured PI uptake as an indicator of cellular death in the CA1 region of hippocampal 
slices in control conditions (CTRL), 48 h after OGD and after OGD followed by D-
JNKI1 treatment. Figure 14B shows percent of cell death in the CA1 region in control 
slices (6.6% ± 1.8, n = 20), after OGD (28.5% ± 4.2, n = 39) and after OGD+D-JNKI1 
(6.0% ± 2.1, n = 9). The neuroprotective peptide significantly reduced the PI uptake 
compared to slices subjected to OGD, indicating a significant 79% reduction of 
neuronal death (p < 0.01) confirming previous findings (Hirt et al., 2004). We then 
investigated the cellular localization of D-JNKI1 in these slices. We performed double-
labelling 48 h after OGD on treated slices using antibodies against D-JNKI1 (green) 
and neurons (NeuN, red) or microglia (Isolectin B4, red) (Figure 14C). D-JNKI1 was 
found in the neuronal CA1 region with a cytoplasmic staining (squares), and a few 
positive cells were localized outside the CA1 neuronal layer (circles). Co-localization 
of D-JNKI1 was observed mainly in CA1 neurons (Figure 14C1, arrow heads) and in 
few microglia outside or at the border of the CA1 region (Figure 14C2, arrowheads). 
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Figure 14. Co-localization of D-JNKI1 in neurons and microglial cells 48 h after OGD in 
hippocampal slices 
(A) Schematic representation of the experimental protocol. OGD for 30 min was performed 8 
days after in vitro culture (DIV), 12 nmol/l D-JNKI1 or saline solution was added into the culture 
medium 6 h after OGD. Neuronal death and immunofluorescence were analyzed 48 h after 
induction of ischemia. (B) Effect of D-JNKI1 on neuronal death assessed by cellular PI uptake. 
Representative photomicrographs showing PI uptake in the CA1 layer of hippocampal slice 
cultures not exposed (left) and exposed (right) to vehicle or D-JNKI1, respectively. A significant 
decrease of PI uptake was observed 48 h after D-JNKI1 treatment compared to not treated 
slices subjected to OGD. The diagram shows percent of cell death in the CA1 region (CTRL 
versus OGD: p < 0.001; OGD versus OGD+D-JNKI1: p < 0.01), mean ± SEM, n = 9 to 39. (C) 
D-JNKI1 is mainly localized in the CA1 pyramidal cell layer of hippocampal slices 48 h after 
OGD and shows a cytoplasmic staining (outlined by white squares), whereas few stainings are 
localized outside the CA1 region (white circles). Co-localization of D-JNKI1 (green cytoplasmic 
staining) with NeuN (red nuclear labelling) is found in treated slices, predominantly in the CA1 
(C1, magnification: arrowheads). Little co-localization was observed between D-JNKI1 and 
Isolectin B4-positive microglial cells at the border of the CA1 layer (C2, magnification 
arrowheads). 
 
Taken together, these observations showed that D-JNKI1 is localized in the cytoplasm 
of CA1 neurons where it is likely to inhibit the JNK death signaling pathway, and that 
little co-localization of the peptide is observed in microglia, suggesting that D-JNKI1 
could modulate the JNK pathway also in these cells. 
 
3.6 D-JNKI1 MODULATES THE ACTIVATION OF MICROGLIA AFTER OGD 
 
We have demonstrated that D-JNKI1 was neuroprotective in vitro and was found 
mainly in neurons as well as some microglia. To verify the molecular function of the 
peptide in these cells, we examined whether D-JNKI1 could inhibit c-Jun 
phosphorylation and modulate the activation of microglia. First by Nissl staining we 
observed that the CA1 layer is well preserved in control slices (Figure 15A1) and after 
D-JNKI1 treatment in slices subjected to OGD (Figure 15A3), whereas neurons after 
OGD without treatment show the typical shape of dying cells with their pyknotic nuclei 
(Figure 15A2). The same results were obtained using the nuclear specific antibody for 
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neuron NeuN (Figure 15B). Fluorescent double immunolabelling using NeuN and p-c-
Jun(Ser63) showed, as expected, that in control slices there was no p-c-Jun staining in 
the neuronal layer (Figure 15B1). After OGD, the level of p-c-Jun clearly increased in 
the nuclei of neurons (Figure 15B2), whereas in treated slices fewer positive p-c-Jun 
were observed (Figure 15B3). Using the antibody against p-c-Jun(Ser73) we found a 
fibrillary staining in control and OGD+D-JNKI1 slices whereas after OGD p-c-
Jun(Ser73) was activated in the nucleus (Figure 15C, green staining), accordingly with 
published data using the same antibody (Price et al., 2010). Surprisingly, we observed 
no colocalization of p-c-Jun(Ser73) or -(Ser63) in microglia after OGD as well as in D-
JNKI1-treated slices subjected to OGD (Figure 15C and Figure 16). 
 
 
 
Figure 15. Activation of c-Jun after OGD  
(A) Nissl-staining of the CA1 region of control (CTRL), OGD and OGD+D-JNKI1 slices. CA1 
neurons are undergoing ischemic cellular death, shown by pyknotic nuclei (A2), whereas 
treated slices (A3) as well as control slices (A1) show neurons in a healthy state; scale bar: 50 
μm. (B) After OGD nuclear expression of p-c-Jun(Ser63) co-localized with NeuN-positive cells 
(arrows), while NeuN staining is partially lost (B2) compared to control slices (B1). D-JNKI1 (12 
C 
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nmol/l) treatment rescues NeuN staining while it partially attenuates p-c-Jun staining (B3). In 
both OGD (C2) and OGD+D-JNKI1 (C3) groups, no IB4 cells co-localized with p-c-Jun(Ser73) 
(arrowheads). Inserts show high magnification. All fluorescent microphotographs of double 
labelling are from the CA1 hippocampal region. Scale bar: 100 μm. 
 
However, when we analyzed qualitatively microglial morphology in vitro, in control 
slices, we observed microglia with long thin processes, the typical structure of so-called 
resting or surveying microglia, homogeneously distributed throughout the slice (Figure 
16A1-B1), while slices subjected to OGD showed microglia with less ramified 
processes and a round cell body (ameboid microglia) concentrated within the neuronal 
CA1 region (Figure 16A2-B2). In Figure 16A3-B3, D-JNKI1-treated slices show more 
ramified cells not specifically localized in the CA1 layer contrary to OGD slices.  
 
 
 
Figure 16. Effect of D-JNKI1 on microglia activation  
(A-B) In control slices microglial cells are highly ramified and are evenly distributed (A1, red and 
B1). After OGD microglia accumulates in the damaged CA1 layer and changes its morphology 
to an ameboid shape (A2, arrowheads and B2), whereas in treated slices, morphology of 
microglial cells are more similar to ramified cells (A3, insert and B3), and are localized at the 
border or within the neuronal CA1 layer. Inserts show high magnification. (C) Schematic 
presentation of microglial morphological transformation in response to an ischemic insult such 
as OGD in vitro. Our initial hypothesis is that after an insult resting microglia become highly 
activated, further accumulate and could change morphology to a phagocytic state. We suggest 
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that D-JNKI1 may inhibit the activation of microglia and secretion of pro-inflammatory 
mediators. We postulate that part of this inhibition process may be mediated through the JNK 
pathway and lead to neuroprotection. All fluorescent microphotographs of double labelling are 
from the CA1 hippocampal region. Scale bar: 100 μm. 
 
Altogether, these observations suggested that the activation of JNK leading to c-Jun 
phosphorylation is not predominant in microglia, and that treatment with D-JNKI1 after 
OGD could modify microglial activation and localization within the CA1 neuronal 
layer. 
 
As we observed activation of p-c-Jun in neurons and not in microglia, and that D-
JNKI1 was mainly localized in neurons but also in some microglial cells, we may 
assume that D-JNKI1 is more likely to modulate microglial activation in vitro 
indirectly.  
 
Intriguingly, the in vivo results suggest that treatment with D-JNKI1 following 
ischemia does not reduce the recruitment and activation of microglia in the ischemic 
brain territory at 48 h. However, D-JNKI1 appears to alter microglial activation and 
localization following OGD in vitro (Figure 16E: schematic presentation). While this 
may partly be due to the in vitro hypoxia model not reproducing the in vivo ischemia 
model, these observations need to be further explored, for instance by quantitative 
measurements of inflammatory cytokines released by microglia, in animals submitted 
to experimental ischemia with or without treatment. This issue will be addressed in the 
second part. 
 
 
 
 
 
(These results have been in part published as: JNK inhibition and inflammation after 
cerebral ischemia. Benakis C, Bonny C, Hirt L. Brain Behavior and Immunity 24 : 
800–811, 2010). 
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SECOND PART: EFFECT OF NEUROPROTECTION ON THE SECRETION 
OF INFLAMMATORY MEDIATORS 
 
We showed previously that accumulation and activation of microglia within the 
ischemic tissue is not influenced by D-JNKI1. Besides, our in vitro results suggested 
that the modification of microglial morphology we observed after treatment could 
probably be due to subtle local changes, such as the release of pro- and anti-
inflammatory mediators (Benakis et al., 2010). Regarding these findings we 
hypothesized that the neuroprotective action of D-JNKI1 could be due partly to the 
modulation of inflammatory mediators release (Figure 17). Furthermore, as we could 
not detect the peptide by immunohistochemistry in the brain tissue after i.v injection of 
0.1 mg/kg, we addressed the question of a potential effect of D-JNKI1 on the peripheral 
immune system. Therefore we were interested to investigate the release of 
inflammatory mediators after cerebral ischemia and the effect of the neuroprotective 
peptide D-JNKI1 on this release.  
 
 
 
Figure 17. Schematic presentation of the hypothetic role of D-JNKI1 after an ischemic 
insult 
After ischemia neurons are starting to degenerate and inflammatory cells such as microglia 
become activated and change their morphology to a less ramified and phagocytic state. 
Leukocytes such as T lymphocytes are also recruited in the ischemic tissue. D-JNKI1 inhibits 
neuronal death but not microglial activation. We asked whether D-JNKI1 influences the release 
of inflammatory mediators such as cytokines and chemokines. We suggest that D-JNKI1 could 
protect neurons from apoptosis by modulating the secretion of inflammatory mediators. 
 
D-JNKI1 
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Regarding conflicting data on the detrimental or beneficial role of the cytokine IL6 and 
the chemokine KC in cerebral ischemia (see Introduction sections 1.5.3 and 1.5.4) and 
based on recent findings published by others (Chapman et al., 2009) we chose to 
analyze the secretion of these two inflammatory molecules in the systemic circulation, 
in the brain and other peripheral organs (spleen, lung and liver). We performed an 
ELISA at several time points in sham (vehicle or D-JNKI1) and MCAO (vehicle or D-
JNKI1) mice. A schematic diagram of the experimental procedure is shown in Figure 
18. 
 
 
Figure 18. Schematic diagram of the analysis of the release of inflammatory mediators 
Sham or MCAO mice were treated with saline solution or 0.1mg/kg of D-JNKI1 3 h after the 
start of the surgical procedure. Mice were sacrificed at several time points. Plasma, brain and 
peripheral organs were isolated. Plasma samples and supernatants of organ slices incubated 
for 20 h in a culture medium were assessed by ELISA. 
 
3.7 TRANSIENT MCAO INDUCES A RAPID SYSTEMIC SECRETION OF 
INFLAMMATORY MEDIATORS 
 
The secretion of inflammatory mediators after MCAO has never been investigated in 
outbred CD1 mice. Therefore, we assessed the time course of IL6 and KC release in 
sham and MCAO mice, in order to identify the relevant time points for the analysis of  
D-JNKI1 treatment on cytokine/chemokine release. First, we performed transient 
MCAO for thirty minutes and sacrificed the mice after 4 h (n = 6), 7 h (n = 10), 24 h (n 
= 6), 48h (n = 9) and 5 d (n = 6) of reperfusion. Sham mice (n = 5 to 8, except at 24 h, n 
i.v of D-JNKI1 
or saline 
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= 3) were anesthetized for the same duration as ischemic mice and were sacrificed at 
the same time points. (Table 2 in the Appendix shows measurements of cerebral blood 
flow, weight, and temperature of sham and MCAO mice. Weight, temperature and 
neuroscore at sacrifice are also listed). Control mice (no surgical intervention) were 
used as an indicator of the basal level (n = 7). Plasma samples were collected and 
assessed by ELISA for the cytokine IL6 and the chemokine KC. We found a marked 
plasma release of both inflammatory mediators very early after ischemia onset (Figure 
19). Already four hours after the injury, the level of IL6 in the systemic circulation was 
significantly higher than in sham mice (p < 0.05). The increase was still significant at 7 
h (p < 0.05) (Figure 19A). From 24 h to 48 h IL6 release decreased to sham plasma 
levels. As late as five days after ischemia, secretion of IL6 in the plasma increased 
again to an almost significant level compared to sham mice (sham versus MCAO: p = 
0.054). Figure 19B showed that the KC plasma release followed closely the secretion 
pattern of IL6, with a very early induction in the plasma 4 h (p < 0.05) and 7 h (p < 
0.01) after MCAO which dramatically decreased between 24 h and 48 h. Five days 
after the occlusion we found that KC was once again significantly secreted in the 
plasma of MCAO mice compared to sham mice (p < 0.05).  
 
In accordance with previous studies, these results indicate a significant plasma release 
of IL6 and KC early after cerebral ischemia compared to sham mice (Chapman et al., 
2009; Offner et al., 2006). 
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Figure 19. Transient MCAO induces a rapid release of IL6 and KC in the plasma  
The graphs show the square root of IL6 and KC concentrations in pg/ml at different time points. 
(A) Plasma IL6 was induced 4 and 7 hours after MCAO at a significantly higher level than sham 
mice. At 24 h and 48 h IL6 concentration of stroke mice returns to basal level and tends to 
increase 5 days after the occlusion (sham versus MCAO: p = 0.054). (B) Plasma KC was also 
induced early after MCAO compared to sham mice and decreased from 24 h to 5 days. At this 
time point KC concentration was significantly higher than sham mice (sham versus MCAO: p = 
0.03). Control mice: n = 7, sham mice: n = 3 to 8, MCAO mice: n = 6 to 10. *p < 0.05, **p < 0.01 
indicate a significant difference between MCAO mice and sham mice. Results are represented 
as mean ± SEM. ⊗ and × denote a significant difference from the peak concentration at 4 h and 
7 h in MCAO mice, respectively  
 
In Figure 23 we described changes of IL6 and KC release as a function of time. It is 
clearly shown that in MCAO mice plasma release of IL6 at 4 h is significantly higher 
than at 24 h (p < 0.05) and 48 h (p < 0.05) (Figure 23A2) and that this significant 
difference is lost at 5 d. We observed a similar time course for KC plasma release after 
MCAO (Figure 23B2). The secretion of KC at 4 h and 7 h is significantly higher than at 
all late time points (24 h, 48 h and 5 d) even though there is a significant increase of 
KC at 5 d compared to sham mice as described above (see Figure 19B). Furthermore, 
we found a significant release at 4 h, 7 h and 24 h in sham group compared to a control 
group (0 h, no surgical intervention, Figure 23B1) as well as at 4 h and 7 h in MCAO 
mice. These findings suggest that KC is transiently secreted early in the plasma and 
that this might be due at least in part to the stress caused by the surgical procedure. 
 
3.8 BRAIN RELEASE OF INFLAMMATORY MEDIATORS FOLLOWS 
SYSTEMIC INFLAMMATION 
 
In order to investigate the de novo secretion of cytokines and chemokines in the brain 
induced by the ischemic insult, we analyzed by ELISA the supernatants of brain slices 
from sham and MCAO mice incubated for 20 h in a culture medium. We found a 
significant elevation of IL6 (Figure 20A) but not KC (Figure 20B) in the brain of 
MCAO mice compared to sham mice at late time points. Indeed, at 24 h after ischemia, 
IL6 tended to increase compared to sham mice (p = 0.06) and was significantly 
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different at 48 h (p < 0.05). A slight increase was also observed at 5 d, although this did 
not reach statistical significance (p = 0.12). Brain KC release had a slight though non-
significant tendency to increase at 24 h (p = 0.19) and 48 h (p = 0.08) after MCAO. 
Considering the temporal evolution of cerebral cytokine and chemokine secretion, in 
Figure 23C2 and 23D2 we showed that the brain release of IL6 and KC increased 
significantly at 7 h compared to 0 h (control mice) and 4 h in MCAO mice, and 
remained elevated at late time points, especially for KC (KC at 4 h versus 48 h : p < 
0.05, KC at 4 h versus 5 d : p < 0.05, IL6 at 4 h versus 48 h : p =  0.056). In sham mice, 
in contrast, cerebral release of IL6 and KC did not differ from control mice and any 
time point. 
 
 
 
Figure 20. Transient MCAO induces a late release of IL6 but not KC from the brain 
Concentrations of IL6 and KC were measured in the supernatants of brain slice cultures and 
normalized to total protein concentration. The graphs show the square root of IL6 and KC 
concentrations in pg/mg at different time points (A) Secretion of IL6 from the brain tended to 
increase at 24 h (sham versus MCAO: p = 0.06) with a significant difference between sham and 
MCAO mice 48 h after the occlusion. (B) Brain KC was not significantly different from sham 
mice at all time points. Control mice: n = 7, sham mice: n = 3 to 8, MCAO mice: n = 6 to 10. *p 
< 0.05 indicates a significant difference in MCAO mice and sham mice. Results are 
represented as mean ± SEM. # and ⊗ denote a significant difference from the peak 
concentration at 0 h and 4 h in MCAO mice, respectively. 
 
Besides, we observed that the time course of brain secretion of IL6 correlates with the 
evolution of the apparent lesion size as assessed by TTC staining (Figure 21A). Indeed, 
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TTC staining of brain slice after MCAO showed a clearly outlined lesion at 24 h and 48 
h which corresponds to higher brain release of IL6. Besides the plasma release of IL6 
and KC does not correlate with the outlined lesion size. At early (4 h and 7 h) and late 
(5 d) time points the lesion was not detectable by TTC staining. These time points 
correspond to higher plasma release of IL6 and KC, as schematically illustrated in 
Figure 21B (bottom). 
 
 
Figure 21. Lesion size as a function of time after MCAO 
(A) Lesion size is evaluated qualitatively using TTC staining. Mice are sacrificed at 4 h, 7 h, 24 
h, 48 h and 5 d. Brains are removed, sliced in 2-mm-thick sections and one anterior slice is 
stained with 2% TTC. Representative brain slices for one animal at each time point are shown. 
Lesion appears in white at 24 h and 48 h in the left hemisphere. No distinguishable lesion is 
seen at all other time points. (B) Simplified diagram showing the evolution of the lesion and 
cytokine release in the plasma and in the brain. 
 
Preliminary analysis of IL6 and KC release in the supernatants of spleen, lung and liver 
suggest a time course similar observed to that of the plasma in the spleen and liver, and 
no clear direction of change in the lung (data not shown). Further investigations are 
required to confirm these impressions. 
 
Altogether our data showed that systemic inflammation after cerebral ischemia 
occurred before brain inflammation, and that the latter correlates with the apparent 
evolution of the lesion size. Furthermore, we found that de novo brain release of IL6 
 58 
occurs at 48 h when the lesion size is clearly outlined, and that the time course of its 
cerebral secretion seems more protracted than in the periphery. 
 
3.9 NEUROPROTECTION MEDIATED BY D-JNKI1 48 H AFTER INJURY IS 
INDEPENDENT OF PLASMA AND BRAIN CYTOKINE RELEASE 
 
To analyze whether D-JNKI1 could modulate the release of inflammatory mediators 
after cerebral ischemia, we quantified IL6 and KC release in the plasma and brain 
supernatants of mice treated with D-JNKI1. First, in a separate set of experiments mice 
were subjected to 30 min MCAO and injected i.v. with 0.1 mg/kg of D-JNKI1 or saline 
solution 3 h after MCAO onset. Forty-eight hours after surgery, the lesion volume was 
quantified on serial coronal brain slices. The direct lesion volume was 36.4 ± 4.3 mm3 
in saline-injected mice (n = 7), and 19.0 ± 5.5 mm3 in D-JNKI1-treated mice (n = 5), 
providing a significant 50% reduction of the lesion size (p = 0.03), corroborating our 
previous findings (Benakis et al., 2010); (Figure 22A). (Table 3 in the Appendix shows 
measurements of cerebral blood flow, weight, and temperature of mice included in this 
study. Weight, temperature and neuroscore at 48 h are also listed). 
 
Plasma samples of mice subjected to 30 min MCAO and treated with D-JNKI1 were 
then isolated at 4 h (n = 7), 7 h (n = 7), 48 h (n = 8) and 5 d (n= 7) after ischemia and 
tested by ELISA for IL6 and KC (see Figure 18 for experimental procedure). At each 
time point, we did not find any significant difference between MCAO+D-JNKI1 and 
MCAO+vehicle for either of these inflammatory mediators (Figure 22C). Four hours 
after the injury, D-JNKI1 induced a non-significant tendency towards a reduction in 
IL6 release (MCAO+vehicle versus MCAO+D-JNKI1: p = 0.26), but not KC. Five 
days after the injury, we observed again a slight, non-significant reduction of IL6 
plasma release with D-JNKI1 treatment (MCAO+vehicle versus MCAO+D-JNKI1: p = 
0.27). We then assessed the release of IL6 and KC in the supernatants of brain samples 
of mice treated with D-JNKI1. We chose to analyze IL6 and KC release at three 
different time points (7 h, 48 h and 5 d) as we hypothesized that they would be the 
more interesting time points based on our previous results after MCAO (Figure 20). We 
did not find a significant difference of IL6 nor KC brain release at any time point as 
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shown in Figure 22D. However, a slight non-significant reduction of IL6 brain release 
was seen at 5 d (MCAO+vehicle versus MCAO+D-JNKI1: p = 0.25). These results 
suggest that D-JNKI1 does not significantly modulate the secretion of IL6 and KC after 
an ischemic insult, neither systemically nor in the brain. 
 
To rule out an effect of the peptide itself on the release of inflammatory mediators, we 
tested the secretion of IL6 and KC in sham mice treated with D-JNKI1. Plasma and 
brain supernatant samples of sham mice injected with D-JNKI1, sacrificed at 48 h, 
were evaluated for IL6 and KC. We did not find any significant release of both 
inflammatory mediators between sham+vehicle and sham+D-JNKI1 48 h after the 
surgical procedure (data not shown). 
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Figure 22. Effect of D-JNKI1 on lesion volume, survival and cytokine/chemokine 
secretion  
(A) Late intra-venous administration of 0.1 mg/kg D-JNKI1 after transient occlusion of the MCA 
leads to neuroprotection. MCAO was induced for 30 minutes and the lesion volume was 
measured on consecutive coronal brain slices 48 h after reperfusion. A significant reduction of 
the lesion size was observed in treated mice compared to vehicle mice (p < 0.05). 
Representative examples of Nissl staining are shown above. (B) Survival curves show no 
significant difference between mice treated with D-JNKI1 or vehicle from the end of surgery 
until 96 hours. At 5 days post-surgery mice not treated with D-JNKI1 have a worse outcome 
compared to treated mice. (C) IL6 and KC release were measured at 4 h, 7 h, 48 h and 5 days 
in plasma samples of mice subjected to MCAO and treated with D-JNKI1. No statistical 
difference was found between MCAO+vehicle and MCAO+D-JNKI1. (D) IL6 and KC release 
were measured at 7 h, 48 h and 5 d in brain slice supernatants of mice treated with D-JNKI1. 
No statistical difference was found between treated and vehicle animals. Control mice: n = 7, 
MCAO+vehicle mice: n = 6 to 10, MCAO+D-JNKI1 mice: n = 7 to 8. Results are represented as 
mean ± SEM. #, × and ⊗ denote a significant difference from the peak concentration at 0 h, 4 h 
and 7 h, respectively.  
 
In order to complement the demonstration of a reduction in lesion size by D-JNKI1 
treatment, we analyzed the survival of MCAO+vehicle compared to MCAO+D-JNKI1 
mice using Kaplan-Meier analysis (Figure 22B). A total of 102 animals were included 
in this analysis (MCAO+vehicle: n = 57, MCAO+D-JNKI1: n = 45). The survival 
appears better in the D-JNKI1-treated group, the overall difference was not statistically 
significant (Log-rank Mantel-Cox Test: p = 0.19; Table 4 in the Appendix shows 
survival proportions in each group, no death was reported in the sham group). 
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Interestingly, our results showed that neuroprotection mediated by D-JNKI1 measured 
48 h after the injury is independent of early systemic inflammation as well as late brain 
inflammation. Looking carefully at the survival curves of MCAO+D-JNKI1 mice, no 
death was noted from 24 h in this group compared to the MCAO+vehicle group. In 
addition, we observed a slight decrease of IL6 plasma and brain release as a function of 
time in the MCAO+D-JNKI1 group, especially at 5 d after reperfusion. Thus, we could 
formulate the hypothesis that a sustained or a secondary inflammatory response would 
be unfavorable for survival prognosis at later time points. This hypothesis needs to be 
further explored, as for instance by the investigation of IL6 and KC release at 7 days 
and 14 days after ischemia. 
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Figure 23. Effect of time on IL6 and KC release  
Secretion of IL6 and KC in the plasma and from the brain in sham mice and mice subjected to 
MCAO treated with D-JNKI1 or saline solution were first compared to control mice. ⊗P<0.05 
indicates a significant difference in sham, MCAO+vehicle and MCAO+D-JNKI1 mice versus 
control mice (0 h). For each group, cytokine/chemokine release was analysed as a function of 
time. *p < 0.05; **p < 0.01; ***p < 0.001 indicate a significant difference between time points. 
(A) In the plasma of MCAO mice treated with D-JNKI1 (A3) or vehicle mice (A2) there is a 
significant release of IL6 at early time points compared to control mice (A2: 4 h, p = 0.037; A3: 
7 h, p = 0.046). In MCAO mice, the secretion of IL6 at 4 h is significantly higher than at 24 h 
and 48 h (A2). There was no difference between different time-points in treated mice (A3) as 
well as in sham mice (A1). (B) The KC release in the plasma of sham (B1), MCAO+vehicle 
(B2), MCAO+D-JNKI1 (B3) was significantly different than in control mice at early time-points 
(B1: 4 h, p = 0.002; 7 h, p < 0.0001; 24 h, p = 0.036; B2: 4 h, p < 0.0001; 7 h, p < 0.0001; B3: 4 
h, p = 0.001, 7 h, p < 0.0001). In all three groups the release of KC is significantly higher at 
early time points (4 h and 7 h) than at late time points (24 h or 48 h and 5 d). (C and D) The IL6 
and KC release from brain tissue is significantly higher at 48 h after MCAO+vehicle (C2, D2) 
and MCAO+D-JNKI1 (C3, D3) compared to control mice (0 h). (C2) In MCAO mice, the 
secretion of IL6 at 7 h is already significantly higher than at 4 h and tends to increase at 48 h (4 
h versus 48 h: p = 0.056). There was no difference between different time-points in treated 
mice (C3) or in sham mice (C1). (D2) In MCAO mice, the secretion of KC at 7 h, 48 h and 5 d is 
significantly higher than at 4 h. No difference between  different time-points was found in 
treated mice (D3) or in sham mice (D1). Control mice: n = 7; Sham mice: n = 3 to 8; 
MCAO+vehicle mice: n = 6 to 10; MCAO+D-JNKI1 mice: n = 7 to 8. Results are represented as 
mean ± SEM. 
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4. DISCUSSION 
 
In the first part of this study, we showed that microglia was activated throughout the 
lesion 48 h after experimental stroke. However, in the context of neuroprotection, 
neither was there an inhibition of the activation of microglia nor a reduced number of 
activated microglia 48 h after the inhibition of neuronal cell death. Thus we showed 
that protection of neurons is independent of the activation of microglia in the ischemic 
tissue. In the second part of this project, we emphasized that early systemic release of 
inflammatory mediators is not a marker for irreversible brain lesion after experimental 
stroke. Indeed we obtained neuroprotection measured at 48 h even though there was an 
increase of IL6 and KC plasma levels very early after the onset of cerebral ischemia. 
Furthermore we found that the IL6 concentration in the brain was not different in 
groups given intravenous saline solution or the neuroprotective peptide D-JNKI1, 
whereas we obtained a significant reduction of the lesion size in the treated group. 
Altogether, we showed that the inhibition of the JNK signaling pathway using D-
JNKI1 does not lead: 1) to an inhibition of microglial activation in terms of 
morphology and cell number, 2) to a decreased level of early systemic release of 
cytokines/chemokines, 3) to a reduction of de novo brain secretion of inflammatory 
mediators, despite a reduction of the lesion volume. This strongly suggests that brain 
inflammation (showed particularly by the activation of microglia and the release of 
IL6) is not linked to the severity of the lesion, and that early systemic inflammation is 
independent of the neurological outcome. 
 
FIRST PART: EFFECT OF NEUROPROTECTION ON INFLAMMATORY 
CELLS 
 
In the normal healthy brain, microglial cells are known to continually screen their 
microenvironment by quickly moving their processes (Kreutzberg, 1996; Nimmerjahn 
et al., 2005; Hanisch & Kettenmann, 2007). Controlled activation of microglia induces 
the production of trophic factors and elimination of cell debris, leading to the protection 
of surrounding cells (Raivich et al., 1999; Streit et al., 1999; Aloisi, 2001). An ischemic 
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insult could cause an exaggerated activation of microglia with excessive release of 
inflammatory mediators and uncontrolled phagocytotic function (Kreutzberg, 1996; 
Rossum & Hanisch, 2004). It was postulated that this over-activation might be 
deleterious for the survival of neurons whereas controlled activation of microglia might 
be neuroprotective (Biber et al., 2007). The lack of knowledge on the role of microglial 
activation after brain ischemic injury led us to investigate how microglia react in a 
neuroprotective condition and if they participate in brain injury or repair.  
 
Based on the hypothesis that inflammatory cells are deleterious for tissue recovery, we 
raised the question whether D-JNKI1 protects neurons through the inhibition of 
microglial activation. In this first part, we investigated in experimental models of 
cerebral ischemia whether the neuroprotective effect of D-JNKI1 was due to an 
inhibition of microglial activation and second whether it was dependent of the JNK 
signaling pathway.  
 
4.1 EFFECT OF NEUROPROTECTION ON MICROGLIAL ACTIVATION  
 
Our results indicate that 0.1 mg/kg of D-JNKI1 was strongly neuroprotective when 
injected i.v. 3 h after transient MCAO. Despite efficiently attenuating neuronal death 
by inhibition of the JNK pathway, D-JNKI1 did not reduce the accumulation of 
microglia in vivo as shown by the quantification of CD11b-positive microglial cells 
(Figure 13C). These interesting findings indicate that neuroprotection due to D-JNKI1 
treatment in this transient ischemic model is independent of the accumulation of 
microglia observed 48 h after injury. Furthermore, our analysis of correlation between 
the infarct volume and the number of microglia in the ischemic tissue of vehicle 
animals reveals that there is a strong correlation: the larger the lesion, the more 
activated microglial cells are present in the infarct. Linear regression comparison 
between groups showed no statistical difference. However, in the group treated with D-
JNKI1, the correlation between the lesion volume and number of microglia was not 
significant, in contrast to the vehicle group (Figure 13D). Overall, while we cannot 
unequivocally state that microglia are neuroprotective, we suggest that their presence in 
the ischemic region might not be detrimental. Indeed, others showed a significant 
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improvement of behavioral tasks by intra-cerebroventricular injection of labeled 
exogenous microglia 1 h after induction of MCAO in rats, compared to non-injected 
rats (Kitamura et al., 2005). Other authors using transgenic mice with a selective 
ablation of endogenous microglia found an exacerbated size of the ischemic lesion after 
transient MCAO compared with wild type mice (Lalancette-Hébert et al., 2007). Both 
studies used drastic interventions which might explain the measured effect: an obvious 
neuroprotective effect is seen in models when microglia are injected in the brain 
parenchyma after cerebral ischemia, and an increased damage is observed when 
microglia are depleted. 
 
To complement the investigation of the effect of D-JNKI1 on microglial accumulation 
following cerebral ischemia, we performed a qualitative study aimed at detecting 
morphological changes of microglia in vehicle and treated animals subjected to 
MCAO. We assumed that neuroprotection mediated by D-JNKI1 might inhibit the 
change of microglial morphology from a resting state towards an activated or ameboid 
state, the latter commonly associated with neurotoxic activity. Our results indicate no 
morphological difference between vehicle and D-JNKI1 animals subjected to ischemia 
(Figure 13A). Microglia exist in three distinct morphologies correlating with their state 
of activation, as schematically illustrated in Figure 4. In the context of a tissue injury, it 
is expected that a graded microglial response will be observed, associated with several 
morphologies instead of one single state. Indeed microglia react rapidly to subtle local 
changes caused by damaged neurons. Therefore, one might not be able to see an overall 
morphological change within the total ischemic infarct, since the degree of microglial 
activation could vary with the severity of the injury (Raivich et al., 1999; Schwartz et 
al., 2006; Lynch, 2009). Indeed, it is suggested that the population of ameboid 
microglia is more abundant in the irreversibly damaged tissue (necrotic cell death) 
whereas activated ramified microglia might be recruited into the salvageable peri-
infarct region (apoptotic cell death) (Zhang et al., 1997; Stoll et al., 1998). Therefore, it 
would be useful to discriminate between these different regions and quantify the local 
effect of D-JNKI1 on the morphologic changes of microglia by using different markers 
for each state of activation. Indeed, previous work showed a suppression of microglial 
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activation and proliferation in a delimited area: the cortex boundary zone, after MCAO 
using roscovitine as a cell cycle inhibitor leading to neuroprotection (Zhang et al., 
2009). Furthermore, it is still unclear whether the different ‘grades’ of microglial 
response to brain tissue injury are associated with a specific functional role. Thus, one 
type of morphology does not necessarily correspond to one specific phenotype. Even 
though D-JNKI1 does not inhibit the activation of microglia based on a qualitative 
morphological study, we cannot rule out a possible effect of the neuroprotective 
peptide on the functional modification of microglia, as for instance a change from a 
pro-inflammatory towards an anti-inflammatory secretion profile.  
 
Altogether, D-JNKI1 inhibits neuronal death without affecting the accumulation of 
microglia, and without an obvious effect on microglial activation state, suggesting that 
the activation of microglia does not necessarily exacerbate neuronal damage induced by 
transient cerebral ischemia.  
 
4.2 EFFECT OF D-JNKI1 ON T LYMPHOCYTES AND ASTROCYTES 
 
In accordance with previous reports, we found accumulation of T lymphocytes (TCRβ+ 
cells) and dendritic cells (CD11c+) in the ischemic tissue 48 h after MCAO (Kato et 
al., 1996; Raivich et al., 1999; Kostulas et al., 2002; Reichmann et al., 2002; 
Gelderblom et al., 2009). The release of inflammatory mediators from activated glial 
cells and the opening of the blood brain barrier (BBB) following stroke (Barone & 
Feuerstein, 1999) induced the recruitment of circulating leukocytes (granulocytes, 
monocytes/macrophages, lymphocytes). Several publications have described that 
blocking leukocyte infiltration decreases secondary injury linked to inflammatory 
process by inhibiting the formation of reactive oxygen species (nitric oxide, 
superoxide) and preventing the breakdown of the blood brain barrier which leads to 
hemorrhagic complications (Iadecola et al., 1995; Parmentier et al., 1999; Barone & 
Feuerstein, 1999; Zoppo & Hallenbeck, 2000; Zoppo et al., 2000; Rosell et al., 2008). 
Thereby, the reduction of T lymphocytes in the ischemic tissue might be 
neuroprotective. Activation of the JNK pathway leads to the transcription of 
inflammatory molecules, such as chemokines which could further drive the activation 
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and recruitment of T lymphocytes. The inhibition of the JNK pathway in microglia 
reduces in some cases the expression of inflammatory mediators (see Introduction, 
section 1.7.2). Therefore, we could hypothesize that the reduction of inflammatory 
mediators through the inhibition of JNK would result in a diminution of T lymphocyte 
recruitment in the ischemic parenchyma. Thus, D-JNKI1 would indirectly modify the T 
cell response after ischemia, and therefore decrease the neuronal damage. The 
astrocytic response after stroke is not well understood yet, since astrocytes secrete pro-
apoptotic signals, inflammatory mediators as well as growth factors (Anderson et al., 
2003). It has been shown that astrocyte proliferation after endothelin-1 stimulation 
depends on c-Jun induction (Gadea et al., 2008). In agreement with these findings we 
showed an activation of the nuclear target of JNK, phospho-c-Jun, in reactive 
astrocytes after MCAO. D-JNKI1 could therefore modulate the JNK pathway in 
astrocytes and probably the inflammatory response after stroke. 
 
We and others clearly demonstrated that microglia and other inflammatory cells were 
activated in the ischemic tissue. All these cells could potentially be influenced by the 
inhibition of the JNK pathway (Waetzig et al., 2005; Raivich & Behrens, 2006). 
Therefore it would be of great interest to investigate the possible effect of D-JNKI1 on 
T lymphocytes, DCs and astrocytes in our model of brain ischemia. Indeed, based on 
the hypothesis that modulation of inflammation could be neuroprotective, it would be 
interesting to investigate the effect of D-JNKI1 on different cell types rather than 
focusing on microglial cells only. 
 
4.3 ACTIVATION OF THE JNK SIGNALING PATHWAY IN MICROGLIA 
 
As microglia are capable of various responses depending on the type of injury, and 
since changes in morphology and upregulation of surface expression markers do not 
always reflect microglial activation, it will be necessary to go on to investigate its 
function as for instance the release of inflammatory mediators (Feuerstein et al., 1998; 
Hanisch, 2002; Garden & Möller, 2006; Clausen et al., 2008). Previous studies have 
reported that the ischemic damage is attenuated by inhibiting pro-inflammatory 
cytokines or transcription factor such as nuclear factor-κB (NF-κB), by diminishing 
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free radicals generated by inducible nitric oxide synthase (iNOS) or cyclooxygenase- 2 
(COX-2), (Iadecola et al., 1995; Yang et al., 1998; Parmentier et al., 1999; Nijboer et 
al., 2009). As the JNK pathway is also involved in the regulation of inflammatory 
molecules (Hidding et al., 2002; Waetzig et al., 2005), D-JNKI1 could therefore 
modulate cytokine secretion. Several studies have described the involvement of the 
mitogen-activated protein kinase pathway (MAPKs family, including JNK, ERK and 
p38) in the regulation of inflammatory mediators [for review see (Kaminska, 2005) and 
Introduction, section 1.7]. In vitro, the JNK pathway is activated in microglial cultures 
stimulated by TNFα, thrombin or LPS. CEP-11004 (an inhibitor of mixed lineage 
kinases) reduces LPS-induced phosphorylation of JNK and c-Jun and attenuates 
microglial morphological changes (Hidding et al., 2002) and SP600125 (an ATP-
competitive JNK inhibitor) reduced microglial metabolic activity and proliferation 
(Waetzig et al., 2005). Here, we report for the first time that phospho-c-Jun was 
activated in microglia after transient MCAO in mice, which led us to test whether D-
JNKI1 could modulate microglial activity through the regulation of the JNK pathway. 
Unless we found activation of the JNK pathway in microglia, D-JNKI1 could not 
modify its activation state. Thus JNK may not be the predominant or only pathway 
required for microglial activation in the brain after cerebral ischemia. As JNK and p38 
are up-regulated after stress, one could imagine that inhibition of more than one 
pathway would be necessary for complete inhibition of microglial activation. An 
inhibitor of p38 mitogen-activated protein kinase (SB239063) has been shown to 
reduce microglial activation after OGD in hippocampal cultures when administrated 2 h 
before and until 24 h after the deprivation (Strassburger et al., 2008). Thereby, 
combined inhibitors of the MAPK pathways could affect more significantly the 
activation of microglia in vivo. 
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4.4 EFFECT OF D-JNKI1 ON MICROGLIA IN VITRO  
 
With the aim to understand the molecular mechanisms of the JNK pathway in 
microglia, we investigated the role of D-JNKI1 in vitro. In our OGD model of 
ischemia, we showed that the peptide prevented neuronal cell death in the CA1,  
reflected by a reduction of propidium iodide uptake, as previously described (Hirt et al., 
2004). We found a strong activation of phospho-c-Jun in CA1 neurons 48 h after OGD. 
Treatment with D-JNKI1 did not completely block c-Jun activation but rescued 
neurons from OGD-induced death. It is well described that levels of activated JNK are 
found in neurons under basal conditions, indicating that the JNK pathway is also 
important for other metabolic processes (Harris et al., 2002; Besirli et al., 2005), 
suggesting that a complete suppression of c-Jun could impair different important 
functions and not be neuroprotective. In agreement with our results, experimental 
studies on mice harboring conditionally inactivated c-Jun and non-phosphorylating c-
Jun mutant do not show a reduction of the lesion size after transient MCAO (Vogel et 
al., 2007). 
 
In slices subjected to OGD and treated with D-JNKI1, we found a co-localization of D-
JNKI1 with neuronal markers and, to a much lesser extent, with microglia. 
Interestingly, we observed morphological changes of microglia in vitro: while 
microglial cells were in a well ramified state in control slices, they became more 
rounded after OGD, and D-JNKI1 inhibited this morphological change. The JNK 
pathway modulates the phosphorylation of actin and microtubules and could thereby 
modify the microglial morphology (Waetzig et al., 2005). Besides modification of 
microglial morphology after D-JNKI1 treatment in vitro, we found a change in 
microglial localization after OGD and after OGD+D-JNKI1. In control slices microglia 
were homogenously distributed whereas after OGD microglia were predominantly 
localized within the damaged neuronal CA1 layer. Treatment with D-JNKI1 modified 
slightly the localization of microglia, which were found at the boundary of the neuronal 
CA1 layer as well. Modification of microglial cell localization at the site of injury has 
been previously reported in hippocampal slice cultures (Heppner et al., 1998; Montero 
 72 
Domínguez et al., 2009). Altogether, OGD induced changes in microglial morphology 
(ramified to ameboid) and accumulation in the degenerating neuronal CA1 layer. These 
changes were modified by D-JNKI1. We may hypothesize that D-JNKI1 exerts a 
neuroprotective effect directly on neurons (shown in this in vitro study by localization 
of D-JNKI1 in NeuN-positive cells and by previous data in neuronal cultures, (Borsello 
et al., 2003), and modifies the cellular signaling from affected neurons to microglia. 
Thus, D-JNKI1 would act indirectly on microglia through signals secreted by neurons 
influencing microglial activity and localization. 
 
Interestingly, the hippocampal slice hypoxia-hypoglycemia model may not reproduce 
mechanisms of microglial activation observed in the in vivo stroke model. Indeed, D-
JNKI1 showed no effect on microglial activation and accumulation at 48 h after 
MCAO, while changes in morphology and localization were observed in vitro. This 
may reflect species, age differences (adult mice used in vivo versus newborn rats in 
vitro) and different concentration of the inhibitor, which might cause discrepancies. 
Furthermore, in vitro models are only partially representative of the in vivo situation 
concerning the microglial response. Indeed, we saw DCs and infiltration of 
inflammatory cells, such as T lymphocytes after MCAO (Figure 9), which evidently 
does not occur in vitro. These cells could modulate microglial activation and may 
explain the differences seen in the two models. Besides the activation and accumulation 
of glial and inflammatory cells in the brain parenchyma are time dependent 
(Gelderblom et al., 2009). Thus in vivo we might not observed an effect on microglial 
activation 48 h after the injury, but probably we could found changes at later time as 
the inflammatory response in the tissue last for several days (Dirnagl, 1999). It is worth 
noting that in a complex situation such as brain inflammation following stroke which 
depends of several paramaters (time, type of cells, localization), it would not be 
suprising that we obtained different results in our models. 
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4.5 CONCLUDING REMARKS OF THE 1ST PART 
 
Here we demonstrated that D-JNKI1, a selective JNK inhibitor and highly 
neuroprotective peptide, does not attenuate the activation and accumulation of 
microglia in the ischemic tissue in an in vivo MCAO model of stroke at 48 h. This 
finding adds to the knowledge that neuroprotection via inhibition of JNK is 
independent of microglial accumulation or activation. It also indicates that the JNK 
pathway might be not essential to microglial activation after ischemia, and that the 
presence of activated microglia in the ischemic area is not necessarily detrimental to 
neurons. Additionally, our study suggests that D-JNKI1 could be safely used in clinical 
stroke patients, as it does not exacerbate inflammatory responses after cerebral 
ischemia. Our in vitro data point towards an effect of D-JNKI1 on microglial 
recruitment as well as morphological changes, which is likely to be an indirect effect of 
the peptide through its action on neurons.  
 
There are many controversies about the protective or detrimental role of microglia on 
neuronal survival after cerebral ischemia, namely whether activated microglia are 
enhancing or reducing neuronal damages. At this point, we can assume that the 
activation of microglia is not detrimental. However, investigating the morphology of 
microglia is not  sufficient to completely rule out this hypothesis. Therefore, looking at 
the pattern of secreted pro- and anti-inflammatory mediators in brain ischemia with and 
without D-JNKI1 treatment will help to characterize the role of inflammation during 
cerebral ischemia. Furthermore, as D-JNKI1 was not detected in the brain by 
immunohistochemistry, it could also possibly inhibit peripheral JNK activation, which 
could lead to a modulation of peripheral inflammatory processes and indirect 
neuroprotection. The second part of the discussion will address this issue. 
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SECOND PART: EFFECT OF NEUROPROTECTION ON THE SECRETION 
OF INFLAMMATORY MEDIATORS 
 
Most inflammatory reactions are mediated by the secretion of cytokines and 
chemokines, such as for instance upregulation of adhesion molecules, recruitment and 
stimulation of leukocytes, activation of glial cells, induction of intracellular 
inflammatory signaling pathways (Wang et al., 2007). An increase of pro- and anti-
inflammatory mediators has been reported in experimental models of cerebral ischemia 
as well as in patients with acute stroke. The association between inflammatory 
mediators and brain damage as well as stroke progression and prognosis is not well 
defined. Many discrepancies actually exist among several investigations both in animal 
stroke models and clinical studies. These contradictory results have been discussed in 
the second part of the Introduction. Thus, there is a great need to understand the 
inflammatory processes after stroke and whether they lead to tissue repair or damage, 
in the purpose of better targeting drugs or of avoiding research on the wrong target. 
Taking advantage of our mouse model of potent neuroprotection following cerebral 
ischemia, we investigated the systemic and local brain inflammatory response in order 
to better characterize the role of post-stroke inflammation and to assess whether 
cytokine/chemokine modulation is dependent on the JNK signaling pathway. 
Regarding the potential regulation of IL6 and KC by the JNK pathway (see 
Introduction, sections 1.5.3 and 1.5.4) and based on recent findings that these two 
mediators displayed the most significant changes in release following cerebral ischemia 
(Chapman et al., 2009), we chose to analyze the secretion of these two inflammatory 
molecules in the systemic circulation and in the brain following experimental cerebral 
ischemia. Our concluding remarks are therefore extrapolated from our results on these 
two inflammatory mediators. 
 
4.6 SYSTEMIC INFLAMMATION FOLLOWING STROKE 
 
It has now been well described that a systemic increase of cytokine and chemokine 
levels occurs very early following stroke. In accordance with previous clinical and 
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experimental studies, we found a significant plasma release of IL6 and KC between 
four and seven hours after the onset of cerebral ischemia compared to sham mice 
(Figure 19), (Yamasaki et al., 1995; Emsley et al., 2003; Offner et al., 2006; Chapman 
et al., 2009). The chemokine CXCL1/KC is thought to generate an environment which 
could induce a gradient and favor leukocyte recruitment to the brain and potentiate the 
ischemic damage (see Introduction, sections 1.5.2 and 1.5.4). The implication in the 
lesion development of the early systemic IL6 secretion following stroke, despite 
extensive studies, is far from clear (see Introduction, section 1.5.3). It is thus not well 
established whether the increase of systemic inflammatory mediators plays a 
pathogenic part in cerebral ischemia, reflects the ischemic brain injury or has other 
physiological roles. Taking advantage of the established neuroprotective effect of D-
JNKI1 in experimental mouse models of cerebral ischemia (Wiegler et al., 2008; 
Benakis et al., 2010), we assessed the secretion of IL6 and KC in the plasma of mice 
injected intravenously with a single dose of D-JNKI1, 3 h after the onset of ischemia. 
Surprisingly, we found no significant difference neither in early systemic IL6 release 
nor KC release between the vehicle and D-JNKI1-treated groups, even though we 
measured a significant decrease by half of the lesion volume 48 h after MCAO (Figure 
22). These interesting findings reveal that the early systemic release of IL6 and KC is 
not correlated with an unfavorable outcome. Thus, the early increase of systemic 
inflammatory mediators following cerebral ischemia is not a relevant biomarker for 
poor prognosis, at least in our model.  
 
Even though we showed that early systemic inflammation following stroke is 
independent of poor outcome, it would be of great interest to understand the causes and 
consequences of this increase of plasma cytokine/chemokine secretion, as for instance 
investigating their source of production. We assessed the secretion of both these 
inflammatory mediators also in the ischemic brain at several time points. In accordance 
with others, we found no significant difference of both IL6 and KC brain release at four 
and seven hours between MCAO and sham mice (Figure 22), (Chapman et al., 2009). 
Because we measured an increase of cytokine/chemokine early in the plasma and not in 
the brain, thus we assumed that the brain was not the main source of early systemic 
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inflammation. Offner and colleagues found an increased release of several cytokines 
from activated and unstimulated mouse splenocytes 6 h after cerebral ischemia (Offner 
et al., 2006). Chapman et al. found no induction of IL6 in lungs and liver after 
experimental stroke, whereas hepatic and pulmonary expression of CXCL1 was 
elevated in correlation with the systemic temporal profile (Chapman et al., 2009). Thus, 
early after ischemia, peripheral organs are able to secrete inflammatory mediators. 
Altogether, we hypothesize that the peripheral immune system is the main source of 
early systemic inflammation, and probably acts as an early response reflecting the 
ongoing injury rather than a mechanism leading to an increase in cerebral damage: 
firstly, because we obtained neuroprotection despite early systemic inflammation; 
secondly, because systemic inflammation was transient, indeed we reported an increase 
of IL6 and KC in the plasma until 7 h after ischemia and a drastic decrease between 24 
h and 48 h, especially for the non-D-JNKI1-treated group (Figure 23). 
 
How does cerebral ischemia result in an early systemic inflammatory response in the 
absence of a local significant cerebral inflammation? There are several axes of 
communication between the central nervous system and peripheral immune system: the 
hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS), 
(Elenkov et al., 2000; Pedemonte et al., 2006). Thus, within minutes of the occlusion, 
signals from the damaged brain could be sent to the periphery and activate an immune 
response which would drive the secretion of inflammatory mediators. It has to be noted 
that, even though our data suggest that there is no detrimental effect of the early 
systemic inflammation, we still need to understand why a massive activation of the 
peripheral immune system takes place early after brain injury. 
 
We have started to examine the effect of D-JNKI1 on the spleen, liver and lungs. 
Preliminary results indicate a decrease of IL6 release from the spleen at 7 h in mice 
treated with D-JNKI1 and not in vehicle-treated mice, in which this decrease takes 
place later. Thus we propose that D-JNKI1, by reducing neuronal death, might 
indirectly restrain a sustained peripheral inflammatory response which could be 
unfavorable for the late outcome. This issue clearly needs to be further examined.  
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4.7 BRAIN INFLAMMATION FOLLOWING STROKE 
 
Release of IL6 and KC was investigated in the brain of vehicle and D-JNKI1 groups at 
different time points. We could not detect a significant increase of KC in the brain at 
any time point compared to sham mice, contrasting with results published by other 
groups (Chapman et al., 2009; Yamasaki et al., 1995). This difference could have 
several explanations: 1) Chapman et al. performed a longer occlusion duration (60 min 
occlusion, V = 67 mm3), which could explain the increase of KC in their model; 2) 
different animal species were used, which may display different inflammatory reactions 
in response to cerebral ischemia; 3) different anesthetic agents were used, and the 
anesthesia itself might modulate the production of inflammatory mediators (Denes et 
al., 2010b). We found a significant increase of brain IL6 release at 48 h between sham 
and MCAO mice. However, D-JNKI1 did not reduce IL6 secretion at 48 h. Suzuki and 
colleagues suggest that IL6 may contribute to both injury and repair during the acute 
phase of cerebral ischemia. However the peak of IL6 expression would be associated 
with neuroprotection (Suzuki et al. 2009). We assume that brain inflammation 
mediated by IL6 is not detrimental at 48 h, as we found a significant reduction of the 
lesion volume of mice treated with D-JNKI1 (Figure 22). Furthermore, we carefully 
recorded the parameters (temperature, weight and neuroscore listed in Appendix: 
Tables 2) at sacrifice in all three groups. Forty-eight hours after injury, the weight of 
treated mice used in the ELISA study was significantly higher than that of vehicle 
mice, which shows a better well-being of treated mice at this time point and confirms 
the neuroprotection in this separate set of experiments. It is worth noting that we used a 
moderate model of MCAO (transient occlusion for 30 minutes), which commonly leads 
to striatal and cortical lesions or, in some animals, to a striatal lesion only. The 
variability of the lesion size in this model could explain that we do not measure a 
significant difference of cytokine/chemokine release between groups. 
 
Another interesting issue that needs to be discussed is the survival analysis after 
MCAO in both groups. We noticed that, even though the survival prognosis showed no 
overall significant difference between groups, no death was recorded from 24 h after 
the injury onwards in the D-JNKI1-treated group compared to the vehicle group 
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(Appendix, Table 4). The survival proportion in the vehicle group starts to decrease to 
65% at 4 days and reaches 55% at 5 days, whereas that of the D-JNKI1 group remains 
stable until 5 days (91%). Therefore, we assume that D-JNKI1 may have an effect on 
IL6 release at late time points, especially on the plasmatic concentration. Indeed, we 
observed a trend towards a reduction of IL6 concentration in the plasma and slightly in 
the brain of treated animals five days after the injury (Figure 22, pplasma = 0.27, pbrain = 
0.42). However, this potential reduction of IL6 release might not be apparent in our 
data because of the higher proportion of death at 48 h and 5 days in vehicle mice than 
in treated mice. Overall, we can suppose that mice with a better prognosis would have a 
reduced inflammatory response at late time points. This effect might be mediated by 
the neuroprotective effect of D-JNKI1. Thus, we suggest that systemic and brain 
inflammation at late time points are a consequence of the neuronal damage and could 
favor poor outcome, but are not the direct cause of the injury. This hypothesis needs 
further investigation. 
 
4.8 REGULATION OF THE JNK PATHWAY AND SECRETION OF 
INFLAMMATORY MEDIATORS 
 
The regulation of IL6 and IL8 (KC/CXCL1) expression, among other inflammatory 
mediators, is partly mediated by the activation of the JNK intracellular signaling 
pathway, as these genes contain an AP-1 site in their promoter region (Waetzig et al., 
2005). JNK is activated during cerebral ischemia, therefore we assumed that D-JNKI1 
would modulate the secretion of both cytokines through the inhibition of the JNK 
pathway. Furthermore, the peptide was injected intravenously; thus, we could expect a 
peripheral effect on cytokine secretion, as JNK is expressed ubiquitously. However, as 
described above, we did not find any significant difference in the level of brain and 
systemic IL6 and KC secretion following ischemia between groups treated with D-
JNKI1 or not. Nijboer and colleagues evaluated the effect of a short half-life inhibitor 
of JNK, L-JNKI1, on the mRNA expression of several cytokines and chemokines in a 
model of perinatal hypoxia–ischemia (HI). The inhibition of the JNK/AP-1 pathway 
did not reduce brain cytokine/chemokine expression 3 h after induction of HI, even 
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though the peptide was neuroprotective. We found similar results on the de novo brain 
synthesis of inflammatory mediators using a JNK inhibitor with a longer half-life. 
Thus, neither the mRNA expression nor the secreted cytokine/chemokine are down-
regulated by the inhibition of JNK (Nijboer et al., 2010). These results strongly suggest 
that the JNK pathway, which leads to the synthesis of inflammatory mediators, is not 
affected by JNK inhibitors after cerebral ischemia. Furthermore, these findings suggest 
that not all JNK targets are inhibited by L- or D-JNKI1. This in itself is of great 
interest, as it would be detrimental to totally inhibit the JNK pathway, since it has 
diverse physiological functions that might be necessary for cell survival. 
 
4.9 CONCLUDING REMARKS OF THE 2ND PART 
 
Here we demonstrated that D-JNKI1, a highly neuroprotective peptide, does not 
attenuate the release of IL6 and KC in the systemic circulation early after the ischemic 
injury. This very interesting finding adds to the knowledge that increased plasma levels 
of inflammatory mediators are not a biomarker for an irreversible brain lesion. Several 
clinical and experimental studies report an increase of systemic inflammatory 
mediators after stroke and an association with an unfavorable outcome. Indeed, in 
vehicle mice subjected to MCAO, we noticed at first that systemic inflammation 
precedes brain inflammation and, importantly, the onset of the visible lesion in the 
brain parenchyma (Figure 21). Thus, a linear relationship of cause and effect could 
easily be inferred: the systemic inflammation increases the brain injury. It may be for 
this reason that much experimental research focused on this early post-stroke process to 
target neuroprotective drugs. However, our results clearly indicate that neuroprotection 
occurs despite the early increase of systemic inflammation. Thus, there is no point in 
therapeutic drugs targeting this early event. Furthermore, we found a trend towards a 
reduction of the systemic concentration of inflammatory mediators as late as five days 
after ischemia in mice treated with D-JNKI1 as well as a tendency towards better 
survival. Therefore, we suggest that the systemic increase of inflammatory mediators 
reflects the ongoing injury, particularly at late time points, and might have a 
consequence on the overall impairment of the patient's condition. In addition, we 
 80 
showed that de novo cytokine secretion in the brain did not decrease after 
neuroprotective treatment, while we observed a reduction of the lesion volume.  
 
Together with our results described in the first part of this project, we showed that 
neuroprotection occurs independently of microglial activation and cytokine release in 
the brain and systemic circulation. Besides, the inhibition of the JNK pathway, one of 
the main regulators of inflammatory genes transcription, is not sufficient to inhibit 
inflammatory mediator secretion and microglial activation.  
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5. CONCLUSION AND PERSPECTIVES 
 
Throughout the past twenty years, the brain inflammatory reaction to an ischemic 
stroke has been carefully examined. Nowadays it is incontestable that inflammatory 
cells and mediators are present in and around the ischemic brain tissue. However, the 
beneficial or detrimental role of inflammation during cerebral ischemia is still hotly 
debated. This project aimed at better characterize the highly regulated post-stroke 
inflammation process. 
 
The first key result of this work is that neuroprotection occurs even though there is 
inflammation following experimental stroke. Indeed, after cerebral ischemia, we 
observed in the brain parenchyma that microglial cells are activated, cytokines and 
chemokines are secreted independently of the reduction of the neuronal death. In the 
systemic circulation, level of inflammatory mediators is elevated early after ischemia 
regardless the outcome. Our second important result is that inhibition of the 
intracellular JNK signaling pathway using the highly neuroprotective peptide D-JNKI1 
does not influence directly post-stroke inflammation. Altogether, we report that 
inhibition of inflammation is not necessarily required to obtain a high degree of 
neuroprotection after cerebral ischemia. Thus, post-stroke inflammation might not be 
detrimental for the tissue recovery.  
 
These findings may be seen as negative results because they were not what we 
expected, namely we did not obtain inhibition of inflammation in a model of 
experimental cerebral ischemia as we first postulated in our hypothesis. Editors and 
even authors are not always eager to publish negative results, which may be seen as 
less interesting. However, it is a mistake not to report studies that are negative but 
cautiously designed and which lead to interpretable results. In this regard, we need to 
address the fact that our negative results could be explained by two important aspects 
that need to be mentioned. First, our MCAO model was carried out in outbred mice. 
This is a very relevant strain for clinical issues because these mice represent a human 
population better than inbred mice, which are genetic clones. However, the use of non-
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consanguineous mice leads to a potentially higher degree of variability, and we are 
aware that it could potentially hide the differences between treatment groups. Second, 
inflammatory processes and intracellular signaling pathways are highly regulated and 
redundant mechanisms. This means that shutting down one pathway, one type of 
inflammatory cells or one cytokine or chemokine would not necessarily induce a 
significant phenotype because of compensating mechanisms. In this respect, we could 
increase the number of animals per group to see if we observed a difference between 
groups. Furthermore, it would be interesting to inhibit several intracellular signaling 
pathways that could have a more pronounced effect on the secretion of inflammatory 
mediators. Overall, carefully performed experimental studies which lead to either 
positive or negative results bring us closer to a better understanding of the disease and 
of its underlying cellular and molecular mechanisms, to an improvement of the 
potential treatments and of the way to test them in clinical trials. Even though negative 
results may not be the final step toward a new treatment, they certainly help researchers 
to raise new hypotheses. 
 
Despite the fact that we found interesting ‘negative’ results, this project is far from 
having answered all the questions about the role of inflammation after stroke and, in 
our case, the effect of the JNK inhibitor D-JNKI1 on inflammation. Many routes still 
need to be investigated. In this section, we propose experiments which could lead to a 
better understanding of the regulation of the JNK pathway and of the inflammatory 
process. We have mentioned (Introduction, section 1.5.3) that activation of JAK/STAT 
pathway was induced by IL6 binding to its associated receptor, leading to a series of 
phosphorylation events, which stimulates the transcriptional activities of Stat3. 
Activated Stat3 induces the expression of the SOCS3. The suppressor of cytokine 
signalling (SOCS) proteins have a broad range of effects, including the modulation of 
cytokine signaling in various diseases of the CNS (Baker et al., 2009). In experimental 
models of cerebral ischemia, SOCS3 expression is up-regulated. In addition, antisense 
knockdown of SOCS3 protein expression increased the lesion volume, suggesting a 
neuroprotective role of SOCS3 (Bates et al., 2001; Raghavendra Rao et al., 2002). 
Interestingly, Stat3 can undergo phosphorylation at several sites, some of which may 
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lead to an inhibition of its transcriptional activity. For instance, activation of the JNK 
pathway inhibits Stat3 DNA binding and its transcriptional activities after stimulation 
by IL6 (Lim & Cao, 1999; Schuringa et al., 2000; Heinrich et al., 2003). Thus, the JNK 
pathway appears to negatively regulate Stat3 and therefore probably also SOCS3. We 
can hypothesize that when JNK is inhibited by D-JNKI1, Stat3 would be up-regulated 
and induce SOCS3 expression, which could lead to neuroprotection via cytokine 
modulation. According to this hypothesis, we propose to analyze the phosphorylation 
state of Stat3 in our MCAO model with or without D-JNKI1. We could therefore 
obtain a new pathway of the regulation of the JNK pathway by D-JNKI1 stimulated by 
IL6. Altogether, we hypothesize that p-Stat3 activation mediated by IL6 through the 
JAK/STAT pathway as well as the inhibition of the JNK pathway could be associated 
with neuroprotection. Figure 24 illustrates this hypothesis on the intracellular pathways 
that could be regulated by D-JNKI1. 
 
Figure 24. Hypothesized effect of D-
JNKI1 on the intracellular pathway 
activated by IL6 
On the left part, we show the effect of D-
JNKI1 inhibition on the AP1 complex 
transcription activity. On the right part, 
we illustrate the activation of the 
JAK/STAT pathway. We hypothesize 
that D-JNKI1, by inhibiting JNK, could 
up-regulate Stat3 and lead to the 
transcription of SOCS3, which could be 
neuroprotective in MCAO models. 
(Figure was produced using Servier 
Medical Art). 
 
This proposed experiment illustrates that D-JNKI1 could have an effect on post-stroke 
inflammation through modulation of intracellular pathways. However based on results 
of the present work, the direct link between inflammation and inhbition of JNK in our 
experimental models is not yet elucidated. In the state of our current knowledge we 
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suggest that D-JNKI1, by reducing the neuronal death, could ameliorate the overall 
condition of the subject and would indirectly modulate at late time points the 
inflammation of peripheral organs and probably also inflammatory mechanisms in the 
brain tissue. Therefore, we would like to investigate the secretion of inflammatory 
mediators after MCAO in the plasma and in the brain, spleen, liver and lungs at later 
time points (such as 7 days and 14 days) in vehicle and treated animals. Additionally, 
information of the inflammatory profile in the lungs after stroke would be interesting as 
we could investigate the phenomenon of stroke-induced ‘immunosuppression’ and the 
occurrence of pneumonia, and whether D-JNKI1 inhibits this unfavorable outcome.  
 
We have seen that inflammation after cerebral ischemia is a very complex mechanism 
which is far from being understood, as many discrepancies between experimental 
findings exist. I think that controversial ideas on the beneficial and especially the 
detrimental role of post-stroke inflammation could stem from preconceived notions. 
Indeed, in other diseases of the CNS such as multiple sclerosis, cerebral damage is 
universally thought to be a direct consequence of brain inflammation. Therefore, 
cerebral inflammation comes to be seen as uniformly detrimental. However, in the 
context of stroke, I propose that inflammation occurring in the brain may be better seen 
as necessary to rescue the damaged tissue and even to mediate tissue repair. It would 
therefore not exacerbate the neuronal death, but on the contrary limit it and promote 
recovery. Furthermore, I deem essential to better appreciate the distinctive temporal 
and spatial contributions of systemic and brain inflammation following stroke. I 
suggest that early systemic inflammation is the reflect of the ongoing injury, then that 
brain inflammation is activated to clear the damaged tissue, and later that systemic and 
brain inflammation mirror the general condition of the subject. Despite the 
discouraging of clinical trials of neuroprotection so far, I suggest that it is of great 
interest for patients to continue the development of therapeutic drugs based on 
neuroprotective agents, because they could prevent neuronal death and indirectly late 
inflammatory processes, which altogether would be greatly beneficial for a better 
recovery after stroke. 
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6. APPENDIX 
 
Tables 2 (Figures 19, 20, 22C, 22D, 23) 
MCAO 30 min – Sacrifice at 4 h, 7 h, 24 h, 48 h, 5d – Cytokine assay 
Results are presented as mean ± SEM, except for neurological score expressed as 
[median, min, max]. *p<0.05 indicates a significant difference in MCAO+vehicle mice 
versus MCAO+D-JNKI1 mice. #p<0.05 ; ##p<0.01; ###p<0.001 indicate a significant 
difference between sham mice and MCAO (vehicle or D-JNKI1) mice. There was a 
better reperfusion in the D-JNKI1 treated group sacrified at 7 h (*p < 0.05). In the 
group sacrified at 48 h, weight at sacrifice was lower in vehicle- and D-JNKI1-treated 
mice than sham mice (###p < 0.001 and ##p < 0.01, respectively). Furthermore, there 
was a less weight loss in the D-JNKI1 group than the vehicle group (*p < 0.05). At 5 d, 
weight at sacrifice of vehicle- and D-JNKI1-treated mice was lower than sham mice 
(#p<0.05). 
 
 
 
4h Sham (n = 5) Vehicle (n = 6) D-JNKI1 (n= 7) 
CBF during ischemia (%) - 11.0 ± 1.2 13.0 ± 1.1 
CBF after ischemia (%) - 67.5 ± 6.5 67.9 ± 8.3 
Weight (g) 28.6 ± 2.1 28.2 ± 1.7 27.9 ± 1.0 
Weight at sacrifice (g) 27.6 ± 1.6 26.5 ± 1.7 26.4 ± 1.2 
T during ischemia (°C) 36.5 ± 0.2 36.7 ± 0.06 36.6 ± 0.1 
T at sacrifice (°C) 36.1 ± 0.5 35.5 ± 0.3 35.1 ± 0.1 
Neuroscore at 4 h - 2.0, 1.0, 3.0 1.75, 1.0, 2.0 
7h Sham (n = 5) Vehicle (n = 10) D-JNKI1 (n= 7) 
CBF during ischemia (%) - 11.6 ± 1.4 10.9 ± 0.9 
CBF after ischemia (%) - 57.0 ± 2.9 76.4 ± 6.9* 
Weight (g) 30.4 ± 1.7 29.6 ± 0.9 28.9 ± 1.7 
Weight at sacrifice (g) 29.7 ± 1.7 28.1 ± 1.0 26.9 ± 1.7 
T during ischemia (°C) 36.6 ± 0.1 36.8 ± 0.05 36.6 ± 0.2 
T at sacrifice (°C) 36.1 ± 0.2 35.9 ± 0.4 35.4 ± 0.2 
Neuroscore at 7 h - 2.0, 1.5, 3.0 1.5, 1.0, 3.0 
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24h Sham (n = 3) Vehicle (n = 6) 
CBF during ischemia (%) - 13.7 ± 1.6 
CBF after ischemia (%) - 69.2 ± 8.6 
Weight (g) 28.3 ± 2.8 28.7 ± 1.9 
Weight at sacrifice (g) 28.0 ± 2.0 23.8 ± 1.7 
T during ischemia (°C) 36.6 ± 0.2 36.8 ± 0.1 
T at sacrifice (°C) 36.0 ± 0.7 35.4 ± 0.4 
Neuroscore at 48 h - 1.25, 1.0, 2.0 
48h Sham (n = 7) Vehicle (n = 9) D-JNKI1 (n = 8) 
CBF during ischemia (%) - 12.0 ± 1.2 12.5 ± 2.3 
CBF after ischemia (%) - 60.3 ± 4.3 62.6 ± 2.7 
Weight (g) 27.9 ± 1.1 28.0 ± 0.7 30.8 ± 1.0 
Weight at 24 h (g) 27.3 ± 1.2 23.0 ± 0.5 26.0 ± 0.9 
Weight at sacrifice (g) 29.0 ± 0.9 21.4 ± 0.6### 24.6 ± 1.2##/* 
T during ischemia (°C) 36.4 ± 0.2 36.5 ± 0.1 36.5 ± 0.06 
T at 24 h (°C) 35.4 ± 0.3 35.0 ± 0.3 35.0 ± 0.2 
T at sacrifice (°C) 35.6 ± 0.3 34.4 ± 0.3 34.3 ± 0.4 
Neuroscore at 24 h  1.5, 1.0, 2.0 1.75, 1.0, 2.0 
Neuroscore at 48 h - 1.5, 1.0, 2.0 1.5, 1.0, 3.0 
5d Sham (n = 8) Vehicle (n = 6) D-JNKI1 (n = 7) 
CBF during ischemia (%) - 15.3 ± 2.0 9.8 ± 1.4 
CBF after ischemia (%) - 63.3 ± 5.7 63.1 ± 6.6 
Weight (g) 28.1 ± 1.3 29.7 ± 1.4 28.9 ± 0.8 
Weight at sacrifice (g) 30.3 ± 1.4 24.5 ± 2.0# 23.4 ± 1.4# 
T during ischemia (°C) 36.3 ± 0.1 36.9 ± 0.2 36.7 ± 0.1 
T at sacrifice (°C) 35.7 ± 0.2 34.7 ± 1.0 34.7 ± 0.3 
Neuroscore at 48 h - 1.25, 1.0, 1.5 1.0, 0, 1.5 
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Table 3 (Figure 22A) 
MCAO 30 min – 48 h reperfusion – PFA fixation 
Results are presented as mean ± SEM, except for neurological score expressed as 
[median, min, max]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 (Figure 22B) 
Survival proportions [%] of mice in the vehicle group or treated with D-JNKI1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Vehicle (n = 7) D-JNKI1 (n = 5) 
CBF during ischemia (%) 11.3 ± 2.0 9.4 ± 1.2 
CBF after ischemia (%) 61.6 ± 5.5 57.4 ± 6.0 
Weight (g) 29.6 ± 0.6 29.6 ± 0.9 
Weight at sacrifice (g) 22.7 ± 0.9 23.2 ± 1.0 
T during ischemia (°C) 36.6 ± 0.1 36.6 ± 0.06 
T at sacrifice (°C) 34.7 ± 0.4 34.5 ± 0.5 
Neuroscore at 48 h 1.5, 1.5, 2.0 1.0, 1.0, 1.5 
Hours [min] Vehicle (n = 57) D-JNKI1 (n = 45) 
0.000 100.000 100.000 
4.000 98.24561 100.000 
5.000 96.2807   
6.000 94.31579   
7.000 94.31579 100.000 
24.000 91.83379 90.625 
48.000 91.83379 90.625 
96.000 64.28366   
120.000 55.10027 90.625 
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Summary
It is well-known that inflammation plays a major role
in the genesis of the atherosclerotic plaque and thus
favours the occurrence of stroke. But, inflammation is
also involved after an ischaemic event affecting the
brain. In this case, one can observe the infiltration of
numerous inflammatory cells at the site of the lesion,
the activation of the microglia and of pro-inflammatory
cytokines, etc. It is usually thought that this post-
stroke inflammation is rather deleterious, as suggested
by the fact that, after an experimentally-induced is-
chaemic stroke, blockade of the inflammatory response
improves the neurological condition of mice. Neverthe-
less, until now, the application of such experimental
treatments in humans has revealed unsuccessful. One
of the possible explanations for this phenomenon might
be that inflammation also has some beneficial effects,
such as clearance of damaged tissue, promotion of an-
giogenesis, or still tissue remodelling and regeneration.
After this first “basic science” part, we will briefly
review some clinical aspects of the most significant in-
flammatory diseases that can cause stroke, i.e., the
vasculitis. Among them, Takayasu’s arteritis, giant cell
temporal arteritis (Horton’s disease), and primary
angiitis of the central nervous system will be discussed.
We will also shortly address the question of the an-
tiphospholipid syndrome.
Key words: cytokines; ischaemia; microglia; neuro-
protection; vasculitis.
Inflammatory mechanisms related
to an ischaemic stroke
Brain ischaemia
Stroke is a leading cause of long-term disability and re-
mains the third cause of death in developed countries
(World Health report 2007, World Health Organisa-
tion). While haemorrhagic stroke triggers cerebral
oedema and inflammation, this short review focuses on
the more common ischaemic stroke. Importantly, while
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Figure 1
Ischaemic stroke in the left middle cerebral artery.
A Perfusion cerebral computerised tomography (CT) shows an is-
chaemic core (red) surrounded by penumbra (green) [52]. The
core corresponds to the irreversible ischaemic insult (infarction),
whereas the penumbra represents brain parenchyma which is
suffering from ischaemia but which can be rescued if the blood
perfusion is rapidly restored.
B The diffusion sequences on brain MRI show a hyperintensity in the
territory of the left middle cerebral artery. Of note, only the in-
fracted territory, which corresponds to the core in (A) is visible.
C Angiographic sequences of cerebral CT show a sub-occlusion
of the left middle cerebral artery (arrow).
D The patient benefited from an intra-venous thrombolysis with
recombinant tissue plasminogen activator (rtPA). Few days later,
angiographic sequences on brain MRI showed a complete reper-
meabilisation of the left middle cerebral artery, which paralleled
a favourable clinical outcome. (With courtesy of Dr A. Croquelois
and the Division of Neuroradiology, Lausanne, Switzerland.)
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ischaemia at first induces only a loss of function at its
very early stages, structural damage appears rapidly
thereafter and progresses as minutes and hours go by.
Reduction of cerebral blood flow leads to a lack of oxy-
gen and glucose supply to the brain parenchyma. This
nutrient deficiency triggers multiple events including a
dramatic depletion of ATP, perturbation of the cellular
ionic homeostasis, neurotransmitter release and acti-
vation of many cytotoxic enzymes. The release of the
excitatory neurotransmitter glutamate leads to exces-
sive excitotoxic stimulation of glutamate receptors in
energy deprived neurons. Excitotoxicity is a major
mechanism in the early stages of the progression of is-
chaemic brain injury. Other detrimental events include
peri-infarct depolarisation, apoptosis and inflammation
(fig. 1) [1, 2].
Several therapeutic strategies aimed at decreasing
the effect of these ischaemia-induced phenomena have
been successful in animal stroke models, but not so far
in stroke patients. The only successful treatment in the
acute phase for stroke patients is thrombolysis, the
goal of which is to restore the blood flow to the brain [3,
4]. As it needs to be administered intra-venously within
3 hours to 4.5 hours or intra-arterially within 6 hours
from symptom onset it is limited to a small number of
patients [5]. Beyond this time-window restoring cere-
bral blood flow is no longer beneficial and there is an
increased risk of developing a symptomatic intracere-
bral haemorrhage [6]. Furthermore, the recombinant
tissue plasminogen activator (rtPA)
enhances excitotoxicity and in-
creases the lesion volume in our
mouse MCAo model [7, 8]. Thus,
there is a need for new treatments
for the patients who can not be
thrombolysed.
An important delayed mecha-
nism beginning within hours from
the onset of ischaemia is the robust
inflammatory response in the is-
chaemic tissue. There is increasing
evidence showing a detrimental ef-
fect of the post-ischaemic inflam-
matory reaction [9, 10]. Therefore
therapeutic strategies targeting the
delayed inflammatory response
could inhibit the progression of the
tissue damage providing an ex-
tended therapeutic window for neu-
roprotection.
Neuroinflammatory response
after ischaemia
The brain immune defence system
is essential to protect neurons
against infectious agents. In cere-
bral ischaemia, the inflammatory
response plays a role in the clear-
ance of cell debris; however it also
enhances the damage to the tissue.
An immune response at the site
of injury is characterised by the in-
filtration, accumulation and activa-
tion of inflammatory cells. Within
hours after the onset of focal cere-
bral ischaemia peripheral leuko-
cytes adhere to the cerebral en-
dothelium, cross the vessel wall
and invade the damaged
parenchyma [11, 12]. At the same
time astrocytes and microglia be-
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Figure 2
Diagram showing inflammation after stroke. Within minutes after cerebral ischaemia excitotoxic mecha-
nisms are activated in neurons in the territory of the occluded artery which lead to apoptotic cell death
independently of inflammatory mediators. These injured neurons both in the core (shown in red) and
periphery (shown in green) of the lesion and glial cells in the core are producing pro-inflammatory mediators
(such as cytokines and reactive oxygen species) which highly activate glial cells, leading to more cytokines
and chemokines being released from activated microglia and astrocytes, and to an upregulation of adhesion
molecules in vascular endothelial cells. Adhesion molecules and chemokines mediate the recruitement of
circulating leukocytes to the vessel wall. Their infiltration or diapedesis into the ischaemic tissue occurs via
highly specific receptor-ligand interactions between endothelial cells and leukocytes. In the next few hours
after injury, once activated in the parenchyma, leukocytes and microglia (red boxes) produce more inflam-
matory mediators such as cytokines, nitric oxide (NO) through inducible nitric oxide synthase (iNOS), reactive
oxygen species (ROS) and metalloproteinases (MMPs). Stress signalling pathways (JNKs) are also up-regu-
lated and induce transcription of cytotoxic and inflammatory genes (blue boxes). This local inflammatory
response contributes to secondary injury to potentially viable tissue and leads within hours and days to
apoptotic or necrotic neuronal cell death (adapted from [12]).
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come activated. These cellular events depend on the se-
cretion of inflammatory mediators which are produced
by neural and glial cells in response to an ischaemic in-
sult. Once activated in the site of injury inflammatory
cells start to secrete a large variety of cytotoxic agents
such as cytokines, chemokines and promote the ex-
pression of adhesion molecules, matrix metallopro-
teinases (MMPs) with an increased production of free
radicals. Stress signalling pathways, such as the c-Jun
N-terminal kinases (JNKs) pathway are also activated.
Both the JNK pathway and pro-inflammatory media-
tors further potentiate the brain tissue injury and lead
within hours and days to apoptotic and necrotic cell
death of the potential viable tissue [13–15]. Figure 2
provides a schematic diagram illustrating the inflam-
matory response after ischaemic stroke.
Glial cell activation
Microglia are the resident macrophages of the brain.
They are very sensitive to subtle alterations in their
neuronal microenvironment. Resting microglia has a
very ramified cytoplasm, covering a territory of 30–40
mm in diameter. In response to an injury, they quickly
become activated and undergo morphological transfor-
mations as well as functional changes. They start to re-
tract their long processes and their shape becomes
rounded – so called phagocytotic, amoeboid microglia
[16–18]. The degree of microglial activation depends on
the severity of neuronal injury. The mildest injuries
may only cause ramification of microglia with a bushy
appearance, whereas in acute pathological cases mi-
croglia are characterised by hypertrophic bodies and
less arborised processes. If neurons die, microglia
transform into brain macrophages. These stimulated
cells rapidly proliferate to focal sites of injury due to an
increasing expression of immunoreactive cell surface
molecules and to the secretion of various inflammatory
molecules such as chemotactic factors which induce the
recruitment of other microglial cells. Figure 3 shows
the changes in microglial morphology and accumula-
tion of activated microglia in a mouse stroke model (48
hours after transient 30 minutes
middle cerebral artery occlusion).
This phenomenon is accompanied
by an increased expression of cy-
tokines: interleukins (IL-1b, IL-4,
IL-6, IL-10), tumor necrosis factor-
a (TNFa), interferons and
chemokines such as MCP-1 [19, 20].
The surrounding astrocytes are
sensitive to the increased release of
these immunomodulatory peptides
and therefore severe ischaemia also
compromises astrocytic function.
Astrocytes modulate the phagocytic
functions of microglia and promote
the expression of adhesion mole-
cules in the neurovascular unit on
endothelial cells and circulating
leukocytes [21, 22]. These early in-
flammatory processes are likely to
be deleterious for neuron survival.
Leukocyte infiltration
Shortly after the onset of injury the
blood brain barrier opens by the
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Figure 3
Activation and accumulation of microglia after cerebral ischaemia. Shown are examples of immunohisto-
chemical staining for CD11b, an integrin surface marker on microglial cells, after 48 hours of reperfusion
following 30 minutes middle cerebral artery occlusion (MCAo) in mice. Hyper-ramified (A, arrow heads) or
activated microglia (A, white arrows) can be detected in the hippocampus (nuclei are stained in blue with
DAPI). Phagocytotic microglia are present in the injured brain tissue (B, black arrows). Cresyl violet stained
sections of ischemic brains are shown above, red boxes locate the immunolabelled ischaemic tissue in the
hippocampus and the striatum shown in A and B. Magnification 20×. Accumulation of activated amoeboid
microglia is found in the ischaemic striatum (C), while the contralateral healthy region shows no CD11b pos-
itive staining (D). The dashed red circle outlines the ischaemic tissue. Magnification 5×.
Table 1
Classification of different vasculitis types.
Vasculitis
Primary Secondary
Large-size arteries Systemic lupus erythematosus ±
anti-phospholipid syndrome
Giant cell temporal arteritis (Horton) Behçet disease
Takayasu arteritis Sjögren syndrome
Middle-size arteries Neuro-sarcoidosis
Primary angiitis of the central Rheumatoid arthritis
nervous system
Polyarteritis nodosa Scleroderma
Small-size arteries Inflammatory bowel diseases
Churg Strauss Infections, e.g., varicella-zoster
virus vasculopathy
Wegener Others
Microscopic polyarteritis
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Figure 4
Therapeutic interventions targeting the inflammatory response after ischaemia. Experimental and clinically tested approaches to reduce brain da-
mage and inflammation after stroke. In red is shown thrombolysis used to dissolve the blood clot [3]. In black, strategies to block excitotoxic path-
ways, such as the inhibition of glutamate receptors [53] and JNK stress signaling pathway [33, 34]. In blue are shown therapeutic interventions tar-
geting inflammation, such as inhibitors of free radicals [41, 54, 55] and anti-inflammatory molecules [38, 40, 56–58]. And in pink other potential
targets such as MMPs [59], PARP-1 [60, 61], inhibitors of caspase-1 or caspase-3 [62, 63] and erythropoietin (EPO) as a neuroprotective agent [64].
Table 2
Target Effects Reference
Thrombolysis tPA (alteplase) Restores blood flow [3]
Anti-excitotoxicity NMDA and AMPA antagonists, Block excitotoxicity pathways [33, 34, 53]
strategies channel blockers, JNKs inhibitors
Anti-oxidants iNOS and COX inhibitors, Free radical production inhibitors [41,54,55]
NXY-059
Anti-inflammatory Leukoytes depletion Reduces the number of circulating neutrophils [56]
agents Anti-ICAM-1 (Enlimomab) Blocks leukocytes adhesion and transendothelial migration [40]
TNF Prevents TNF from interacting with its receptor [57]
Interleukin-1 receptor antagonist (IL-1ra) Prevents IL-1 from interacting with its receptor [38]
Minocycline Inhibits cytotoxic agents secreted by microglia [58]
Other PARP inhibition Blocks cell death [60, 61]
MMP inhibition: MMP-9 knock-out mice Reduction of proteolytic degradation of BBB [59]
Erythropoietin (EPO) Neuroprotective [64]
Caspase inhibitors: Casp-1,-3 Inhibition of apoptosis [62, 63]
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disruption of the endothelia tight junctions [23]. The
release of inflammatory mediators from activated glial
cells induces the expression of proteins on the outer cell
membrane of vascular endothelial cells and leukocytes.
The opening of the barrier and the release of inflam-
matory mediators leads to the migration of circulating
leukocytes to the site of injury. Infiltration of leuko-
cytes occurs in three steps: rolling on the surface of en-
dothelial cells, adhesion to the endothelial wall and mi-
gration or diapedesis. The initial capture and migra-
tion is mediated by three main groups of cell adhesion
molecules: selectins (P-, E- and L-selectins), im-
munoglobulins (VCAM-1, ICAM-1) and integrins
(CD11a-c) [11, 24]. Circulating monocytes/macrophages
are also recruited at the site of injury and will pene-
trate into the parenchyma. The proportion of invading
macrophages in the ischaemic tissue can not be dis-
criminate from resident activated microglia.
Activation and accumulation of leukocytes (granu-
locytes, monocytes/macrophages, lymphocytes) at the
site of injury results in further damage. Current evi-
dence suggests a detrimental role of inducible or im-
munological nitric oxide synthase (iNOS) and cy-
clooxygenase-2 (COX-2) from neutrophils and vascular
cells in the ischaemic brain [25, 26]. They induce the
formation of reactive oxygen species: nitric oxide (NO)
and superoxide respectively, leading to the generation
of peroxinitrite [14, 27] which is a powerful oxidant
which triggers damage to DNA and other cell con-
stituents [1]. Up-regulation of pro-inflammatory mole-
cules and reactive oxygen species after cerebral is-
chaemia are not the only cause of secondary injury. Ex-
pression of metalloproteinase genes is related to the
presence of inflammatory cells in ischemic tissue. A re-
cent study has demonstrated the infiltration of metal-
loproteinase-9 positive (MMP-9+) neutrophils after
human stroke [28]. MMP-9 is involved in the degrada-
tion of components of the extracellular matrix and
basal lamina which may potentiate haemorrhagic com-
plications after ischaemic stroke.
Transcriptional regulation of inflammation
The secretion of inflammatory molecules in cerebral is-
chaemia triggers the activation of several transcription
factors involved in the inflammatory response. The nu-
clear factor-kappa B (NF-kB) when activated, induces
the expression of genes encoding cell adhesion mole-
cules, cell surface receptors and cytokines [29, 30].
Iadecola and colleagues have shown an attenuation of
the inflammatory response induced by focal cerebral
ischaemia in mice with a null mutation in the CD36
receptor which recognises pathogens and induces an
inflammatory response through the activation of NF-
kB [31]. Interference with the nuclear factor-kappa B
activation may therefore be beneficial to secondary
ischaemic injury.
Mitogen activated protein kinases (MAPKs) are a
family of key proteins which are activated in response
to stress signals. MAPK signalling pathways positively
regulate transcription of inflammatory genes, such as
those coding for TNF-a, IL-1b, IL-6, IL-8, COX-2 (for
review [9, 32]). D-JNKi-1, a specific inhibitor of the
JNK pathway, was shown to induce a strong neuropro-
tective effect in a range of experimental cerebral is-
chaemia model [33, 34]. Besides, the inhibition of MAP
kinases, especially p38 and JNK, could lead to a re-
duction in pro-inflammatory molecule production by in-
flammatory cells, especially microglia/macrophages in
which the MAPK cascades are highly activated after
an ischaemic injury [35,36].We are therefore currently
investigating the effect of D-JNKi-1 on the inflamma-
tory response and the progression of the tissue damage
after ischaemia.
Neuroprotective approaches targeting
inflammation
Different strategies aimed at preventing the inflam-
matory response after cerebral ischaemia have been
successful in rodent models. Ischaemic damage was
shown to be attenuated, together with systemic leuko-
cyte depletion by preventing the expression of, or by
blocking adhesion molecules, by inhibiting pro-inflam-
matory cytokines or by diminishing the free radical
generating enzymes iNOS or COX-2 (for review [1, 37]).
Attempts to translate therapeutic interventions to
stroke patients have been more disappointing than
promising. For instance the selective IL-1 receptor an-
tagonist (IL-1ra) which limits the pro-inflammatory ac-
tion of IL-1, has been tested in randomised patients
with acute stroke [38]. Despite a conclusive phase II
study no recent publications have reported IL-ra as a
therapeutic agent for acute stroke.
More than a thousand of potential agents under-
went clinical evaluation [39]. However none of these
drugs have demonstrated benefit in stroke clinical tri-
als as for instance the application of murine mono-
clonal anti-ICAM-1 in Enlimomab trial [40] and XY-
059, a nitrone-based free radical trapping agent [41]. A
non-exhaustive list of therapeutic strategies targeting
especially inflammation after ischaemic stroke is
shown in figure 4 and table 2.
Experimental studies to clinical trials:
lost in translation
Reasons for failure have been discussed before [42] and
include morphological and functional differences be-
tween rodents and humans, timing of the intervention,
evaluation of efficacy, pharmacokinetic issues (plasma
concentration of drugs) and side effects. Anti-inflam-
matory strategies have also in some cases promoted
deleterious infections and fever [40]
Until now, researchers have focused mostly on the
negative role of inflammation after stroke and thus
have looked to therapeutic means to inhibit post-stroke
Kardiovaskuläre Medizin 2009;12(5):143–150
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inflammation. Nevertheless, there is evidence suggest-
ing that inflammation might also be beneficial in
stroke: it is a crucial mechanism to clear damaged tis-
sue after an infarction, it promotes angiogenesis, tis-
sue remodelling and regeneration [1, 43]. Therefore,
there is clearly the need to better understand the sub-
tle balance between the beneficial and deleterious
effects of inflammation in stroke. Furthermore, exper-
imental studies on cerebral ischaemia have mostly tar-
get one cell type, i.e., neurons, while endothelium, as-
trocytes and microglia have been considerably neg-
lected. Future research on experimental stroke models
should considered the important role of non-neuronal
cells and the bivalent function of inflammation. A bet-
ter insight in these aspects is important before plan-
ning future clinical trials.
Autoimmune and infectious aetiologies
of stroke
We have discussed on the inflammatory response after
cerebral ischaemia and its consequences. In this sec-
ond part of this review we will illustrate how a disorder
affecting the immune system could lead to stroke.
Therefore, we will briefly review the vasculitis which
can cause stroke. Primary vasculitis is classified into
three categories, depending on the size of the affected
arteries. This classification is relevant for the clinician.
Indeed, magnetic resonance angiography or even con-
ventional arteriography can provide good information
on large-size arteries, are of variable value in middle-
size arteries vasculitis and are useless in small-size ar-
teries vasculitis, since in the latter case, the lesions are
below the threshold of detection (tab. 1). In other terms,
a normal neuro-imaging study does not rule out a mid-
dle-size or a small-size arteries vasculitis. Ameningeal
and brain parenchymal biopsy might thus be war-
ranted. Another important fact is that most vasculitis
that can cause strokes are systemic diseases and thus
other organs, including the heart, are frequently in-
volved, for instance the Takayasu arteritis (TA) which
affects the large arterial trunks. TA must always be
ruled out in young patients with stroke, especially if
they are female and of Asian descent. Stroke, either is-
chaemic or haemorrhagic occurs in 20–30% of TA.
Treatment consists in a combination of corticosteroids,
immunosuppressive therapies and surgery [44].
By contrast, temporal arteriitis (Horton’s disease)
affects elderly people (usually >60 years old) and is
characterised by headaches and a high erythrocyte sed-
imentation rate (>50 mm/hour) (fig. 5). When suspect-
ing Horton’s disease, one must immediately adminis-
ter high doses of corticosteroids,
since there is a risk of occlusion of
the central artery of the retina,
leading to definite loss of vision.
Stroke may occur in 10% of patients
with Horton’s disease. Other mani-
festations include fever, fatigue,
jaw claudication and its very fre-
quent association with polymyalgia
rheumatica. Of importance, tempo-
ral artery biopsy, which is the gold
standard diagnostic procedure, re-
mains positive up to 7–10 days
after corticosteroids were started.
The duration of corticosteroid ther-
apy depends on the erythrocyte sed-
imentation rate and the clinical
symptoms. Usually, the treatment
lasts a minimum of one year [45].
Primary angiitis of the central
nervous system (PACNS) is a rare
condition, but very difficult to diag-
nose. Indeed, in contrast to other
vasculitis, PACNS affects only the
vessels of the brain (middle-size ar-
teries), without any other systemic
manifestations. Its mode of presen-
tation is variable including, in ad-
dition to ischaemic or haemorrhagic
strokes, confusion, cognitive deteri-
oration, headaches, etc. Extensive
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Figure 5
Giant cell temporal arteriitis (Horton’s disease).
A Angiographic CT of the head and neck showing skipped stenosis of the right temporal artery in a patient
suffering from Horton’s disease.
B Three-dimensional reconstruction precising the anatomy and the lesions of this artery.
(With courtesy of the Division of Neuroradiology, Lausanne, Switzerland.)
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blood tests are not contributory. Cerebrospinal fluid ex-
amination is abnormal in 50–90% of cases, but of little
help, since it shows only aspecific findings, i.e., a mild
to moderate increase in proteins, and/or leucocytes,
and/or erythrocytes.
Nevertheless, if a PACNS is suspected, it is of im-
portance to establish the diagnosis as the treatment is
heavy, consisting in long-term corticosteroids and cy-
clophosphamide. Therefore, a meningeal and parenchy-
mal brain biopsy is often necessary [46].
We will not address here the other primary vas-
culitis causing stroke (tab. 1), as strokes are relatively
rare in those vasculitis and, usually, other organs are
affected before the central nervous system. The same is
true for secondary vasculitis. Nevertheless, it is worth
to mention here the problem of the anti-phospholipid
syndrome (aPLs). Indeed, this condition is found in
40% of the cases of systemic lupus erythematosus, but
can also be primary, i.e., not associated with any un-
derlying condition. aPLs may cause arterial and venous
thrombosis. Typical manifestations include: sponta-
neous abortion beyond 10 week of gestation, cardiac
valve abnormalities, thrombocytopenia, haemolytic
anaemia. A neurological involvement is frequent, con-
sisting in strokes, migraine-like phenomenon, chorea,
and transverse myelopathy. The diagnosis of aPLs is
based on the Sapporo criteria established in 1999 and
revised in 2004 in Sydney. Detailing these diagnostic
criteria would be well beyond the purpose of this small
review and we advise the avid reader to consult the fol-
lowing references: [47–49].
From a neurological standpoint, it is recommended
to rule out an aPLs in patients younger than 45 years-
old who present with an ischaemic stroke. But it is cru-
cial to follow the above-mentioned modified Sapporo
criteria in order to avoid over-diagnosis of aPLs. In-
deed, this diagnosis often implies a long-term antico-
agulation treatment [50].
Conclusion
Our knowledge on pathophysiology of cerebral is-
chaemia has greatly improved because of experimen-
tal in vitro and in vivo studies. A large number of drugs
have been developed in the purpose to inhibit the com-
plex cascade taking place after stroke including excito-
toxicity and inflammation. Despite those efforts none of
the potential therapeutic agent has been successful in
clinical trials so far.
In this short review we have shown that inflam-
mation can cause an occlusion of a brain artery and
therefore drive to cerebral ischaemia, as well as be the
direct consequence of stroke and exacerbate damage.
Furthermore, stroke induces immunodepression and
favors opportunistic infections such as bronchopneu-
monia [51].
Therefore, in stroke therapy there is a great need
to identify new approaches which could block the detri-
mental inflammatory response as well as inducing neu-
roprotection or perhaps in combination with thrombol-
ysis.
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a b s t r a c t
The c-Jun-N-terminal kinase signaling pathway (JNK) is highly activated during ischemia and plays an
important role in apoptosis and inflammation. We have previously demonstrated that D-JNKI1, a specific
JNK inhibitor, is strongly neuroprotective in animal models of stroke. We presently evaluated if D-JNKI1
modulates post-ischemic inflammation such as the activation and accumulation of microglial cells.
Outbred CD1 mice were subjected to 45 min middle cerebral artery occlusion (MCAo). D-JNKI1 (0.1 mg/
kg) or vehicle (saline) was administered intravenously 3 h after MCAo onset. Lesion size at 48 h was sig-
nificantly reduced, from 28.2 ± 8.5 mm3 (n = 7) to 13.9 ± 6.2 mm3 in the treated group (n = 6). Activation
of the JNK pathway (phosphorylation of c-Jun) was observed in neurons as well as in Isolectin B4 positive
microglia. We quantified activated microglia (CD11b) by measuring the average intensity of CD11b label-
ling (infra-red emission) within the ischemic tissue. No significant difference was found between groups.
Cerebral ischemia was modelled in vitro by subjecting rat organotypic hippocampal slice cultures to oxy-
gen (5%) and glucose deprivation for 30 min. In vitro, D-JNKI1 was found predominantly in NeuN positive
neurons of the CA1 region and in few Isolectin B4 positive microglia. Furthermore, 48 h after OGD,
microglia were activated whereas resting microglia were found in controls and in D-JNKI1-treated slices.
Our study shows that D-JNKI1 reduces the infarct volume 48 h after transient MCAo and does not act on
the activation and accumulation of microglia at this time point. In contrast, in vitro data show an indirect
effect of D-JNKI1 on the modulation of microglial activation.
! 2009 Elsevier Inc. All rights reserved.
1. Introduction
Cerebral ischemia induces neuronal damage in the territory of
the occluded artery within minutes of the onset of ischemia. The
injured neurons undergo cellular degeneration through excitotoxic
mechanisms such as the expression of apoptotic proteins and cyto-
toxic enzymes as well as the up-regulation of stress-signaling
pathways (Dirnagl et al., 1999; Mehta et al., 2007). This emergency
state strongly activates nearby glial cells leading to the release of
inflammatory mediators within the ischemic tissue and to the
expression of adhesion molecules in vascular endothelial cells.
The inflammatory response leads to the accumulation and activa-
tion of microglial cells as well as the recruitment of circulating T
lymphocytes to the infarct area (Petty and Wettstein, 2001; Ishik-
awa et al., 2004; Wang et al., 2007; Benakis et al., 2009). It is pos-
tulated that this local inflammatory response contributes to the
secondary injury to potentially viable tissue which could lead to
a larger cerebral infarct and impaired clinical outcome in patients
with ischemic stroke (Barone and Feuerstein, 1999; del Zoppo
et al., 2001).
Despite promising data in experimental research, the inhibition
of the delayed inflammatory response has failed to improve the
outcome after stroke in clinical trials (Enlimomab Acute Stroke
Trial Investigators, 2001; Sughrue et al., 2004). There is a great
need to further characterize the cellular and molecular mecha-
nisms underlying inflammation to improve chances of identifying
promising therapeutic targets to prevent secondary injury. Fur-
thermore, it is now clear that the efficacy of neuroprotective agents
is greater if they target not only one single aspect of the ischemic
cascade, but multiple mechanisms such as combined inhibition
of neuronal cell death and of the detrimental effects of inflamma-
tion after stroke (Kaminska, 2005). Experimental protocols there-
fore need to explore such combined approaches.
D-JNKI1 is a selective non-ATP-competitive inhibitor that pre-
vents the interaction of JNK with its targets including c-Jun (Bonny
et al., 2001). This peptide prevents NMDA-induced neuronal death
in primary cultures (Borsello et al., 2003; Centeno et al., 2007) as
well as rescues the evoked potential response recorded in the
CA1 region after oxygen and glucose deprivation (OGD) in organo-
typic hippocampal slice cultures (Hirt et al., 2004). Moreover, D-
JNKI1 remarkably attenuates the lesion size in transient and per-
manent models of cerebral ischemia in both rats and mice (Borsello
0889-1591/$ - see front matter ! 2009 Elsevier Inc. All rights reserved.
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et al., 2003; Hirt et al., 2004; Repici et al., 2007; Esneault et al.,
2008), even with delayed intravenous administration (Wiegler
et al., 2008). These experimental studies have also shown that D-
JNKI1 improves functional outcome at later time-points after
ischemia. All together, these data strongly suggest that inhibition
of the JNK pathway is a very promising target for stroke patients.
The JNK pathway is also activated in microglial cell cultures
after stimulation by LPS or thrombin (Hidding et al., 2002; Waetzig
et al., 2005), which leads to the expression of inflammatory mole-
cules such as TNFa. It is well described that microglia undergo
morphological changes after cerebral ischemia with accumulation
and proliferation at the site of injury and secretion of inflammatory
modulators, such as cytokines, chemokines and toxic factors (Feu-
erstein et al., 1998; del Zoppo et al., 2000).
Our aim was to test whether D-JNKI1 was also inhibiting the
JNK pathway in microglia and if this contributed to the strong neu-
roprotective effect of delayed D-JNKI1 administration in our mod-
els. We examined whether the activation of microglia was reduced
in D-JNKI1-treated animals, subjected to middle cerebral artery
occlusion (MCAo), by investigating morphological changes and
accumulation within the infarct area. Our data show that D-JNKI1
does not influence global morphology and number of microglia
in vivo. We showed that D-JNKI1 is present mainly in neurons
and in few microglia when administered in an in vitro ischemia
model by subjecting hippocampal slice cultures to OGD. Interest-
ingly, we identified changes in microglia in vitro, such as a modifi-
cation of microglial morphology and localization after OGD or
OGD + D-JNKI1. While D-JNKI1 has a strong neuroprotective effect
in our stroke model, it does not appear to attenuate the activation
by morphological criteria and accumulation of microglia in ische-
mic tissue at 48 h.
2. Materials and methods
2.1. Animals
Male Crl:CD1/ICR mice (20–30 g, 4- to 5-week-old) and gestant
Sprague–Dawley (OFA) rats were purchased from Charles River
Laboratories Inc. (Charles River France, L’Abresle, France). All pro-
cedures were in accordance with the Swiss Federal Law on Animal
Welfare and were approved by the Swiss Federal Veterinary Office.
2.2. Transient middle cerebral artery occlusion (MCAo)
Focal cerebral ischemia was induced as previously described
(Wiegler et al., 2008), but with a different anaesthesia protocol
and a longer ischemia duration. CD1 mice were anesthetized and
maintained with 1–3% isoflurane in 70% N2O and 30% O2 using a
face mask. Body temperature was maintained at 37 ± 0.5 "C
throughout surgery (FHC Inc., Bowdoinham, ME, US). Regional
cerebral blood flow (CBF) was continuously recorded by laser
Doppler flowmetry (LDF, Periflux 5000, Perimed, Sweden) during
a period covering the induction of ischemia until 10 min after the
end of ischemia. Transient left MCAo was induced as previously de-
scribed (Lei et al., 2009) with a silicone-coated nylon monofilament
(diameter: 0.17 mm, Doccol Co., Redlands, CA, USA) inserted
through the common carotid artery and withdrawn after 45 min
to allow reperfusion. Mice were given 0.025 mg/kg of buprenor-
phine subcutaneously for post-surgery analgesia and were housed
in an incubator at 31 "C for 24 h for recovery.
2.3. Groups, treatments and neurological deficits
Randomly, saline solution (NaCl 0.85% Medium, bioMérieux) or
D-JNKI1 (0.1 mg/kg, Xigen Pharmaceuticals) was injected intrave-
nously (i.v.) into the tail vein of mice using a 1 ml syringe (Omni-
fix-1 ml, Terumo needle 25G) and a mouse restrainer (Braintree
Scientific Inc.) 3 h after ischemia onset. The lesion volume was
evaluated 48 h after cerebral ischemia and immunostainings were
performed at 9 h, 24 h, 48 h and 7 days after surgery. The neurolog-
ical deficit was assessed at 48 h. Neuroscore was graded for sever-
ity using the following scale: 0 = no observable neurological deficit,
1 = failure to extend the right forepaw, 1.5 = intermittent circling
behavior, 2 = circling behavior, 3 = loss of walking or uncontrolled
movement (Bederson et al., 1986; Hirt et al., 2004).
2.4. Tissue preparation and immunohistochemistry
Mice were anesthetized with intra-peritoneal injection of 8 mg/
kg xylazine (Rompun# 2%, Bayer) + 100 mg/kg ketamine (Ketanar-
kon 100, Streuli Pharma AG) and transcardially perfused with PBS
followed by 4% paraformaldehyde. Serial coronal 20-lm thick,
720-lm distant cryostat sections were used for lesion size mea-
surements and immunolabelling.
2.4.1. Histological evaluation of neuronal damage
Digitalized images of the Nissl stained tissue were acquired un-
der a light stereomicroscope (Leica MZ16FA) and the ischemic area
was measured by a blinded observer with ImageJ 1.38x software
(NIH, http://rsb.info.nih.gov/ij/). The direct infarct volume was cal-
culated by multiplying the sum of the infarct areas on each section
by the distance between the sections.
2.4.2. Staining of degenerating neurons: FluoroJade B
FluoroJade B staining (0.0004% FluoroJade# B, Millipore, UK)
was performed on frozen sections according to the Chemicon Inter-
national Company protocol. Sections were then mounted in Eukitt
(O. Kindler GmbH & Co., Freiburg, Germany).
2.4.3. Immunohistochemistry staining for glial and inflammatory cells
Sections were blocked in 0.3% H2O2 for 20 min at room tempera-
ture (RT) followed by 10% normal goat serum (NGS, Invitrogen, Pais-
ley, UK) in PBS with 1% bovine serum albumin (BSA) for 1 h at RT.
Sections were incubated overnight at 4 "C with the following pri-
mary antibodies: rat anti-CD11b (Mac-1, 1:100, AbD SEROTEC) or
biotinylated Isolectin B4 (1:500,Griffonia simplicifolia lectin I, Vector
Laboratories) to labelmicroglia,mouse anti-GFAP (1:500,Millipore)
for astrocytes, hamster anti-TCRbeta (1:200, BioLegend) for T lym-
phocytes, hamster anti-CD11c (1:200, BioLegend) for dendritic cells.
Using the immunoperoxidase method, biotinylated anti-rat (1:500,
BA-9400, Vector Laboratories, Burlingame, CA), anti-mouse (1:500,
Vector Laboratories, Burlingame, CA) or anti-hamster (1:500, Bioleg-
end) IgG antibodies were applied for 1 h followed by avidin–biotin–
horseradish peroxidase complex (Vectastain kit, Vector Laborato-
ries, Burlingame, CA). Incubation with biotinylated secondary anti-
body was omitted for Isolectin B4. The immunocomplex was
visualized by 3,30-diaminobenzidine (DAB kit, Vector Laboratories,
Burlingame, CA) and mounted with Eukitt.
2.4.4. Double immunofluorescence
After blocking in 10% NGS (±0.1% Triton X-100) sections were
incubated overnight at 4 "C in various combinations of the follow-
ing primary antibodies: mouse anti-NeuN (1:500, Millipore),
mouse anti-GFAP (1:500), biotinylated Isolectin-B4 (1:500) and
rabbit anti-phospho-c-Jun(Ser63) or phospho-c-Jun(Ser73)
(1:100, Cell Signaling). Antigens were visualized with the appropri-
ate fluorochrome-conjugated secondary antibodies: alexa fluor
488 anti-rabbit (1:500, Invitrogen), alexa fluor 594 anti-mouse
(1:500, Invitrogen), Cy3-conjugated Streptavidin (1:500, Jackson
ImmunoResearch Laboratories) for 1 h at RT. Sections were coun-
terstained with DAPI (1:10,000, 1 mg/ml, SIGMA) and mounted in
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Vectashield Mounting Medium (Vector Laboratories, Burlingame,
CA). Images were acquired with the Aviovision v3.1 software in a
Zeiss Axiovision microscope. No specific immunoreactivity was ob-
served in control sections prepared by omitting primary
antibodies.
2.5. Quantification of CD11b positive cells
Rat CD11b antigen was revealed using the secondary antibody
IRDye 800-labeled anti-rat IgG (1:2000, Rockland) for 1 h at RT.
CD11b infra-red emission was measured at 800 nm with an Odys-
sey infrared imaging scanner (Li-COR, Biosciences, Lincoln, Nebras-
ka, USA). The sections were counterstained with Nissl after the first
scan to avoid detection of Nissl blue staining in the 800 nm chan-
nel, and rescanned at 700 nm for delimitation of the ischemic
zones. The average intensity of microglia (AvIntCD11bTotal) was
calculated within the ischemic region for each brain as follows:
AvIntCD11bTotal = (RiRawIntensity/Ripixels) ! AvIntBackground, with
i = ith coronal section of a brain, RiRawIntensity/Ripixels = AvI-
ntCD11b without background correction and AvIntBackground = aver-
age intensity of the background measured by omitting the primary
antibody. One animal was excluded in the vehicle-treated group,
because of unconvincing IRD-800 labelling.
2.6. Organotypic hippocampal slice cultures (OHC)
Three hundred and fifty micrometers thick coronal hippocampal
slices from10- to 12-day-old Sprague–Dawley ratswere culturedon
porous membrane units (Millicell-CM, Millipore, UK) in wells con-
taining 1 ml of culture medium with 25% horse serum (Oxoid, UK),
50% minimal essential medium supplemented with HEPES and so-
dium bicarbonate (MEM, Gibco, UK), 25% Hanks’ balanced salt solu-
tion (HBSS, Gibco, UK), 2 mM L-glutamine and 36 mM D-glucose.
Cultures were grown at 33 "C, 100% humidity and 5% CO2. After
3 days themediumwas replaced by fresh culturemediumand, after
6 days, by a medium with 15% horse serum, 60% MEM, 25% HBSS,
2 mM L-glutamine and no glucose (Badaut et al., 2005).
2.7. Oxygen and glucose deprivation (OGD) and quantification of cell
death
Hippocampal slice cultures were subjected to in vitro ischemia
by exposure to reduced oxygen and glucose concentrations as de-
scribed previously (Hirt et al., 2004). At day 8, slices were trans-
ferred to a serum-free hypoglycemic medium, DMEM (D5030;
Sigma, USA) supplemented with 1 mM D-glucose and 2 mM L-glu-
tamine, in a humidified hypoxia chamber (COY, USA) with a hyp-
oxic atmosphere of 5% O2, 5% CO2 and 90% N2 at 37 "C for
30 min. Control cultures were placed at 37 "C for 30 min, in a hu-
mid normoxic atmosphere. D-JNKI1 diluted in PBS (final concen-
tration 12 nM) or an equal volume of PBS was added 6 h after
OGD. Cell death was determined in the CA1 region using the fluo-
rescent viability indicator propidium iodide (PI, final concentration
5 lg/ml, Sigma). PI fluorescence emission (excitation wavelength
568 nm) was measured 48 h after OGD and quantified densitomet-
rically, using ImageJ software. After subtracting the background
fluorescence, the results were expressed as a percentage of maxi-
mal cell death obtained by incubating the hippocampal slice cul-
tures in PBS for 24 h at 4 "C. Cell death was averaged for the four
slices of each culture.
2.8. Slice preparation and immunofluorescence
OHC were fixed in 4% paraformaldehyde for 1 h at 4 "C, blocked
1 h at RT in 10% NGS and incubated overnight at 4 "C with the fol-
lowing primary antibodies: biotinylated Isolectin-B4 (1:500),
mouse anti-NeuN (1:500), rabbit anti-phospho-c-Jun(Ser63) or
phospho-c-Jun(Ser73) (1:100) and rabbit anti-D-JNKI1 (1:300, Xi-
gen Pharmaceuticals, Switzerland). After rinsing in PBS, slices were
incubated with Cy3-conjugated Streptavidin (1:5000), alexa fluor
594 anti-mouse (1:200) or alexa fluor 488 anti-rabbit (1:200) for
1 h at RT, mounted using Vectashield Mounting Medium and
viewed under a Leica SP5 confocal laser-scanning microscope.
2.9. Statistical analysis
Results are expressed as mean ± SEM, except for neurological
score which is expressed as [median, min, max]. Data were ana-
lyzed using two-sample t-test (GraphPad Prism software 5.0).
Analyses of correlation were done using the SAS software package.
Normalization test was performed to check for significant viola-
tions in the distribution assumptions. P values <0.05 were consid-
ered significant.
3. Results
3.1. Transient MCAo induces an accumulation of inflammatory cells in
the ischemic tissue at 48 h
In order to evaluate the effect of D-JNKI1 on inflammation, we
investigated the activation and accumulation of glial and inflamma-
tory cells after focal cerebral ischemia in mice by immunohisto-
chemistry. We first characterized microglial activation at different
time-points after ischemia onset (9 h, 24 h, 48 h and 7 days). In our
MCAo model, we found a peak of CD11b positive microglial cells in
the ischemic tissue at 48 h (Supplementary Fig. 1 online). At earlier
time-points, there was either no detectable CD11b-staining (9 h),
or microglia were in a ramified state with a less dense staining
(24 h). At 48 h, there were numerous microglia in the infarct area
with an ameboid morphology. Seven days after MCAo, highly rami-
fied microglia were present only in the injured hippocampal tissue,
whereasnopositive stainingwas seen in the striatal ischemic region.
Further experiments with microglia were performed 48 h after sur-
gery when CD11b staining was most prominent.
At 48 h after 45 min transient MCAo, infarct areas were local-
ized in the striatal and cortical regions of the left hemisphere
(Fig. 1A, left) highlighted by a specific marker for degenerating
neurons (FluoroJade B, Fig. 1B). The cellular changes resulting in
reactive astrocytes are an important component of glial activation
after ischemia. It has been previously described that the function of
reactive astrocytes is to create a physical barrier between damaged
and healthy cells (Anderson et al., 2003). In our model of MCAo, we
found that glial fibrillary astrocytic protein positive cells (GFAP+)
with a stellate morphology were restricted to the infarct border,
outside the ischemic zone, while hypertrophic GFAP+ cells were
found within the ischemic tissue, suggesting a reactive gliosis
48 h after MCAo (Fig. 1C). Activated microglia, characterized by
an increase in size of the cell body and a decrease of ramifications,
were highly present in the ischemic tissue as shown by Isolectin B4
and CD11b positive staining (Fig. 1D and E). It has been postulated
that microglia could differentiate into dendritic cells (DCs) and
have a phagocytic function (Reichmann et al., 2002). Staining for
DCs using CD11c was found in the ischemic region (Fig. 1F). Activa-
tion of microglia, dendritic cells and restriction of the extent of
damaged tissue by astrocytes after stroke as well as the breakdown
of the blood brain barrier could promote the infiltration and accu-
mulation of T lymphocytes within the infarcted area (Raivich et al.,
1996; Ishikawa et al., 2004). We performed immunohistochemis-
try using antibody against the beta chain of a T cell receptor (TCRb)
and found positively stained T lymphocytes especially in the ische-
mic striatum (Fig. 1G1).
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Our data show marked inflammatory changes 48 h after tran-
sient MCAo with a high degree of activation of glial cells, with reac-
tive astrocytes surrounding the lesion and an accumulation of
microglia within the ischemic tissue as well as the presence of
inflammatory cells such as DCs and T cells.
3.2. MCAo induces c-Jun phosphorylation in neurons and glial cells
Activation of the JNK pathway after ischemia is well de-
scribed, resulting in the phosphorylation of JNK targets, includ-
ing transcription factors in the nucleus such as the immediate
early gene c-jun (Borsello and Bonny, 2004; Gao et al., 2005;
Repici et al., 2007). Using specific antibodies directed against
the phosphorylated Serine-63 or -73 residues of c-Jun, we found
phospho-c-Jun(Ser73) in cortical region as early as 9 h after
MCAo (Supplementary Fig. 2 online) even though we could not
detect marked tissue damage, by Nissl staining (see Supplemen-
tary Fig. 1). When the lesion was formed, activation of c-Jun was
detected essentially in the cortical infarcted areas 24 h after
MCAo, while at 48 h positive staining was in both cortical and
striatal regions. As late as 7 days after MCAo induction we still
observed p-c-Jun labelling in the ischemic hemisphere. The same
time course was observed using the specific anti-phospho-c-
Jun(Ser63) antibody (data not shown).
Fig. 1. Glial and inflammatory cells in the ischemic tissue. CD1 mice were subjected to 45 min MCAo and brain sections immunostained 48 h after surgery. (A) Representative
Nissl-stained 720-lm distant coronal sections of the total infarct area 48 h after MCAo (left). Striatal and cortical damaged regions of the ipsilateral hemisphere are
represented in blue-green and purple, respectively. The location of striatal (blue-green square) and cortical (purple square) ischemic areas where all immunohistochemistry
data were analyzed are shown in the upper right panel. (B) Representative histological section 48 h after MCAo showing degenerating neurons (FluoroJade B) located within
striatal (B1) and cortical (B2) ischemic lesions in the territory of the left MCA. (C) Reactive astrocytes (GFAP positive cells) are predominantly located in the spared
parenchyma bordering the ischemic zone (C1, arrow head), whereas hypertrophic astrocytes are within the demarcated area (C2, arrow head). (D and E) A robust
inflammatory response shown by activated (Isolectin B4 and CD11b positive) microglial cells is restricted to the infarct area clearly separated from immediately adjacent
viable neural tissue. Inserts show high magnification of typical activated microglia. (F and G) Dendritic cells (CD11c) and T lymphocytes (TCRb), especially in the striatum (G1)
are also detected within the ischemic area and not in the healthy contralateral parenchyma.
C. Benakis et al. / Brain, Behavior, and Immunity 24 (2010) 800–811 803
In order to further characterize the role of the JNK inhibitor D-
JNKI1 not only in neurons but also in glial cells, we performed dou-
ble-labelling of p-c-Jun(Ser63) using different cell-specific markers
as NeuN (neurons), Isolectin B4 (microglia) and GFAP (astrocytes)
within the ischemic tissue 48 h after MCAo. Despite early activa-
tion of c-Jun at 9 and 24 h, we chose to analyze a possible effect
of D-JNKI1 at 48 h after ischemia onset, because we detected a
peak of microglial activation (see above) and c-Jun is activated in
the entire ischemic tissue at this time point (see Supplementary
Figs. 1 and 2). p-c-Jun(Ser63) (green) was detected as expected in
the nucleus of apparently non-degenerating neurons, located pre-
dominantly in the cortex (red preserved shape, Fig. 2A1, arrow
heads), while in the striatal ischemic region we found dying neu-
rons and rare co-localization with p-c-Jun (Fig. 2A2, arrow). We
also found a high degree of co-localization of microglia with p-c-
Jun (Fig. 2B1–B2, arrow heads). Higher magnification shows nucle-
ar localization of p-c-Jun in microglial cells in an activated ame-
boid-phagocytic macrophage-like morphology. p-c-Jun was also
detected in GFAP+ cells in the cortical and striatal ischemic areas
(Fig. 2C, arrow heads).
Taken together, these data demonstrate that c-Jun phosphoryla-
tion occurs in the ischemic areas (Fig. 2, boxes on the coronal brain
section in the upper left) and is detected in neurons as well as in
glial cells 48 h after MCAo.
Fig. 2. Activation of c-Jun in neurons and glial cells. The boxes on the brain section in the upper left show the striatal (blue-green) and cortical (purple) ischemic areas where
immunofluorescence experiments were carried out. (A–C) MCAo promotes nuclear phosphorylation of c-Jun(Ser63) (p-c-Jun) (lines A1–C1). (A and B) Double fluorescent
immunolabelling experiments show that p-c-Jun was highly detected in neurons (NeuN) with an apparently preserved, non-degenerating shape (A1 and A2, arrow heads) as
well as in activated microglia (Isolectin B4, B1 and B2, arrow heads). (C) Cytoplasmic GFAP positive cells merged with p-c-Jun are found in the striatal and cortical ischemic
areas (C1 and C2, arrow heads). Inserts show high magnification of double labelling. Scale bar: 100 lm.
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3.3. The highly neuroprotective JNK inhibitor D-JNKI1 does not reduce
the accumulation of microglia in the ischemic tissue 48 h after MCAo
To analyze whether D-JNKI1 has an inhibitory function on the
activation and accumulation of microglia at 48 h, we quantified
microglial cells after MCAo in treated and non-treated groups
(vehicle or D-JNKI1). First, mice were subjected to 45 min MCAo
and treated i.v. with D-JNKI1 or vehicle 3 h after MCAo onset.
48 h after surgery, the lesion area could be clearly outlined by Nissl
staining (Fig. 3A, dashed line in microphotographs above the dia-
grams). The direct lesion volume was 28.2 ± 8.5 mm3 in saline-in-
jected mice (n = 7), and 13.9 ± 6.2 mm3 in the D-JNKI1-treated
mice (n = 6), providing a significant 51% reduction of the lesion size
(p = 0.0057), confirming our previous findings (Wiegler et al.,
2008), (Fig. 3A). Fig. 3B illustrates a typical Doppler curve measur-
ing the cerebral blood flow from the beginning of the surgery until
10 min after reperfusion. Regional cerebral blood flow was mea-
sured by laser Doppler in all animals and is shown in Table 1. Data
indicate satisfactory reduction in laser Doppler flow during ische-
mia in all animals and satisfactory reperfusion, slightly better in
the D-JNKI1-treated group (p = 0.033). This minor difference in le-
vel of reperfusion does not explain the important reduction in le-
sion volume. Table 1 also shows similar weight and temperature
measurements during surgery in both groups. Temperature at sac-
rifice was lower in vehicle-treated animals than in D-JNKI1-treated
mice (p = 0.048), which correlated with the reduction of the infarct
volume in the D-JNKI1-treated group. Surprisingly, there was no
difference in weight between groups before and 48 h after the
operation, probably due to the high distribution level of the lesion
size in this MCAo model. Neuroscore scaled from 0 (best functional
outcome, no deficit) to 3 (worst outcome) was not significantly
better in the D-JNKI1-treated group (1.0, 0, 2.0) than in vehicle-
treated group (1.0, 1.0, 2.0); p = 0.701, most likely due to the lack
of sensitivity of this test. We have shown previously a beneficial ef-
fect of D-JNKI1 on functional outcome after MCAo using more sen-
sitive tests (Borsello et al., 2003; Hirt et al., 2004; Wiegler et al.,
2008).
In order to investigate the effect of D-JNKI1 treatment on the acti-
vation of microglia, we performed immunohistochemistry using a
CD11b-specific antibody in sections from all animals 48 h after sur-
gery. In a blinded study we could not identify morphologic changes
(activated-ameboid microglia versus resting-ramified cells) be-
tween animals and groups (data not shown, representative CD11b
immunostainings of oneanimal per groupare shown in Fig. 4A), sug-
gesting that D-JNKI1 does not influence changes in microglial shape
in our MCAo model. We then quantified the number of microglial
cells by measuring the average intensity of CD11b (Fig. 4B, green)
in the total ischemic area (Fig. 4B, red, dashed line) in untreatedmice
(n = 6) and D-JNKI1-treated mice (n = 6) 48 h after MCAo. Quantifi-
cation analysis of CD11b average intensity did not showa significant
difference between the vehicle-treated and D-JNKI1-treated group
(Fig. 4C), suggesting thatD-JNKI1doesnotprevent the accumulation
ofmicroglia in the ischemic tissue. Fig. 4D shows the correlation be-
tween the expression of CD11b and the brain lesion volume in both
groups. As no modification of microglial activation was detectable
after D-JNKI1 treatment, we hypothesized that there was a direct
link between the activation of microglia and the size of the lesion
independently of the treatment. There was a strong linear correla-
tion between CD11b and lesion volume in the vehicle-treated group
(black circle, R = 0.94, p = 0.005). In the D-JNKI1 treated group, this
correlationwas negative butwas not significant (black empty circle,
R = !0.01, p = 0.9). Linear regression analysis between groups
showed that there was no significant difference (R = !0.01, p = 0.9).
These data show that in our stroke model, D-JNKI1 strongly re-
duces the infarct volume but has no effect on the morphology and
accumulation of microglia within the damaged tissue 48 h after
MCAo. This suggests that neuroprotection with D-JNKI1 could oc-
cur independently of microglial activation in our cerebral ischemia
model.
3.4. D-JNKI1 is present mainly in neurons and in some microglial cells
48 h after OGD
The finding that MCAo activates p-c-Jun in microglia and that
D-JNKI1 fails to inhibit the activation and accumulation of microg-
Fig. 3. Neuroprotection with D-JNKI1 3 h after transient MCAo. (A) Intravenous administration of 0.1 mg/kg D-JNKI1 3 h after 45 min MCAo highly significantly reduced the
infarct volume compared to vehicle injected controls. Nissl-stained coronal sections show typical examples of lesion (p = 0.0057; **p < 0.01), circles represent individual
animals. (B) Representative diagram of the cerebral blood flow (CBF) as a function of time. The CBF was monitored from the beginning of the surgery until 10 min after
withdrawal of the filament to follow the reperfusion.
Table 1
The table shows measurements of cerebral blood flow, weight and temperature in the
group treated with vehicle or D-JNKI1. There was a slightly better reperfusion in the
D-JNKI1 treated group (p = 0.0331; *p < 0.05). Temperature at sacrifice was lower in
vehicle- than in D-JNKI1-treated mice (p = 0.0477; *p < 0.05).
Vehicle (n = 7) D-JNKI1 (n = 6)
CBF during ischemia (%) 15.4 ± 2.1 13.2 ± 1.5
CBF after ischemia (%) 50.7 ± 2.3 63.0 ± 4.9*
Weight (g) 25.1 ± 0.9 25.0 ± 0.7
Weight at sacrifice (g) 19.6 ± 1.7 18.5 ± 1.0
T during ischemia ("C) 37.0 ± 0.1 36.7 ± 0.1
T at sacrifice ("C) 35.4 ± 0.2 36.3 ± 0.3*
Neuroscore at 48 h 1.0, 1.0, 2.0 1.0, 0, 2.0
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lia despite a strong neuroprotective effect prompted us to investi-
gate the localization of D-JNKI1. The peptide was not detectable in
the brain after i.v. injection. Co-localization experiments were
therefore assessed in our in vitromodel of cerebral ischemia as de-
picted schematically in Fig. 5A. First, we exposed organotypic hip-
pocampal slice cultures to OGD for 30 min and treated cultures 6 h
after OGD with 12 nmol/l of D-JNKI1. We measured PI uptake as an
indicator of cellular death in the CA1 region of hippocampal slices
in control conditions (data not shown), 48 h after OGD and after
OGD followed by D-JNKI1 treatment. Fig. 5 shows that treating
slices with the neuroprotective peptide significantly reduced the
PI uptake from 35.3 ± 8.0% in non-treated slices (n = 4) to
4.7 ± 2.9% in D-JNKI1-treated slices (n = 4), indicating a significant
87% reduction of neuronal death (p = 0.012) confirming previous
findings (Hirt et al., 2004).
We then investigated the cellular localization of D-JNKI1 in
these slices. We performed double-labelling 48 h after OGD on
treated slices using antibodies against D-JNKI1 (green) and neu-
rons (NeuN, red) or microglia (Isolectin B4, red) (Fig. 5C). D-JNKI1
was found in the neuronal CA1 region with a cytoplasmic staining
(squares), and a few positive cells were localized outside the CA1
neuronal layer (circles). Co-localization of D-JNKI1 was observed
mainly in neurons of the CA1 (Fig. 5C1, arrow heads) and in few
microglia outside or at the border of the CA1 region (Fig. 5C2, ar-
row heads).
Taken together, these observations show that D-JNKI1 is local-
ized in the cytoplasm of CA1 neurons where it is likely to inhibit
the JNK death signaling pathway, and that some co-localization
of the peptide is also observed in microglia, suggesting that D-
JNKI1 could modulate the JNK pathway also in these cells.
3.5. D-JNKI1 modulates the activation of microglia after OGD
We have demonstrated that D-JNKI1 was neuroprotective
in vitro and was foundmainly in neurons as well as somemicroglia.
To verify the peptide’s molecular function in these cells, we exam-
ined whether D-JNKI1 could inhibit c-Jun phosphorylation and
modulate the activation of microglia.
First by Nissl staining we observed that the CA1 layer is well
preserved in control slices (Fig. 6A1) and after D-JNKI1 treatment
in slices subjected to OGD (Fig. 6A3), whereas neurons after OGD
without treatment show the typical shape of dying cells with their
pyknotic nuclei (Fig. 6A2). The same results were obtained using
the nuclear specific antibody NeuN (Fig. 6B). Fluorescent double
immunolabelling using NeuN and p-c-Jun(Ser63) shows, as ex-
pected, that in control slices there was no p-c-Jun staining in the
neuronal layer (Fig. 6B1). After OGD, the level of p-c-Jun clearly in-
creased in the nuclei of neurons (Fig. 6B2), whereas in treated
slices fewer positive p-c-Jun were observed (Fig. 6B3). The same re-
sults were obtained using an antibody against p-c-Jun(Ser73) (data
not shown). Surprisingly, we observed no colocalisation of p-c-
Jun(Ser73) in microglia after OGD and in D-JNKI1-treated slices
subjected to OGD (Fig. 6C2–C3).
However, when we analyzed qualitatively microglial morphol-
ogy in vitro, in control slices, we observed microglia with long thin
processes, the typical structure of so-called resting microglia,
homogeneously localized within the slice (Fig. 6D1), while slices
subjected to OGD showed microglia with less ramified processes
and a round cell body (ameboid microglia) concentrated within
the neuronal CA1 region (Fig. 6D2). In Fig. 6D3, the CA1 layer of
D-JNKI1-treated slices shows ameboid-like microglia and more
ramified cells localized at the border and within the CA1 neuronal
layer, respectively. Therefore, these observations suggest that
treatment with D-JNKI1 after OGD modifies microglial activation
and localization within the CA1 neuronal layer.
Fig. 4. Quantification of microglia in the ischemic region in treated and untreated
groups. (A) Representative CD11b immunohistochemistry of vehicle- and D-JNKI1-
treated animals. Inserts show high magnification of CD11b+ microglia. (B)
Representative CD11b infra-red emission staining (green) and Nissl-stained section
(red) 48 h after MCAo. The measurements were done in the outlined ischemic area
(dashed line). Merged scanned microphotograph shows that CD11b staining is
localized within the ischemic tissue. (C) Quantification of CD11b average intensity
in vehicle- (n = 6) and D-JNKI1-treated (n = 6) animals in the ischemic tissue. (D)
Correlation between infarct volume and the average intensity of CD11b in treated
(empty black circle) and untreated groups (black circle). There is a correlation
between the infarct volume and the average intensity in vehicle-treated group
(R = 0.94, p = 0.005; **p < 0 .01). This correlation is negative and not significant in D-
JNKI1-treated group (R = !0.36, NS). Linear regression analysis of slopes of treated
and not treated groups gives a non-significant difference between groups
(R = !0.01, p = 0.9, NS). NS, not significant.
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As we observed activation of p-c-Jun in neurons and not in
microglia, and that D-JNKI1 was mainly localized in neurons but
also in some microglial cells, we may assume that D-JNKI1 is more
likely to indirectly modulate microglial activation in vitro.
Intriguingly, the in vivo results suggest that treatment with D-
JNKI1 following ischemia does not reduce the recruitment and acti-
vation of microglia in the ischemic brain territory at 48 h. How-
ever, D-JNKI1 appears to alter microglial activation and
Fig. 5. Co-localization of D-JNKI1 in neurons and microglial cells 48 h after OGD in hippocampal slices. (A) Schematic representation of the experimental protocol. OGD for
30 min was performed 8 days after in vitro culture, 12 nmol/l D-JNKI1 or vehicle was administrated in the culture medium 6 h after OGD. PI uptake and immunofluorescence
was analyzed 48 h after induction of ischemia. (B) Effect of D-JNKI1 on neuronal death assessed by cellular PI uptake. Representative photomicrographs showing PI uptake in
the CA1 layer of hippocampal slice cultures not exposed (left) and exposed (right) to vehicle or D-JNKI1, respectively. A significant decrease of PI uptake was observed 48 h
after D-JNKI1 treatment. Diagram shows percent of cell death in the CA1 region in both groups (p = 0.012; *p < 0.05). Control slices not exposed to OGD had no PI uptake (data
not shown). (C) D-JNKI1 is mainly localized in the CA1 pyramidal cell layer of hippocampal slices 48 h after OGD and shows a cytoplasmic staining (outlined by green
squares), whereas few stainings are localized outside the CA1 region (green circles). Co-localization of D-JNKI1 (green cytoplasmic staining) with NeuN (red nuclear labelling)
is found in treated slices, predominantly in the CA1 (C1, arrow heads). Some co-localization was also observed between D-JNKI1 and Isolectin B4-positive microglial cells at
the border of the CA1 layer (C2, arrow heads).
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Fig. 6. Activation of c-Jun after OGD and effect of D-JNKI1 on microglia activation. (A) Nissl-staining of the CA1 region of control (CTRL), OGD and OGD + D-JNKI1 slices. CA1
neurons are undergoing ischemic cellular death, shown by pyknotic nuclei (A2), whereas treated slices (A3) as well as control slices (A1) show neurons in a healthy state;
scale bar: 50 lm. (B) After OGD nuclear expression of p-c-Jun(Ser63) co-localized with NeuN-positive cells (arrows), while NeuN staining is partially lost (B2) compared to
control slices (B1). D-JNKI1 (12 nmol/l) treatment rescues NeuN staining while it partially attenuates p-c-Jun staining (B3). In both OGD (C2) and OGD + D-JNKI1 (C3) groups,
no Isolectin B4 cells co-localized with p-c-Jun(Ser73) (arrow heads). (D) In control slices microglial cells are highly ramified and are evenly distributed (D1, red). After OGD
microglia accumulates in the damaged CA1 layer and changes its morphology to an activated state (ameboid microglia) (D2, arrow heads), whereas in treated slices,
morphology of microglial cells are heterogeneous: ameboid (D3, arrow heads) and ramified cells (D3, insert), and are localized at the border or within the neuronal CA1 layer,
respectively. Inserts show high magnification. (E) Schematic presentation of microglial morphological transformation in response to an ischemic insult such as OGD in vitro.
Our initial hypothesis is that after an insult resting microglia become highly activated, further accumulate and could change morphology to a phagocytic state. We suggest
that D-JNKI1 may inhibit the activation of microglia and secretion of pro-inflammatory mediators. We postulate that part of this inhibition process may be mediated through
the JNK pathway and lead to neuroprotection. (B–D) All fluorescent microphotographs of double labelling are from the CA1 hippocampal region. Scale bar: 100 lm.
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localization following OGD in vitro (Fig. 6E: schematic presenta-
tion). While this may partly be due to the in vitro hypoxia model
not reproducing the in vivo ischemia model, these observations
need to be further explored, for instance by quantitative measure-
ments of inflammatory cytokines released by microglia, in animals
submitted to experimental ischemia with or without treatment.
4. Discussion
In the normal healthy brain, microglial cells are known to con-
tinually screen their microenvironment by quickly moving their
processes (Kreutzberg, 1996; Nimmerjahn et al., 2005). Controlled
activation of microglia induces production of trophic factors and
elimination of cell debris, leading to a protection of surrounding
cells (Raivich et al., 1999; Streit et al., 1999; Aloisi, 2001). An ische-
mic insult causes an exaggerated activation of microglia with
excessive release of pro-inflammatory mediators and uncontrolled
phagocytic function (van Rossum and Hanisch, 2004; Kreutzberg,
1996). It has been postulated that this over-activation might be
deleterious for the survival of neurons whereas controlled activa-
tion of microglia might be neuroprotective.
The purpose of this study was to investigate whether the strong
neuroprotective effect of D-JNKI1 in our models of cerebral ische-
mia was due to a modulation of microglia activation through the
JNK pathway. We found that D-JNKI1 was strongly neuroprotective
when injected i.v. 3 h after transient 45 min MCAo. Despite effi-
ciently attenuating the damaging neuronal events by inhibition
of the JNK pathway (Waetzig et al., 2005; Raivich and Behrens,
2006), D-JNKI1 did not reduce the accumulation and morphologi-
cal activation of microglia in vivo as shown by our quantification
of CD11b+ cells (Fig. 4). This result does not completely rule out
that D-JNKI1 could inhibit microglia at earlier steps, as CD11b
labelling was positive at 24 h after MCAo. Alternately, as D-JNKI1
was not detected in the brain, it could also possibly inhibit periph-
eral JNK activation, which could lead to reduced inflammatory pro-
cesses and indirect neuroprotection. These findings show that
neuroprotection due to D-JNKI1 treatment in this model is inde-
pendent of the peak of microglial activation observed at 48 h.
Furthermore, our analysis of linear regression between the in-
farct volume and the number of microglia in the ischemic tissue
of vehicle-treated animals reveals that there is a strong correlation:
the larger the lesion, the more activated microglial cells are present
in the infarct. Treatment with D-JNKI1 does not significantly
change this trend. Therefore, D-JNKI1 inhibits neuronal death
without affecting the accumulation of microglia, nor by having
an obvious effect on microglial activation state, suggesting that
activation of microglia does not necessarily exacerbates neuronal
damage. As microglia are capable of various responses depending
on the type of injury, and since changes in morphology and upreg-
ulation of surface expression markers does not always reflect
microglial activation, it will be necessary to go onto investigate
the inflammatory capacity in this model (Feuerstein et al., 1998;
Hanisch, 2002; Garden and Moller, 2006; Clausen et al., 2008). Pre-
vious studies have reported that ischemic damage is attenuated by
inhibiting pro-inflammatory cytokines or transcription factor such
as nuclear factor-jB (NF-jB), by diminishing free radicals gener-
ated by inducible nitric oxide synthase (iNOS) or cyclooxygenase-
2 (COX-2) (Iadecola et al., 1995; Yang et al., 1998; Parmentier
et al., 1999; Nijboer et al., 2009). As the JNK pathway is involved
in regulation of inflammatory molecules (Hidding et al., 2002;
Waetzig et al., 2005), D-JNKI1 might therefore modulate cytokines
secretion. Investigating pro- and anti-inflammatory mediators
with or without D-JNKI1 treatment will complete our understand-
ing of microglial function after ischemia.
Several studies have described the involvement of the mitogen-
activated protein kinase pathway (MAPKs, including JNK, ERK and
p38) in the regulation of inflammatory mediators (for review see
Kaminska, 2005). In vitro experiments have shown that the JNK
pathway is activated in microglial cultures stimulated by TNFa,
thrombin or LPS (Hidding et al., 2002; Waetzig et al., 2005). They
also showed that CEP-11004 (an inhibitor of mixed lineage ki-
nases) or SP600125 (an ATP-competitive JNK inhibitor) reduced
LPS-induced phosphorylation of JNK and c-Jun and significantly re-
duced microglial metabolic activity and proliferation, respectively.
Here, we report for the first time that phospho-c-Jun was activated
in microglia after transient MCAo in mice, which led us to test
whether D-JNKI1 could modulate microglial activity through the
regulation of the JNK pathway. However, JNK may not be the only
predominant pathway required for microglial activation in the
brain after cerebral ischemia (Fig. 4). As all three MAPKs are up-
regulated after stress (Kaminska, 2005), one could imagine that
inhibition of more than one pathway is necessary for complete
inhibition of microglial activation. An inhibitor of p38 mitogen-
activated protein kinase (SB239063) has been shown to reduce
microglial activation after OGD in hippocampal cultures when
administrated 2 h before and until 24 h after the deprivation
(Strassburger et al., 2008). Thereby combined inhibitors of the
MAPK pathways could affect more significantly the activation of
microglia in vivo.
Towards an understanding of the molecular mechanisms of the
JNK pathway in microglia, we investigated the role of D-JNKI1
in vitro. In our OGD model of ischemia, we showed that the peptide
prevented neuronal cell death in the CA1 by a reduction of propi-
dium iodide uptake, as previously described (Hirt et al., 2004).
We found a strong activation of phospho-c-Jun in CA1 neurons
48 h after OGD. Treatment with D-JNKI1 did not completely block
c-Jun activation but rescued neurons from OGD-induced death.
In slices subjected to OGD and treated with D-JNKI1, we find co-
localization of D-JNKI1 with neurons and to a much lesser extent
with microglia. Interestingly, we observed morphological changes
of microglia in vitro: while microglial cells were in a well ramified
state in control slices, they became more rounded after OGD, and
D-JNKI1 inhibited this morphological change. The JNK pathway
modulates the phosphorylation of actin and microtubules and
could thereby modify microglial morphology (Waetzig et al.,
2005). Our in vitro observations suggest an effect of D-JNKI1 on
microglia and could be further confirmed by assessing microglial
function, such as cytokine release. The JNK pathway was for in-
stance shown to be involved in microglial pro-inflammatory cyto-
kine production (Kaminska, 2005) and we have started to
investigate cytokine secretion in vitro after OGD as well as in vivo
after MCAo.
Besides modification of microglial morphology after D-JNKI1
treatment in vitro, we found a change in microglial localization
after OGD and after OGD + D-JNKI1. In control slices microglia were
homogenously distributed whereas after OGD microglia were pre-
dominantly localized within the damaged neuronal CA1 layer.
Treatment with D-JNKI1 modified the localization of microglia
which were found at the boundary of the neuronal CA1 layer. Mod-
ification of microglial cell localization at the site of injury has been
previously reported in hippocampal slice cultures (Heppner et al.,
1998; Montero et al., 2009). Altogether, OGD induced changes in
microglial morphology (ramified to ameboid) and accumulation
in the degenerating neuronal CA1 layer. These changes were mod-
ified by D-JNKI1. We may hypothesize that D-JNKI1 exerts a neuro-
protective effect directly on neurons (shown in this in vitro study
by localization of D-JNKI1 in NeuN-positive cells and by previous
data in neuronal cultures, Borsello et al., 2003), and modifies the
intracellular signaling from affected neurons to microglia. Thus,
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D-JNKI1 would act indirectly on microglia through signals secreted
by neurons influencing microglial activity and localization.
Interestingly, the hippocampal slice hypoxia model may not
reproduce mechanisms of microglial activation observed in the
in vivo stroke model. Indeed, D-JNKI1 showed no effect on microg-
lial activation and accumulation at 48 h after MCAo, while changes
in morphology and localization were observed in vitro. This may
reflect species or age differences (adult mice used in vivo versus
newborn rats in vitro) which might cause discrepancies. Further-
more, in vitro models are only partially representative of the
in vivo situation concerning the microglial response. Indeed, we
saw DCs and infiltration of inflammatory cells, such as T lympho-
cytes after MCAo (Fig. 1), which evidently does not occur in vitro.
These cells could modulate microglial activation and may explain
the differences seen in the two models. The different effects ob-
served in the models deserve further investigation to highlight
the possibility that neuronal injury and microglial activation may
happen independently.
Here we demonstrated that D-JNKI1, a selective JNK inhibitor
and highly neuroprotective peptide, does not attenuate the activa-
tion and accumulation of microglia in the ischemic tissue in an
in vivo MCAo model of stroke at 48 h. This finding adds to the
knowledge that neuroprotection via inhibition of JNK is indepen-
dent of the late microglial accumulation or activation. It also indi-
cates that the JNK pathway is not essential to microglial activation
after ischemia, and that the presence of activated microglia in the
ischemic area is not necessarily detrimental to neurons. Addition-
ally, our study suggests that D-JNKI1 could be safely used in clini-
cal stroke patients, as it does not exacerbate inflammatory
responses after cerebral ischemia. Our in vitro data point towards
an effect of D-JNKI1 on microglial recruitment as well as morpho-
logical changes, which is likely to be an indirect effect of the pep-
tide through its action on neurons. Therefore, investigating the
pattern of pro- and anti-inflammatory secreted mediators in brain
ischemia with and without D-JNKI1 treatment will help to charac-
terize its role on inflammation during cerebral ischemia.
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